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Abstract 
Background 
Colorectal liver metastases (CRLM) are more prevalent with advancing age.  
Worldwide trends towards longer life expectancy result in a more prevalent 
disease in an increasingly aged co-morbid population. Utilising enhanced 
recovery after surgery (ERAS) and better preoperative assessment of 
patients using cardiopulmonary exercise testing (CPET) may in part mitigate 
the challenges of dealing with a more elderly co-morbid population. However 
significant challenges remain.  
Prehabilitation seeks to prevent injury, or minimise its impact before it occurs. 
This thesis describes the development and validation of a prehabilitation 
program in patients prior to hepatectomy for colorectal liver metastases.   
Methodology 
An exercise program was developed within a laboratory and validated in 12 
health volunteers.  This program was then tested in a randomized clinical trial 
of patients prior to hepatectomy for colorectal liver metastases. 
The measurement of liver function and prediction of post hepatectomy liver 
failure (PHLF) is a challenge.  Further work measuring liver function is 
needed, and a component of this thesis demonstrated the application of liver 
slicing as a model of human hepatic functioning. 
    xv 
Results 
The part of this thesis demonstrates that a 4 week exercise program can 
deliver meaningful (1.5 ml.kg-1.min-1) improvements in the Oxygen uptake 
(Vo2 uptake ml.kg-1.min-1)  at the anaerobic threshold (AT). 
Within the main component of this thesis (the randomized trial) 38 patients 
were randomized (20 prehabilitation, 18 standard care).  35  (25 male, 10 
female) completed both preoperative assessments and were analysed. There 
were no differences in baseline characteristics. Prehabilitation led to 
improvements in the preoperative Vo2 uptake (Oxygen uptake ml.kg-1.min-1)  
at both anaerobic threshold (AT) (+1.5 ml.kg-1.min-1, 95% Confidence Interval 
(CI) 0.2 - 2.9 ml.kg-1.min-1) and peak exercise (+2.0 ml.kg-1.min-1, 95% CI 0 – 
4.0 ml.kg-1.min-1). The O2 pulse (Oxygen uptake per heart beat) at the 
anaerobic threshold improved (+0.8 ml.beat-1, 95% CI 0 - 1.9 ml.beat-1) and a 
higher peak work rate (+13 watts, 95% CI 4 – 22 Watts) was achieved.  This 
was associated with improved preoperative QoL, with overall SF-36 
increasing by 11 (95% CI 1:21) (p<0.05) and overall SF-36 mental health by 
11 (95% CI 1:21)(p<0.05). 
Conclusions 
Prehabilitation can deliver improvements in CPET scores, and QoL. This may 
impact on perioperative outcome. 
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Chapter 1: Introduction  
An aging increasingly morbid population undergoing treatments of greater 
complexity means that even preserving current outcomes is challenging. 
However there is a desire for better results in all aspects of healthcare.  This 
is at a time where there is worldwide pressure on healthcare budgets, leaving 
less funding to address these challenges.   
Consequently innovative approaches to improving care and delivering cost 
effective treatment is urgently needed.  This thesis seeks to explore the 
surgical management of patients with colorectal liver metastases and identify 
areas where care can be improved and develop strategies to address these 
areas. 
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1.1 Colorectal Cancer 
1.1.1 Incidence and prevalence of Colorectal Cancer 
Colorectal cancer is a common malignancy with 1.2 million new diagnoses 
annually worldwide and 42,000 in the United Kingdom1. Worldwide colorectal 
cancer is estimated to cause 608,000 deaths annually, whilst in the United 
Kingdom it is the 3rd highest cause of cancer related death, accounting for 
10% of all cancer deaths2.The incidence of colorectal cancer in 2012 was 
55.6 and 36.7 per 100,000 population in men and women respectively.  
Standardised mortality rates of 20.6 and 13.7 per 100,000 populations in men 
and women respectively equates to a cancer related mortality of 37% of all 
the patients diagnosed with bowel cancer3. This represents an increase in 
the incidence of colorectal cancer from 2008 figures, in tandem with a climb 
in the mortality rate from the 2008 estimate of 34%3,4. Data from cancer 
research UK suggests that in 2014 there was a slight fall in new cases, 
however the survival to 10 years following a cancer diagnosis has continued 
to fall, and now stands at 57%1.  This probably reflects a changing 
demographic of the patient population, with an increasing burden of frailty5. 
The UK incidence and mortality have been highlighted as areas of concern, 
as survival here appears to be worse than comparable countries6.  
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1.2 Colorectal Liver metastasis  
Blood borne spread via the portal system is common, and a compulsory first 
visceral step7. This is evident in the frequency of hepatic metastasis, where 
20 - 25% of patients have liver metastasis evident at diagnosis and up to 40 - 
50% of all patients develop hepatic metastases during the course of the 
disease8. 
The liver is often the first site of metastasis, and in 30-40% the only site of 
metastatic spread8.  One of the keys principals in hepatic resection is a belief 
that resection of liver metastases before further systemic spread can be 
curative7. 
1.2.1 Incidence and prevalence of colorectal liver metastases 
Whilst hepatic metastases are common, only 30–40% of patients will have 
disease confined to the liver9.  In these patients only a minority are eligible for 
curative intent liver surgery, currently estimated at around 20-25%.  This 
means only around 3-5% of all patients are considered for hepatectomy, and 
6-10% with advanced colorectal cancer10. 
1.2.2 Changing patterns of disease 
To effectively develop strategies to improve outcomes for patients with 
colorectal liver metastases (CRLM) it is important to have an appreciation of 
the current demographic of the patient population presenting with the 
Improving the perioperative management of resectable colorectal liver metastases 
 
4 
 
disease, and how this is likely to change.  Understanding the changing 
demographic of the patient population is challenging and is likely to be 
effected by global population changes, national health initiatives, and 
treatment strategies.   
1.2.2.1 Aging populations 
Whilst the prediction of the numbers of patients presenting with resectable 
CRLM is uncertain, there can be greater confidence in predicting the likely 
changes to the age demographic.   The worldwide and UK populations are 
increasingly elderly, with the over 65 population expected to make up around 
20% of the UK population by 2025, compared to just 17% currently5,11 .   
Cancer in general, and colorectal cancer in particular, are directly linked to 
age, with 70% of colorectal cancer diagnoses occurring after the age of 65, 
and 50% in patients over 705.  Thus, as populations continue to age, we can 
expect more cases to be diagnosed in an increasingly aged population5.   
This has significant implications for practice where age has been shown to be 
associated with poorer short-term peri-therapeutic , and long-term oncologic 
outcomes12-15. The reasons underpinning this may relate to differences in 
tumour and patient biology, but inaccurate perceptions of poor outcomes in 
older patients by clinicians have been identified as significant contributors14-
18.  A UK Department of Health review, published in 2012, acknowledged that 
age may be a surrogate marker for other factors that may make less 
aggressive treatment justifiable19.  However, even taking this into account it 
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was suggested that age discrimination in UK cancer care was leading to 
inappropriate under investigation and treatment.  It was suggested this led to 
detrimental effects on cancer survival in older people.  This highlighted the 
need to focus on improving outcomes in elderly patients19. 
A key aim should be to devise pathways to select appropriate treatment for 
elderly patients, ensuring that those with significant co-morbidity are not 
inappropriately over treated, whilst still being able to select those in whom 
aggressive treatment can be tolerated. 
1.2.3 Defining resectable CRLM  
1.2.3.1 Criteria of resectability 
When hepatectomy was first undertaken for CRLM, it was performed in 
highly selected physiologically fit patients believed to have the best 
prognostic features. Using these criteria around 10% of patients with liver 
only metastases were resectable20.   
Gradually these early resection criteria were challenged with evidence 
demonstrating that patients beyond these limited criteria could experience 
long-term survival following liver resection21,22.  
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The latest UK national guidance written in 2011 recommended that resection 
of CRLM should be offered provided: 
• The patient is assessed fit enough to undergo surgery 
• Complete resection or ablation can be achieved leaving an adequate 
future liver remnant (FLR).  
Extrahepatic disease was not considered a contra-indication to resection 
provided the disease is potentially resectable23. There are no absolute 
contraindications to resection issued in this guidance, but the relative 
contraindications to liver resection or ablation in normal circumstances are 
summarised in Table 1-123. 
Table 1-1 Relative contraindications to resection or ablation of CRLM 
 
This shift to defining resectability based on what will remain, rather than by 
what is removed, has led to an increase in the number of patients eligible for 
resection at diagnosis from 10% in 1999 to around 25% currently10.    
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1.3 Assessment of fitness  
The first criterion in assessing CRLM resectability is making an assessment 
of the fitness of a patient to undergo major cancer surgery. Establishing that 
it is technically feasible to resect disease, and preserving an adequate 
hepatic functional volume, is irrelevant without an appreciation of whether or 
not the patient has physiologically capable of surviving a proposed 
intervention. Consequently the assessment of fitness should be seen as an 
integral part of the preoperative assessment process. 
Specifically targeted research defining fitness for hepatectomy is limited, but 
methods of defining preoperative fitness include scoring systems 
questionnaires and quantitative fitness measures (Table 1-2)24. 
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Table 1-2 Methods of assessing patient fitness 
 
The American Society of Anaesthetists (ASA) score is widely employed and 
has been shown to correlate with outcome25, but ASA is deemed insufficient 
to adequately risk stratify patients19.   Other scoring systems and 
questionnaires have yet to be validated in patients undergoing hepatectomy, 
and are often seen as open to bias and subjective interpretation26. 
Quantifying patient fitness in an objective fashion is an attractive concept, 
and two common methods that address this are the 6-minute walk test, and 
cardiopulmonary exercise testing (CPET)27,28. 
1.3.1 CPET  
CPET is a non-invasive method for evaluating cardiopulmonary fitness, and 
can help to identify hidden cardiorespiratory limitations that could suggest 
significant underlying pathology27,29,30. The test requires patients to exercise 
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using a fixed cycle, treadmill or arm based system.  This allows tailoring of 
the exercise for different patient groups (lower limb joint surgery patients can 
be assessed using arm exercises, for example).  Exercise bikes tend to be 
used, as they are safe, familiar, reduce artefact interference during 
continuous monitoring and allow a more accurate quantification of external 
work rate. Higher levels of exertion can be achieved on a treadmill31, but 
patients may require an extended period of familiarisation with the 
equipment32.   The arm crank system as yet lacks evidence for use in the 
clinical setting, and the translation of values produced via the different 
modalities had not until recently been correlated33.  Recent work suggests a 
correlation between arm crank scores, and that generated by a cycle 
ergometer, however it was insufficient to adequately translate across 
modalities for comparative purposes33.  
CPET measures gas exchange, blood pressure, oxygen saturation, and 
electrocardiogram (ECG) in response to an increasing workload.   Optimal 
exercise time is 8-12 minutes, as shorter exercise times may underestimate 
VO2max (described in Table 1-3)29-31. During the exercise protocol, numerous 
variables are monitored including blood pressure, pulse, breath-by-breath 
measurement of inspired oxygen and expired CO2, and peripheral oxygen 
saturation. 7, 8  Using this information a number of physiological values are 
measured, or calculated.  Definition of these parameters is summarised in 
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Table 1-334.  Currently a variety of these variables have been suggested as 
predictive of outcome, in different surgical cohorts. 
Table 1-3 CPET terminology 
 
1.3.2 CPET in surgery  
CPET was first described in the context of abdominal cavity surgery by Older 
et al over two decades ago35. He first demonstrated its use to predict risk in 
patients over the age of 70 undergoing major abdominal surgery35.  More 
recently he has demonstrated the use of CPET to successfully stratify these 
patients’ postoperative care to ward, high dependency unit, or intensive 
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care36.   This work predominantly used ischaemic changes on ECG and the 
anaerobic threshold to predict outcome. 
Since this time CPET variables have been shown to correlate with outcome 
following colorectal surgery, major urological surgery, aortic aneurysm repair, 
oesophagectomy, and in elderly patients following major surgical intervention 
29,30,35,37-41. Many of these studies were un-blinded retrospective analyses of 
practice where CPET was utilised in patient management. Utilising CPET in 
this manner is thought to serve to underestimate its predictive power as 
practice is alerted to mediate the effects of poor cardiopulmonary fitness42.   
two large series where clinicians were blinded to the results of CPET have 
been published, including patients undergoing major pancreatic or sarcoma 
surgery, and including patients deemed of poor fitness by the Veterans 
Activity Questionnaire Index (VASI) undergoing a mix of major intra-
abdominal surgery40,43. The outcome measure for both studies was morbidity 
as assessed by the postoperative morbidity score (POMS).  Both studies 
found that fitness as determined by CPET was strongly correlated with 
postoperative morbidity, with those having lower fitness having more 
postoperative complications.  This finding of poorer fitness correlating with 
poorer outcome is as expected and demonstrates the effectiveness of CPET 
in quantifying patient fitness. 
CPET produces a wealth of variables and two systematic reviews have 
concluded that different variables appear to be more valuable predictors in 
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different surgical contexts29,30.  The explanation for this is unclear, and this 
has been highlighted in the literature as an area for research focus 44.  The 
most consistently identified variable is the relative oxygen uptake at the 
anaerobic threshold, often simply referred to as the anaerobic threshold (AT).  
This variable is attractive for preoperative prediction as it occurs at a low 
level of exercise achievable in most patients, and it is independent of volition.  
In marathon runners it has been shown to strongly correlate with 
performance45.  There is however significant debate about the physiological 
basis and reliability of detection of the anaerobic threshold, particularly in 
patients who acutely hyperventilate 46,47.  Current literature suggests that 
whilst CPET can accurately assess fitness, decisions regarding surgery 
should be based on careful interpretation of the whole CPET data set in light 
of the proposed surgical intervention34. 
1.3.3 CPET in liver surgery 
There are very few studies utilising CPET in hepatic surgery34,40,43,48-50.  In 
patients undergoing hepatic transplantation a small study suggested that a 
peak VO2 of less than 60% of predicted (based on age, sex and weight), or a 
relative VO2 at the AT of <50% predicted was associated with mortality at 
100 days51.  This study, however, had a number of limitations including its 
size, statistical approach, and differences between the management of the 
two cohorts (survivors vs. non survivors).  They did not report any data on 
correlations between CPET values and the extent of the liver disease.  More 
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recently further work has firmly established VO2 at AT as a predictor of 
survival following hepatic transplantation50.  In other liver transplant studies 
CPET has been studied before and after transplantation, with significant 
improvements demonstrated 1 year post graftingn52.  
The largest reported series in hepatectomy (the author’s), used CPET as an 
integral part of management, and also used an enhanced recovery after 
surgery programme 34. This study found where CPET is used in management 
few CPET variables correlate with complications or hospital stay34.  
Specifically the anaerobic threshold does not correlate with outcome, though 
this study is limited by the lack of blinding of clinicians to the results of the 
CPET.  Interestingly those with lower AT undergo less aggressive 
procedures with more critical case use, at greater cost 53.  This may go some 
way to explain the absence of a relationship, and would be in agreement with 
previous suggestions that using CPET in management diminishes its 
predictive capacity42.  
1.4 Defining an adequate FLR  
The second criterion of resectability is establishing the capacity to leave an 
adequate FLR. Postoperative hepatectomy liver failure (PHLF), or hepatic 
insufficiency, where the remaining liver post resection is inadequate to meet 
the needs of an individual, is one of the leading causes of morbidity and the 
leading cause of mortality following liver surgery10,54,55.  It is defined as a 
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postoperatively acquired deterioration in the ability of the liver to maintain its 
synthetic, excretory and detoxifying functions56.  A series of over 2,600 
consecutive resections has identified an overall incidence of hepatic 
insufficiency of 2.6%54.  This, however, underestimates the nature of the 
problem, as many of the patients within this series underwent resections of 
such a low volume hepatic insufficiency would not have been expected.   
In patients undergoing major hepatic resection following chemotherapy, 
hepatic insufficiency has been reported to occur in up to 16%10,57.   The 
expanding armamentarium of chemotherapeutics, and adjuvant therapies 
means patients who have been treated with extended chemotherapy make 
up an increasing proportion of surgical candidates. 
Currently defining the adequate functional reserve is challenging. Hepatic 
functional capacity is widely variable within humans.  One measure of hepatic 
viability, Adenosine triphosphate (ATP), has been shown to vary between 2-
14 nmol mg−1, in comparison to rats where it is typically around 10-12 nmol 
mg−158.  This is likely a result of interplay between underlying genetic 
predisposition, patient factors and the effects of other treatments.  
Surrogate markers of poor hepatic reserve, and consequently a higher risk of 
postoperative hepatic insufficiency and death, include diabetes, advancing 
age, obesity, pre-existing liver disease, portal hypertension, and preoperative 
sepsis59. In addition to these preoperative risk factors, a number of 
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perioperative factors can also affect the risk of postoperative hepatic 
insufficiency. These include smaller liver remnant, prolonged operative time, 
blood loss in excess of 1000ml, and postoperative biliary leaks10. There 
remains considerable debate about the safe limits for liver resection and 
decisions must be based on an assessment of preoperative and likely 
intraoperative factors, in conjunction with an appreciation of an individual’s 
liver function. 59 
Unfortunately, no single test or biological marker has been able to adequately 
identify hepatic function and predict postoperative outcome59.   The most 
commonly used methods include scoring systems, and dynamic liver function 
assays.  This is often done in conjunction with volumetric analysis of 
preoperative and predicted postoperative hepatic volume. 
Scoring systems are typically applied in patients with pre-existing liver 
dysfunction and include the Child–Turcotte–Pugh score and the Model for 
End-Stage Liver Disease (MELD) score60.   These have been shown to be 
reliable predictors of risk in patients with known pre-existing liver disease, but 
are of little value in patients undergoing resection for CRLM, where the 
majority have no known underlying liver disease61.  
Indocyanine green (ICG) test is available to aid in the assessment of hepatic 
functional capacity, but is infrequently used59.  It is a water-soluble agent, 
taken up by hepatocytes and transported into the biliary system.  It is not 
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metabolised by the liver or reabsorbed via the entero-hepatic circulation62.  It 
can be used to estimate functioning hepatic mass, liver blood flow and the 
energy status of the liver63,64.  Retention of ICG of 10-14% at 15 minutes has 
been used in patients with underlying liver disease to help determine a safe 
limit for hepatic resection, with poorer scores precluding major hepatectomy. 
Concerns exist that this may result in patients who could safely undergo 
hepatectomy being denied surgery based on a low ICG clearance62.  
Other tests of preoperative hepatic function include hepatobiliary scintigraphy 
and the MEGX test (metabolism of lidocaine to mono-ethylglycinexylidide)65.  
Hepatobiliary scintigraphy has been shown to correlate with outcomes 
determined by volumetric assay but is affected by tumour burden, and has 
not gained widespread use66. The MEGX test in conjunction with volumetric 
analysis has helped predict patients at risk of PHLF67. The requirement to 
administer lidocaine intravenously, and the concern over individual variability 
due to medication interaction with the Cytochrome P450 pathway have led to 
limited uptake of this test.  
The absence of reliable definitions of hepatic functional reserve has led to 
hepatic volume, and predicted post resection hepatic volume in conjunction 
with patient factors being used to define resectability. 
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1.4.1 Defining the minimum future liver remnant volume 
The volume of hepatic resection is inextricably linked to the risk of PHLF and 
mortality.  The larger the resection the higher the risk of PHLF59.   Given this 
established fact, and the difficulties to quantifying the hepatic function, much 
work has been done to establish safe volumes of resection. 
A variety of techniques have been employed to measure liver volume.  The 
simplest form (Figure 1-1) utilises CT reconstruction to estimate the ratio of 
likely resected volume as a proportion of total liver volume62. Resection of 
more than 75% of total liver volume is associated with a 90% incidence of 
post resection hepatic failure, increased complications and a longer length of 
stay68. 
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Figure 1-1 Overview of volumetric analysis of liver volume 62 
 
Techniques have been developed to take into account non-functioning liver 
that has either been replaced or obstructed by tumour, and incorporate the 
patients size into the calculation69,70,59,71. 
Current standards suggest that in a patient with normal hepatic function, a 
minimum volume of FLR can be considered as 20%72.   This, however, 
needs to be considered in conjunction with other intraoperative factors 
including the expected extent of hepatic ischemia, and the intraoperative 
blood loss.    
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Unfortunately, this safe limit is increasingly difficult to utilise in clinical 
practice as patients undergo more complex treatment pathways, with multi 
agent chemotherapy and intrahepatic therapies.  These treatments, in 
particular chemotherapy, can have negative effects on hepatic function. The 
effect is however idiosyncratic73. As a result defining hepatic function is 
becoming increasingly important in clinical practice.  
1.4.2 Perioperative chemotherapy for CRLM 
In the last 10 years survival (OS) in patients with metastatic colorectal cancer 
has improved significantly74.  Given that only a minority of patients with liver 
limited metastases are potentially treatable with curative intent surgery, much 
of this can be attributed to advances in systemic therapies.  It is outside the 
scope of thesis to explore the detailed chemotherapeutic options for patients 
with colorectal liver metastasis, however they can be broadly considered in 4 
main categories. 
1.4.2.1 Conversion Chemotherapy  
Conversion chemotherapy aims to bring patients with initially irresectable 
hepatic metastases, to curative intent surgery. These patients, brought to 
secondary resection by systemic therapy, enjoy comparable long-term 
survival to patients with upfront resectable disease at the time of presentation 
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(10 year survival 23%vs 30% 75), and far superior to those receiving palliative 
systemic chemotherapy76.  
1.4.2.2 Neo-adjuvant and adjuvant chemotherapy 
Whilst chemotherapy is considered standard of care in patients with high-risk 
stage II and all stage III cancers, 23 in patients with established liver limited 
stage IV disease the role is less clear77.  
Recurrence is common following hepatic resection of CRLM, occurring in 
over two thirds of patients within 2 years of surgery78.  Chemotherapy in 
either neoadjuvant or an adjuvant setting aims to treat occult metastases, 
thereby reducing early recurrence79,80.  Currently UK comprehensive cancer 
network guidelines recommend considering 6 months perioperative 
chemotherapy for all patients with resectable metastatic liver lesions, but the 
paucity of evidence is acknowledged77.  
1.4.2.3 Loco-regional chemotherapeutic therapies  
In addition to systemic chemotherapeutic options for CRLM, there have been 
advances in a variety of other therapies.  It is beyond the scope of this thesis 
to detail these therapies, however they include: 
1. Hepatic arterial infusion (HAI) chemotherapy81,82.  
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2. Drug eluting beads for trans arterial chemo-embolisation (DEB-
TACE)83,84. 
3. Selective internal radiation therapy (SIRT) 85-88.   
1.4.2.4 Chemotherapy induced liver injury 
Whist chemotherapy and liver targeted therapies have a number of potential 
benefits, the consequences of hepatic toxicity must be considered.  The three 
agents most commonly used in in the management of CRLM are 5-
Fluorouracil (5-FU), Irinotecan, and oxaliplatin73.  All can cause hepatic 
injury77. 
Unfortunately, despite understanding that chemotherapy can have significant 
effects on hepatic function, identifying those individuals where significant 
chemo-toxicity has or will occur remains a challenge73.  Developing a model 
of hepatic function and biomarkers of chemo-toxicity to allow this is a 
research priority.  
1.5 Surgery for CRLM 
Early hepatectomy relied on utilising the internal hepatic anatomy to resect 
entire lobes, sections or segments (Figure 1-2)89.  This had the advantage of 
allowing control of haemorrhage intra-operatively, making resection feasible 
before the onset of improved anaesthetic techniques. The disadvantage of 
this original approach meant that in many cases extensive normal hepatic 
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tissue was resected increasing the volume of resection and consequently the 
risk of PHLF 90.  The descriptions were standardised in 2000 using the 
Brisbane criteria and then revised by the International Society of Hepato-
Pancreato-Biliary Surgery (IHPBA)91. 
Figure 1-2 Common anatomical hepatectomies 
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Non-anatomical hepatectomy has evolved as surgical and anaesthetic 
techniques evolved.  It aims to remove all metastatic deposits, preserving as 
much liver tissue as possible.  This is determined by the proximity and 
involvement of the hepatic blood flow, and biliary drainage. This surgery has 
contributed to a progressive reduction in the incidence of major anatomical 
resection, but has led to increasing difficulties in assessing the extent and 
risk of surgery54.  Particularly when parenchymal preserving surgery is used 
in conjunction with other liver directed therapies and advanced surgical 
techniques54.  
1.5.1 Anaesthesia for liver surgery 
Anaesthetic advances have had a significant impact on both the extent of 
feasible surgery, and the outcomes following surgery.  Whilst this thesis does 
not seek to examine the changes in anaesthetic technique one of the 
greatest contributions has been the widespread adoption of low CVP 
anaesthesia. The CVP is kept between 2mmHg and 5mmHg which limits the 
distension of hepatic veins and sinusoids, and consequently the massive 
blood loss previously associated with hepatectomy92. This anaesthetic 
approach has an accepted consequence of a risk of inadequate organ 
perfusion and potential organ injury92.   The complexities of intraoperative 
management in these patients continue to increase as the bounds of surgery 
are extended, particularly with the use of advanced hepatic reconstruction. 
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1.5.2 Laparoscopic liver surgery 
Laparoscopic surgery for CRLM aims to provide curative resection whilst 
reducing the trauma associated with open surgery. There are no randomised 
controlled trials assessing the use of laparoscopic hepatectomy currently 
published. The largest randomised trial in laparoscopic liver surgery, 
ORANGE II, failed to recruit patients. The ORANGE II plus trial is on-going 
and is examining the role of laparoscopic hemi-hepatectomy93.   
Currently evidence is based on retrospective series.  A meta-analysis of 
series published between 1998 and 2005 concluded that laparoscopic liver 
resection has the potential to reduce operative blood loss and allow earlier 
recovery with oncological clearance comparable with open surgery94. It 
cautioned that because of the potential of significant bias arising from case 
series, randomised controlled trials were recommended, to eliminate bias 
and to compare long-term survival rates. 
One of the largest early single-centre experiences of laparoscopic colorectal 
liver metastasis resection included 83 resections within a series of 133 liver 
resections95. The median operating time for laparoscopic resections was 210 
minutes (30-480 minutes), median blood loss 300ml (10-3000ml) and the 
median postoperative stay 4 days (1-15 days). Severe postoperative 
bleeding occurred in 5 patients (3.7%) requiring intensive care management 
or reoperation, overall serious complications occurred in 16 patients (13%).  
More recent studies including 100 patients undergoing consecutive 
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laparoscopic hepatectomies, within a series of 168 consecutive resections for 
CRLM, suggested that laparoscopic surgery is associated with shorter 
operative time, lower blood loss, lower major morbidity, and comparable 
long-term outcomes 96.  However this study had significant selection bias, 
and was not a true comparative study. 
1.5.3 Strategies to increase resectability 
Given the main limitation to the technical aspects of surgical resection is the 
preservation of an adequate future remnant liver a number of strategies have 
been developed to help address this issue. 
1.5.3.1 Ablation 
Ablation has become a widely used method of treating colorectal liver 
metastasis, with an estimated 2000 patients treated annually in the UK. This 
treatment aims to destroy metastases gaining local control in patients 
deemed surgically irresectable either due to insufficient FLR, or poor patient 
fitness97. It facilitates the combined resection and ablation approach to CRLM 
surgery98,99. Ablative therapies commonly employed include radiofrequency 
ablation (RFA)97, microwave ablation99 and irreversible electroporation 
(IRE)100.  These modalities all have specific uses and may be the method of 
choice in specific circumstances; IRE in particular is an attractive option for 
metastases in close proximity to major vascular or biliary structures100.  
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1.5.3.2 Portal vein embolization 
Portal vein embolization (PVE) induces atrophy of the liver to be resected 
and hypertrophy of the liver that will remain (i.e. increases the FLR) with the 
aim of avoiding PHLF. A meta-analysis has confirmed that this technique 
increases significantly the volume of the FLR101.  PVE appears to be safe, 
even when combined with conversion chemotherapy102. 
1.5.3.3 Two stage hepatectomy 
Two-stage hepatectomy is employed in patients where resection of all the 
metastases would leave insufficient functional liver, and where the 
metastases are distributed across both liver lobes. Two-stage hepatectomy 
involves a first stage of non-anatomical resection of metastases from the 
future remnant with PVE (or PV ligation during surgery) of the future liver to 
be resected. This is followed by a period of liver regeneration and a second 
stage resection.  
A systematic review included 459 patients in whom a two-stage resection 
was planned103.  Two-stage resection was completed in 76.6% (range 69-
92%) of patients who underwent first stage. Overall survival at 3 and 5 years 
was 59%, and 42% respectively.  The success of this technique relies on 
patients undergoing hepatic regeneration sufficient to allow a second stage, 
whilst maintaining their fitness, and not developing progressive disease. 
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1.5.3.4 ALPPS (Associating Liver Partition and Portal vein Ligation for 
Staged hepatectomy)  
A purported alternative to the two stage liver resection is the ALPPS 
procedure, which involves an in situ splitting of the liver with portal vein 
ligation followed by a formal hepatectomy at a median of 9 days104.   This has 
been reported to demonstrate a median increase in the future remnant liver 
of 71%.  This represents an exciting development in the field of liver surgery 
that may help to bring more patients to resection.   The long-term results of 
this technique have yet to be validated and the technique remains 
controversial and a subject of debate.  
1.5.3.5 Advanced hepatic reconstruction techniques  
Despite evolving definitions of resectability, there remain a group of patients 
in whom technical resectability is only possible with the use of advanced 
surgical techniques.  Typical cases might have metastases involving the 
hepatic inflow, the hepatic outflow, the inferior vena cava, or all three of these 
structures.  Techniques employed to achieve macroscopic resection in these 
cases have included portal vein resection and reconstruction, hepatic artery 
resection and reconstruction (or arterialisation of the portal vein as an 
alternative), total hepatic vascular exclusion, in situ hypothermic perfusion 
and ex vivo (bench) hepatic resection105-108.  These techniques are at the 
limits of what is currently feasible and are associated with significant 
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morbidity and mortality. Therefore these techniques should be reserved for 
carefully selected individuals with an otherwise poor prognosis.   
1.5.4 Perioperative morbidity and mortality  
In early hepatectomy series published in the 1980’s, in hospital mortality was 
in the order of 5%, despite a highly selective approach to patient selection109. 
This has progressively diminished despite more complex resections being 
undertaken in patients with more extensive disease54. Perioperative mortality 
reported in large series of patients undergoing resection of CRLM is now 
typically between 1-3%25,54,110,111.  Though the data reported from the 
author’s unit reports a mortality of 0.3%112. 
Unfortunately despite a near halving in perioperative mortality, in large series 
postoperative morbidity remains consistently high at around 41.6-45%25,54,113. 
With severe complications (Dindo-Clavien114 Grade 3 and above) occurring in 
14-29.7%25,54. 
Common causes of morbidity following hepatectomy include pulmonary 
complications (6.1-21.9%), cardiac complications (3-10%), biliary leak (4.8-
8.9%), peri-hepatic collections (2.9-7.0%), PHLF (2.6-6%), and wound 
infections (3.4-5.9%)25,54,115.  However there is wide variation in reporting of 
complications, which may in part be due to subjective interpretation 34.  For 
example in the case of a peri-hepatic abscess or bile leak, concurrent 
respiratory complication is common, though may not be included in morbidity 
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scores either due to a failure to identify it or exclusion based on the direct 
cause and effect relationship.  
1.5.4.1 Factors associated with perioperative morbidity and mortality 
Since the Dindo-Clavien114 classification allowed standardisation of the 
measurement of complications a number of studies have sought to elicit 
factors associated with poorer perioperative outcome, in the hope of better 
clarifying the population at risk of complications.  These can largely be 
considered as factors associated with an individual’s premorbid state, factors 
associated with the disease and prior treatments, and factors relating 
specifically to the intervention undertaken.  
1.5.4.1.1 Patient Variables 
Whilst there is debate about the relative impact of cardiopulmonary fitness on 
perioperative outcome, a number of other factors have been identified as 
being associated with increased perioperative risk including increasing age, 
impaired hepatic function, cirrhosis, hepatic steatosis, renal failure and 
medical comorbidity25,54,110,113,115-117. 
Given that we can only expect the number of older patients with increasing 
comorbidity to increase 5, and with the worldwide increasing rates of obesity, 
these associations pose a threat to future perioperative outcomes. This 
makes the aspiration of improving perioperative outcomes challenging to 
deliver.  
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1.5.4.1.2 Treatment related variables 
The only treatment related factor consistently identified, as being associated 
with an increased incidence of perioperative morbidity is the use of 
neoadjuvant chemotherapy. 57,118,119   
Repeat hepatectomy has been associated with increased bile leaks, but not 
overall morbidity and mortality though, given an association with longer 
operating time 120 and increased blood loss, 111,120 the absence of an 
association with increased complication may reflect the selective nature of 
patients considered for repeat hepatectomy.  
The consequences of the newer liver directed therapies including 
Transarterial Chemoembolization (TACE) with irinotecan eluting beads 
(DEBIRI) and Selective Internal Radiation Therapy (SIRT) on postoperative 
morbidity and mortality are not yet clear. 
1.5.4.1.3  Perioperative factors 
The perioperative factors associated with increased perioperative morbidity 
and mortality have been extensively studied. 25,54,111,118,121 The overarching 
theme of these studies suggest, as might be expected, that with increasing 
complexity and magnitude of surgery, there is an increase in perioperative 
morbidity and mortality.  The key factors identified as being associated with 
poorer perioperative outcome are summarised in Table 1-4 25,54,111,118,121. 
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Table 1-4 Intraoperative factors associated with poorer perioperative outcome 
Repeat hepatectomy 
Major hepatectomy 
Longer operating Time 
Increased use of Pringle manoeuvre  
Blood loss 
Transfusion 
Additional extrahepatic resection 
Vascular resection 
Bile duct resection 
Hepatico-jejunostomy construction 
Diaphragm resection 
 
1.5.5 Survival  
Overall survival for patients following hepatectomy for CRLM is reported 
between 36-58% with latter series tending to report better survival.  Survival 
to 10 years is between 23-25%, with this seen effectively as cure122,123.  
Identifying factors associated with either better or worse prognosis can aid 
treatment decisions, and allow a degree of individualised prognostication. 
1.5.5.1 Predictors of survival 
In a similar manner to perioperative outcomes factors associated with 
survival can be considered as patient factors, disease factors, and factors 
relating to the operative intervention.  A number of scoring systems have 
been developed to aid in the prediction of survival, 61,124,125 but changes in 
our understanding of disease biology, and better treatment mean that these 
are no longer as relevant in clinical practice.  
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1.5.5.1.1 Patient variables predictive of survival 
Whilst age has been consistently identified as a predictor of worse 
perioperative survival, the same cannot be said for overall survival61,110,111,117. 
Beyond the initial perioperative period, age does not have a significant effect 
on survival110.  
Factors suggested to be associated with poorer overall survival include 
patients with higher ASA scores 126, sarcopenia (significant loss of muscle 
mass) and fatty liver disease61,127,128.   Though the role of fatty liver disease 
and sarcopenia appear related, the mechanism by which they affect survival 
is unclear.  In a retrospective series, patients with fatty liver disease were 
more likely to have a lymph node positive primary tumour, higher CEA, more 
preoperative chemotherapy, larger metastases, and a positive hepatectomy 
resection margin128. However given that chemotherapy is often given to treat 
those with less-favourable patterns of disease, and is a known cause of fatty 
liver disease, establishing cause and effect is more challenging129.  
This relationship is further complicated as fatty liver disease also serves as a 
surrogate marker for other comorbid conditions such as diabetes. 
1.5.5.1.2  Tumour biology 
After the initial perioperative period the biggest cause of death in these 
patients is related to the disease recurrence.  This has been a major focus of 
research to establish disease related prognostication.  A number of factors 
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have been identified and are summarised in Table 1-5.  These factors often 
serve as surrogate markers of aggressive tumour biology, but even in these 
patients survival is achievable meaning further characterisation of tumour 
biology remains a research priority61,111,130-134. Better understanding of the 
disease should allow improvements in targeted treatment and overall 
survival.  
Table 1-5 Tumour related factors predicting poorer survival 
 
1.5.5.1.3 Perioperative factors 
In the perioperative management of patients with colorectal liver metastases 
factors have been identified that can affect long-term survival61,90,111,135,136.   
These include a positive margin in a resected specimen, intraoperative blood 
loss, use of transfusion, and the development of postoperative 
complications61,111,130,135,137. Methods to reduce complications could therefore 
have a significant effect on cancer survival.  
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Managing these patients outside an MDT environment also appears to 
negatively affect survival, possibly through inappropriate selection, delays to 
treatment and inappropriate use or failure to use additional therapies136. 
1.6 Enhanced recovery after surgery (ERAS)  
Given the impact of perioperative outcomes on both healthcare costs, and 
long term survival following cancer surgery, strategies to minimise the 
consequences of surgery have been developed.   
The seminal paper in the Lancet in 2003 from Kehlet paved the way for what 
would later be known as enhanced recover after surgery or ERAS 138.  This 
was further described in 2005 which set out the components felt to be key to 
a successful ERAS programme139.  
Since this time the use of ERAS has proliferated across surgical disciplines, 
such as colorectal surgery140-142, urological surgery143, and vascular 
surgery144, becoming the standard of care.  They utilise a multimodal 
management strategy to improve perioperative outcome, and have been 
shown to reduce complications, hospital length of stay and hospital costs. 145   
1.6.1 Components of ERAS 
The four main principals of ERAS are139,141: 
1. Optimised preoperative assessment 
2. Reducing the physical stress of surgery 
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3. Improved perioperative management 
4. Early mobilisation 
The individual components of a typical ERAS programme are shown in 
Figure 1-3139. Given the success of ERAS, they are now considered as a 
standard of care in colorectal surgery141.  
Figure 1-3 Components of an ERAS programme 139 
 
1.6.2 ERAS in Liver surgery 
Despite being a standard of care in colorectal surgery, the evidence for the 
use of ERAS in liver surgery is more limited with just six small published 
series identified in a recent systematic review145. Since this systematic review 
only two other studies have been published.  One, the only randomised trial 
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of ERAS versus standard care in liver surgery, included 160 patients (80 in 
either arm) 146.  This study demonstrated that ERAS was associated with 
shorter hospital stay (7 days versus 8 days p-0.018), and lower overall 
complications (30% vs. 47% p-0.03).  There was no difference in the 
incidence of severe complications (Dindo-Clavien 114 grade III-IV).   However 
this study was limited by stringent exclusion criteria, which included any 
resection greater than a hemihepatectomy, any hepatectomy with 
concomitant  bile duct resection, repeat hepatectomy, patients greater than 
65 years of age, any patient with “severe comorbidity”, and any patient with 
bilobar disease.  .  The applicability of this study to typical patients with 
CRLM who are typically over 65, frequently have significant comorbidity, and 
often have bilobar disease being treated with multiple hepatectomies is 
questionable. The applicability of this to our study population is further 
undermined given its concentration on primary liver cancer.  
The other recent publication examining the role of ERAS in hepatectomy was 
a cohort study including 100 consecutives patients undergoing 
hepatectomy147.  This demonstrated that outcomes for patients managed 
within an ERAS programme were good, with 25% morbidity, and a median 
length of stay of 5 and 6 days for minor and major resections respectively.  
There was no postoperative mortality.   
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1.6.3 ERAS for patients undergoing hepatectomy for CRLM  
The largest published series of ERAS in patients undergoing liver resection 
for colorectal metastases was completed during the course of this thesis at 
Aintree University Hospital112. This study included consecutive patients 
undergoing hepatectomy for CRLM between February 2008 and September 
2012. Cardiopulmonary exercise testing, which is not considered part of a 
standard ERAS programme, was introduced on 1st October 2009.  Initially 
this was selective, and expanded to all patients from the 1st October 2011.  
This study demonstrated that ERAS was associated with short hospital 
length of stay (median 6 days), low overall morbidity (38.2%), and low severe 
complications (11%).  Only 64.5% of patients were admitted to level 2 care 
postoperatively, and median length of stay in these patients was 1 day.   
There was only one in hospital death within the study representing a mortality 
of just 0.3%, much lower that other large series 148. 
The findings from this study validate previous studies suggesting positive 
outcomes from ERAS145-147,149.   ERAS should now been seen as a standard 
of care following hepatectomy.  
1.6.4 Evolution of ERAS 
ERAS programmes are often seen as fixed entities with a defined 
management protocol, whereas in reality these programmes are fluid entities 
that mature as staff and patient awareness increases, as well as reflecting 
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developing local and national needs.  Given the benefits of ERAS post 
hepatectomy the Aintree study sought to evaluate how outcomes changed as 
the ERAS programme matured112. 
The study cohort was divided into early and later cohorts that were 
compared.  This demonstrated that as programmes mature, the length of 
stay reduced (p<0.01).  This reduction in hospitalisation was mainly due to a 
reduction in patients requiring prolonged admission (Figure 1-4)112. The 
Kaplan-Meier curve (Figure 1-4) demonstrated that beyond 6 days, the length 
of stay curves separate. The probability of staying in hospital beyond 10 days 
was 25% for the early cohort compared to 7% for the latter cohort. 
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Figure 1-4 Kaplan Meir showing length of stay following hepatectomy in an ERAS 
programme  
 
This is interesting as both overall and serious morbidity was not significantly 
different across the cohorts.  This suggests that as ERAS programmes 
mature, there is a progressive minimisation of the consequences of 
complications on the length of hospitalisation.  Given that complications are 
associated with poorer survival it would be of interest to see whether this 
progressive reduction in the impact of complications, led to changes in the 
impact of complications on survival.  
Over this time period there was also a progressive reduction in the use of 
critical care admission (75.5% early cohort vs. 54.7% in the latter 
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cohort)(p<0.0001) 112.    This reduction was thought to represent a growing 
confidence in the combination of anaesthetic review and CPET to risk stratify 
patients.  The success of this stratification is further underlined by the 
absence of any patient triaged to level 1 care postoperatively subsequently 
requiring emergency critical care admission. 
Taken in conjunction with other published studies, the findings of this work 
demonstrate that ERAS is feasible, and that the benefits accrue with time112. 
The addition of CPET in the risk stratification, has likely contributed to the 
excellent perioperative outcomes, particularly in older patients where defining 
risk is harder14-19.  
1.7 Rehabilitation and exercise therapy 
Prior to the development of formalised ERAS, many have studied methods of 
improving recovery from surgical cancer treatment.  Exercise has been a key 
area of interest for such studies, often delivered in as combinations of 
strength and cardiovascular training.   
Specifically following cancer treatment exercise therapy has been used as 
part of survivorship programmes and has been shown to have a number of 
beneficial effects.  Exercise is now an established method of improving 
recovery from surgery, and other cancer treatments150-154. Other benefits 
include improved strength, improved physical aerobic capacity, reduced 
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depression, and improved quality of life150.   It is also an established 
treatment for post cancer fatigue syndrome150,152,155-157.   
1.7.1 Exercise in metastatic colorectal cancer 
Whilst there are accepted benefits in cancer survivors, a recent systematic 
review identified only 8 studies investigating the role of exercise therapy in 
metastatic cancer, and of these only 3 were randomised controlled trials158.   
The metastatic disease in these studies was of varied origin, and only 3 trials 
included only patients with metastatic disease (Breast 2 Mixed 1). The review 
suggested that adherence was 75-85% and that the benefits of an exercise 
programme were similar to that in other populations with improved quality of 
life being the main outcome.158. There has been no study of exercise 
intervention in patients with CRLM.   
1.7.2 Delivering post treatment exercise therapy 
The majority of cancer survivors are inactive, which is surprising given the 
purported benefits of exercise therapy154, however this does emphasise  the 
difficulties in delivering exercise therapy to this group.  A number of barriers 
to increasing activity have been identified and can be summarised as 
physical, physiological, and institutional.  
1.7.2.1 Physical barriers to exercise therapy 
In the post-surgical setting many patients do not feel physically able to 
exercise, as a result of the cancer treatments they have endured.  This 
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includes pain from surgical interventions and the consequences of intensive 
treatments such as radiotherapy, and chemotherapy153,154.    Inactivity during 
cancer treatment is also common and leads to physical deconditioning.  
Physical consequences of cancer therapy are summarised by the American 
college of sports medicine (Table 1-6)153. 
Table 1-6 Physical consequences of cancer therapy 
 
1.7.2.2 Physiological barriers to exercise therapy 
Psychological disturbance is present in up to 50% of cancer patients, and in 
colorectal cancer nearly a quarter report depressive symptoms159. Symptoms 
deteriorate over the course of cancer treatment160.  Consequently following 
treatment patients are more likely to be depressed, anxious and lacking in 
motivation. This represents a significant barrier to the introduction of exercise 
therapy.  
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A cancer diagnosis and treatment is also associated with the development of 
cancer related fatigue syndrome.  This is a common complication of cancer 
diagnosis and treatment affecting up to 70% of patients161.   The mechanism 
is poorly understood, but is probably multifactorial, including both physical 
and psychological components161.  It results in disabling fatigue that prevents 
patients returning to pre-diagnosis levels of activity.  Aerobic exercise has 
been established as a treatment for this condition, but the challenges of 
getting patients suffering cancer related fatigue to take up exercise are 
acknowledged161. 
1.7.2.3 Institutional barriers to exercise therapy 
Institutions providing cancer care predominantly focus on the delivery of safe 
and effective care.  Care is concentrated in the immediate pre-treatment 
period, during treatment and in the early follow-up time period.  Beyond this 
follow-up is of variable frequency but commonly diminishing.   This lower 
visibility of the patient group post treatment, in conjunction with a lower 
institutional priority for exercise therapy, is suggested as one cause 
underlying the low levels of activity in cancer survivors154. 
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1.8 Prehabilitation 
Prehabilitation is defined as the process of enhancing the functional capacity 
of the individual to enable him or her to withstand a stressful event 162.  Given 
the benefits of ERAS, and post-treatment exercise therapy, pre-treatment 
optimisation and exercise therapy represents an attractive prospect that 
could augment the work of ERAS, and minimise some of the difficulties of 
post treatment rehabilitation. 
Prehabilitation occurs before the development of many of the physical and 
psychological barriers to exercise therapy, which may develop with the 
initiation of cancer treatment.  This should serve to increase the pool of 
patients able to participate, and could lead to reductions in the development 
of incapacitating physical consequences. 
Prehabilitation could reduce the morbidity and mortality associated with 
treatment as accrue the benefits to physical and psychological functioning, 
that prehabilitation could theoretically deliver. 
Exercise prior to treatment gives patients a defined goal that could translate 
into higher adherence and completion. It also serves to make the therapy 
visible to the clinicians involved in providing the cancer treatment, raising the 
awareness of exercise therapy, thus overcoming institutional barriers to 
exercise therapy.   
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1.8.1 Prehabilitation challenges 
Despite the attractions of prehabilitation, there are a number of unique 
problems that must be addressed when developing prehabilitation 
programmes. 
1.8.1.1 Defining fitness 
One of the challenges to improving “fitness” is adequately defining what is 
meant by this concept.  Traditionally employed measures of patient fitness 
such as ASA, performance status and questionnaires, lack the capacity to 
differentiate adequately, and are subjective.  Assessment of fitness before 
and after a prehabilitation programme with such measures risks not detecting 
meaningful changes, or detecting changes related to attitude shift rather than 
a true change in fitness. 
The relatively recent adoption of cardiopulmonary exercise testing has 
allowed accurate measurement and quantification of fitness in a reliable and 
repeatable fashion29., and facilitates the adoption of prehabilitation 
programmes where fitness can be a measured outcome. 
1.8.1.2 Patient group 
The majority of cancer sufferers are sedentary154.   Patients with CRLM are 
often elderly (age >70), with associated comorbidities including heart 
disease, respiratory disease, and arthritic conditions5.  This is in addition to 
metastatic colorectal cancer, where increasingly the metastatic disease is 
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detected at presentation, meaning that patients undergoing prehabilitation 
may have symptomatic primary tumours163.  
This poses a number of challenges for prehabilitation, and any programme 
must be appropriate for this challenging group of patients.  
1.8.1.3 Time duration 
One of the biggest challenges of any prehabilitation programme is the time 
constraints imposed by their cancer diagnosis.  Timely treatment is essential 
to minimise the risk of progression, and the psychological input of having a 
cancer insitu. Current UK targets impose a 62-day time limit from the point of 
referral to the initiation of treatment, and 31 days from the decision to treat to 
the delivery of treatment.  Given that during this time the establishment of the 
diagnosis must take place this leaves very little time to deliver a 
prehabilitation programme, and certainly more than 4-weeks is probably 
unachievable. 
In addition to this, most patients being considered for surgical intervention for 
CRLM have a number of preoperative appointments and scans which will all 
detract from their time to partake in prehabilitation.  So any prehabilitation 
programme must not be of a frequency that is likely to lead to low adherence. 
1.8.2 Prehabilitation in practice 
The majority of work on prehabilitation has been concentrated on joint 
replacement and orthopaedic surgery164,165.  Limited prehabilitation has been 
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undertaken prior to aortic aneurysm repair, lung resection, colorectal 
resection and resection of primary liver malignancy.  The results are 
summarised below. 
1.8.2.1 Prior to lung resection 
There are just two published case series of prehabilitation before lung 
resection166,167.  The earlier study includes 19 patients recruited into an 
interventional study, where preoperative supervised exercise therapy was 
given for a median of 60 days 167. Of these, 17 patients completed the 
preoperative exercise therapy, with adherence of 88%. Only 12 completed 
the pre-surgical assessment of CPET and quality of life measures.  Two 
patients died postoperatively and one was excluded following major 
complications.  Only 9 of the original 19 patients completed prehabilitation 
and subsequent post-surgical assessment. Peak oxygen uptake (VO2peak) 
increased preoperatively in all patients, with correlation between improving 
fitness and improved pre-surgical fatigue scores.  
The second exploratory study randomized 24 patients to either prehabilitation 
with strength and endurance training or to a chest physiotherapy programme 
prior to lung resection.  They found a significant reduction in pulmonary 
complications and hospital length of stay in patients undergoing 
prehabilitation. 166 
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1.8.2.2 Prior to aortic aneurysm surgery  
A randomised study examined the effect of a 6 week supervised exercise 
programme of patients’ fitness prior to aortic aneurysm surgery168.    This 
study recruited 30 patients (20 intervention vs. 10 control), with 17 
completing the exercise intervention, and 8 completing the control arm.  Of 
note, one of the exercise participants suffered a cardiac arrest during the 7th 
exercise intervention. Two of the other withdrawals were for unrelated 
conditions, and the two withdrawals from the control arm were unexplained.  
Patients in the intervention group had a median increase in fitness of 10% (p-
0.0007), with a suggested number needed to treat to produce clinically 
significant improvements of 4.4 patients.  This study did not provide data on 
post-surgical outcome. 
More recently 20 patients awaiting aortic aneurysm surgery partook in a 
prehabilitation study.  When comparing these patients to baseline, they found 
post prehabilitation improvements in VO2peak (18.2 to 19.9 ml.kg-1.min-1), and 
VO2 at AT(12.2 to 14.4 ml.kg-1.min-1) 169. 
Both of these studies were limited by their small size and stopped short of 
recommending adoption of prehabilitation without further randomized 
evidence. 168,169. 
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1.8.2.3 Prior to colorectal cancer surgery 
In colorectal cancer surgery there are 3 reported randomised trials, and one 
case control series162,170,171.  The largest of these trials recruited 112 patients 
to either a home based cycling regime (58 patients), or a sham walking 
breathing arm (54 patients)162.  There were 18 dropouts in the preoperative 
period, where the median exercise programme was 38 days. In this study 
they failed to demonstrate any benefit of exercise prehabilitation, with the 
walking group having better performance in the final 6 minute walk test prior 
to surgery, and the exercise arm actually deteriorating over the study period.  
The prime reason to explain this was the poor compliance with exercise 
intervention.  This group went on to design a new prehabilitation programme 
combining exercise with cognitive therapy and nutritional support.  This has 
been shown to improve fitness in the managed cohort, but is yet to be 
validated by a randomised trial. 170 
A small-randomised study (14 intervention vs. 7 control) used a 4-week 
prehabilitation programme of constant level cycling 7 days per week 171. 
There were two withdrawals from the study arm due to fatigue, and self-
reported adherence to the programme in the remaining was 74%.  This study 
failed to demonstrate significant differences in fitness in the prehabilitation 
arm, but it is likely this is an underpowered study given its size. 
More recently two further studies have investigated prehabilitation in 
colorectal cancer patients.  The first investigated the use of exercise therapy 
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in patients following neoadjuvant chemo-radiotherapy for rectal cancer, in the 
window before operative intervention 172.  This non-randomized study 
compared patients electing to undergo prehabilitation with those declining to 
participate and measured CPET values at baseline and then 3 weekly from 
the completion of chemo-radiotherapy to surgery.  The two groups were not 
comparable in terms of age, ASA status and CR-POSSUM predicted 
mortality.  The intervention group were younger, with lower ASA status, and 
lower predicted morbidity and mortality.  However, the groups had 
comparable VO2peak, and VO2 at AT. Both groups had significant reductions 
in both these CPET values following chemo-radiotherapy, however the group 
undergoing prehabilitation recovered their VO2peak and VO2 at AT to greater 
than baseline before surgery.  Similarly to the vascular trials further larger 
studies have been recommended. 
A further randomised study investigated the benefits of prehabilitation over 
rehabilitation in isolation in 77 patients prior to colorectal resection 173.  This 
study did not utilise CPET, but used the 6-minute walk test as an alternative, 
and demonstrated that patients not undergoing prehabilitation had a 
deteriorating 6-minute walk capacity prior to surgery. This lower capacity 
persisted through the postoperative period.  At the completion of 8 weeks 
rehabilitation the prehabilitation group maintained a greater 6-minute walk 
capacity.  They concluded that prehabilitation offered benefits above that of 
rehabilitation alone 173. 
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Currently recruiting is the PREPARE-ABC trial, an NIHR funded trial174.  This 
trail seeks to establish the impacts of either a home or hospital supervised 
exercise program on perioperative morbidity and mortality in patients 
undergoing colorectal cancer surgery. 
1.8.2.4 Prior to liver resection 
The only prehabilitation study in liver surgery focused on patients with 
chronic liver disease undergoing hepatectomy for hepatocellular 
carcinoma159.  This study recruited 51 patients (26 prehabilitation, 25 control) 
to a combined study of up 1 month’s prehabilitation with 6 months 
rehabilitative exercise therapy. Exercise variables were not reported 
preoperatively, and there was no difference in the perioperative outcomes, 
with morbidity very low at 10% overall, and no mortality.  At 6 months 
postoperatively patients in the intervention arm had higher VO2 at the AT and 
peak, lower fatty mass, higher platelet levels, and lower insulin resistance.  
Whilst the effect of prehabilitation on perioperative outcome was 
disappointing, the decrease in insulin resistance (measured using the HOMA-
IR method of assessing insulin resistance175) suggests a beneficial effect of 
exercise on glucose metabolism, possibly via modulation of hepatic 
gluconeogenesis.  
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1.9 Hepatic function and fitness 
Hepatic gluconeogenesis is responsible for meeting the majority of the 
energy requirements of the human body. Hepatic gluconeogenesis utilises 
either hepatic glycogen stores, or lactate produced through anaerobic tissue 
respiration to produce glucose into the circulation (Figure 1-5).  Only the liver 
and kidney are capable of producing glucose into the circulation, with the 
kidney only contributing in times of significant starvation176.  After 40 hours of 
fasting, hepatic gluconeogenesis from lactate (and other substrates) is 
responsible for 90% of the body’s energy requirements177.  
There is limited work investigating links between gluconeogenic capacity and 
exercise performance178.  This is in part due to the inaccessibility of human 
liver tissue, and the challenges of measuring gluconeogenesis.  An adequate 
model of hepatic functioning including gluconeogenesis could also aid the 
development of strategies to define a more accurate FLR.  
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Figure 1-5 Cori cycle 
 
1.9.1 Gluconeogenesis in animal studies 
The link between hepatic gluconeogenesis and endurance capacity was 
demonstrated in 1986 by John Alder179.   In this study trained and untrained 
rats had gluconeogenesis inhibited by 3-mercaptopicolinic acid (3-MPA), 
which led to a reduction in endurance capacity by 26% in trained animals and 
32% in untrained animals.  This was accompanied by a greater reduction in 
glycogen stores in the quadriceps muscles, suggesting that inhibition of 
hepatic gluconeogenesis led to faster reduction in muscle energy stores.  
Podolin confirmed this in 1996 by demonstrating that 3-MPA led to an 80% 
reduction in rats endurance time 180.  It was also shown that older rats had 
less capacity for hepatic gluconeogenesis. The original hypothesis that this 
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could be due to dropping levels of phosphoenolpyruvate carboxylkinase 
(PEP-CK) was not confirmed.   
In 2008, Hanson took a different approach by genetically manipulating the 
gluconeogenic pathway to study the effects. Introduction of the cDNA for the 
enzyme for α-skeletal actin gene promoter into a mice germ line led to the 
development of mice with a 100 fold increase in skeletal muscle PEP-CK.  
These mice had a 25-fold increase in endurance time, greater longevity, but 
were extremely aggressive181.  This suggested that greater capacity for 
gluconeogenesis either in the liver or muscle contributes to greater 
endurance time, or fitness. 
1.9.2 Gluconeogenesis in human studies 
In human studies measuring gluconeogenic capacity in a similar way to 
animal studies has not been possible due to the risks associated with 
accessing hepatic tissue182.  Thus studies have focussed on measuring in 
vivo levels of hepatic gluconeogenesis at rest, and during exercise using 
radiolabelled glucose studies178,182,183. 
These studies have demonstrated that after 4 hours of moderate exercise 
hepatic gluconeogenesis contributes in the order of 60% of overall glucose 
production, with the rest being produced through glycogen depletion184.  In 
the fasted state this increases progressively as glycogen stores are depleted. 
Negative feedback mechanisms serve to inhibit the tissue utilisation of 
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glucose and overall glucose production, prolonging the glycogen stores176. In 
the normal physiological state glycogen stores can be preserved up until 60 
hours, though beyond this hepatic gluconeogenesis produces almost all the 
energy utilised by the body.  There are no studies of the rate of glycogen 
depletion in the post-surgical state where systemic energy requirements 
increased, but it is likely that hepatic gluconeogenesis will be of increasing 
importance 185. 
The effect of fitness and exercise has been investigated, with endurance 
training associated with a two-fold increase in resting gluconeogenesis and 
threefold increase in gluconeogenesis during exercise183.   
The current conclusion of these studies is that hepatic gluconeogenesis plays 
an integral part in exercise178,183,186,187. 
1.9.3 Postsurgical outcomes 
It has been well established that severe liver disease such as cirrhosis or 
acute hepatitis is associated with poorer surgical outcomes188. Acute 
hepatitis is considered a contraindication to elective surgery188. Surgical 
procedures in patients with cirrhosis have much higher morbidity and 
mortality189.  Early post cholecystectomy studies demonstrated mortality of 
11-25% in patients with significant cirrhosis in contrast to 1.1% in those 
cirrhosis without impaired synthetic hepatic function 190. More recent studies 
have consistently demonstrated mortality is elevated in patients with cirrhosis 
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undergoing major abdominal surgery, with the severity of the cirrhosis 
correlating with the risk of mortality189,191,192. 
Reasons suggested for this trend are a hyper-dynamic circulation, a 
predisposition to anaesthetic related hypoxia, increased bleeding risk, 
increased susceptibility to bacterial infections, altered drug metabolism, poor 
wound healing, and pre-existing malnutrition188,189,193. 
Once outward clinical signs of liver disease are established the classification 
of the severity of the liver disease, as assessed by either the MELD or Child-
Pugh score, directly correlates with the operative risk. 188,193  
Whether better hepatic function in a patient with no outward signs of liver 
disease correlates to lower risk has not been tested.  This has primarily been 
related to the inaccessibility of liver tissue and the challenges of developing a 
reliable model of hepatic function. 
1.10 Ex vivo models of hepatic function 
The gold standard for measurement of hepatic functioning and toxicology is 
in vivo testing.  This, however, has significant challenges including animal 
welfare concerns, time constraints, cost, and most importantly the potential 
lack of applicability of animal studies to human treatment 194.  These 
concerns were highlighted in the National Research Council report in 2007 
195.  A number of in vitro and ex vivo models of hepatic functioning have been 
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developed to help deal with the difficulties of in vivo models.  All of these 
models have both advantages and disadvantages. 
1.10.1 Immortalized Hepatic Cell lines 
There are a number of immortalized liver derived cell lines, with the more 
recently developed hepatoma derived cell lines retaining expression of many 
liver–specific functions.  The expression of liver specific functions is lower 
than that seen in primary hepatocytes, and the applicability of these cell lines 
for modelling hepatic function is limited further by the absence of interactions 
with other hepatic cell types 196. 
1.10.2 Primary Hepatocytes 
Often seen as the gold standard for in vitro testing they can maintain 
functional activities in culture for up to 72 hours.  There is a basic assumption 
that single cells of hepatocytes will behave in a similar manner to 
hepatocytes with the organ.  Evidence has demonstrated that cells under 
traditional hepatocyte culture conditions undergo a series of morphological, 
gene expression and functional activity changes196.   There have been a 
number of approaches to preserve hepatic function with some success, but 
the results have varied between laboratories.   
These variations are, in part, attributable to variation and challenges in the 
isolation of hepatocytes.   The ideal methodology is yet to be established and 
standardised across laboratories 197.  
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Primary human hepatocytes have a limited viability, thus meaning many 
laboratories rely on cryopreserved human hepatocytes for studies.  These 
are purchased at considerable cost, and the quality of cells is variable on 
thawing. 
1.10.3 3D culture systems 
To help overcome the limited viability and loss of functionality demonstrated 
by primary human hepatocytes, 3D culture systems have been developed.  
This rapidly developing field involves the attempted artificial recreation of the 
complex micro-environment of the liver.  3D culture systems have evolved 
greatly over the last decade from formed hepatocyte spheroids to more 
advanced systems involving packed bed reactors and perfusion flow 197,198.  
These complex systems represent the forefront of hepatocytes culture for 
hepatotoxicity studies, but all of these systems are complex to construct and 
maintain 197. 
1.10.4 Stem Cells 
As previously mentioned supply of human hepatocytes is limited and labour 
intensive.  This, in combination with the relatively short viability, has led to the 
desire to develop hepatocytes from stem cells.  This has the aim of producing 
a reliable, robust and reproducible source of human hepatocytes for 
laboratory study.  There has been some success in developing hepatocyte-
like cells from human embryonic cells using supplemental media 199,200. 
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Unfortunately, all differentiation protocols lead to highly variable functionality 
within the cell population developed, and cells lose functionality in a similar 
manner to isolated hepatocytes197.  These cells are also limited in a similar 
manner to primary hepatocytes, in the context of measuring hepatic function. 
1.10.5 Liver slices 
Slices of hepatic tissue, and the function of such slices have been studied for 
nearly 90 years201.  In particular, the technique was utilised in the 1960’s and 
1970’s by a collection of groups including Hans Adolf Krebs to investigate 
carbohydrate metabolism within the liver201-204.  The technique utilizes slices 
of hepatic tissue in its entirety and has the advantages of containing all the 
cell types contained in vivo within the normal tissue structure197.  
One of the early limitations of hepatic slices was the variability of slice 
thickness and the challenge of producing slices thick enough to prevent too 
much structural damage to the hepatic cells (shearing forces) and thin 
enough to prevent early central necrosis within the cells from hypoxia.  This 
difficulty was largely overcome with the development of the Krumdieck 
Precision Liver Slicer205.  This began the modern era of precision cut liver 
slices.  
Precision cut liver slices (PCLS) revolutionised the study of liver physiology 
and function. Whilst the majority of hepatic functions are derived from the 
hepatocytes, which make up around 80% of hepatic volume, their function is 
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known to be highly dependent on the communications with other cells within 
the liver. Thus PCLS are particularly useful in allowing study of hepatocytes 
within a complete liver model58.    
Whilst the liver slices model looks an attractive model of studying human 
hepatic function, there are a number of drawbacks.  In a similar manner to 
the collation of human hepatocytes, it is relatively labour intensive. 
The major limitation of slices remains the relative inaccessibility of human 
liver tissue.  The majority of studies conducted using human liver slices utilise 
liver rejected on a quality basis for transplant.  This by its very nature 
represents liver deemed to be of poor quality either due to disease, or 
problems with ischaemic time. Slicing has benefits over primary hepatocyte 
isolation in that cores of tissue can be taken from smaller liver samples, 
consequently making it easier to obtain when patients are undergoing 
resection 206.  This in itself presents further challenges particularly in 
minimising the time from resection to slicing and incubation, and optimising 
the technique.  
Development of hepatic slicing as a viable model of hepatic functioning could 
allow, investigation of the links between fitness and hepatic functioning, 
better prediction of PHLF, and tailoring of perioperative treatment for the 
increasingly comorbid patients undergoing CRLM treatment.  
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Chapter 2: Aims and objectives 
To further improve the care of patients undergoing surgical treatment of 
colorectal cancer liver metastases this research project has focused on the 
improvement of preoperative fitness, and the development of a viable in vitro 
model of hepatic function, to allow greater study of the effects of exercise on 
hepatic function. 
2.1.1 Aim One 
The first aim of the research programme is to develop an exercise 
programme that would be acceptable to the patient population, and 
deliverable in a time frame consistent with current treatment pathways. 
2.1.2 Aim Two 
Once this fitness programme has been developed this needs to be validated 
in the patient population to demonstrate that it is feasible to make a clinically 
relevant difference in patient fitness, within an acceptable time frame when 
patients are undergoing preoperative treatment and assessment. 
2.1.3 Aim Three 
Alongside this research area I intend to develop and a model of human 
hepatic function utilising PCLS.  This should allow greater study of hepatic 
function and drug metabolism, opening doors to research areas and further 
improvement in the outcomes of patients treated for CRLM.  
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Chapter 3: Prehabilitation programme design 
and validation 
3.1 Introduction 
Designing a prehabilitation programme suitable for patients prior to major 
cancer surgery presents a number of challenges, and there is a paucity of 
literature. Supervised exercise programmes have delivered improvements in 
CPET variables in patients prior to aortic aneurysm 168,169 and lung cancer 
surgery 207. These used exercise programmes of 6 weeks or more, which is 
unlikely to be suitable for most major cancer pathways. Two randomised 
trials of prehabilitation before colorectal surgery failed to demonstrate 
significant improvements in CPET variables with 4 week home based 
programmes 162,171. This may have related to the adherence, and the home 
based nature of the intervention.  
A cancer diagnosis is associated with fatigue and diminished physical 
capacity 208. The cause is poorly understood but contributing factors include 
prior surgery, chemotherapy, direct cancer effects, and the psychosocial 
effects of a cancer diagnosis 209. Exercise has been shown to be beneficial in 
the management of cancer related fatigue, can improve cardiovascular 
fitness, is associated with better quality of life and improved overall survival 
following a cancer diagnosis 150,154,210,211. Despite this there is a prevalence of 
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inactivity among both patients and survivors following a cancer diagnosis, 
meaning any prehabilitation programme must be suitable for a largely 
sedentary population 154,210,211.  
Given these constraints the ideal prehabilitation programme prior to a major 
cancer operation is one that is suitable for the sedentary patient, who is likely 
to elderly.  This is particularly pertinent given that even in individuals 
volunteering to undertake exercise intervention studies, typical adherence is 
in the order of 74-86%, with a dropout rate in the order of 20%171,212-214.  Any 
prehabilitation programme should yield clinically significant improvements in 
fitness within a time period that would be acceptable for a preoperative 
cancer pathway.   It should be easy to deliver in a cost efficient manner.  
When examining the literature at the outset of this research it was felt that 
there was not a suitable validated exercise programme in use, and 
consequently the first task of this research was to design and validate such a 
programme. 
3.2 Aim 
The aim of this study was to design a prehabilitation exercise programme 
suitable for cancer patients, by demonstration of its efficacy in the healthy 
population.  
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3.3 Methods 
The study was conducted with local research approval (11/H1005/3).  All 
volunteer subjects gave informed consent before commencing programme. 
3.3.1 Exercise programme 
Given the success of hospital-based programmes and the failure of the 
home-based programmes in the preoperative setting, a hospital-based 
programme was used.   Cycling was chosen as a modality most likely to be 
well tolerated by the patient group.  The frequency of exercise sessions was 
set at three times per week.  This was to balance the reduction in weeks 
training from prior studies, where frequency was less, whilst trying not to be 
so onerous as to discourage patients.  
3.3.2 Design of exercise programme 
The programme was designed within the exercise laboratory, using two 
individuals towards opposite ends of the fitness spectrum.  It was designed to 
meet specific criteria, based on American College of Sports Medicine 
recommendations 215. 
• An interval training exercise programme 
• An exercise programme of an average intensity in excess of 60% 
VO2peak 
• A peak intensity of a VO2 of around 90% of VO2 peak  
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The relative oxygen uptake at the anaerobic threshold (AT) was used to tailor 
the training programme to the individual. This variable is identifiable, 
independent of volition, and has been shown to correlate with both 
endurance capacity and perioperative outcome 40,43,45.  
The length of the severe intensity component of the exercise programme 
increased gradually over the 4-week period to account for improving fitness, 
with consequent reduction in the light intensity sections. Two light sessions 
were included at the end of the first and last week, to allow recovery. These 
involved 3 bouts of 15 minutes cycling at light intensity.  The design of the 
exercise programme was based on just one cardiopulmonary exercise test. 
The entire programme is summarised in tables 3-1 and 3-2. 
Table 3-1 Overall exercise programme structure  
 
 
 
! Duration! Wattage!
(as!a!percentage!of!workload!
achieved!at!anaerobic!threshold)!
Warm;up! 7!minutes! 50%!
Interval!
session!
30!minutes!
(6!x!5minute!cycles)!
High!intensity!–!120%!
Recovery!intensity!–!50%!
Recovery! 3!minutes! 60%!
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Table 3-2 Length of interval intensities 
 
3.3.1 Delivery of exercise programme 
The programme was delivered using an Optibike cycle ergometer (Ergoline, 
Bitz Germany).  The ergometer utilises cards, which were programed at the 
initiation of the exercise programme. 
Subjects sat upon the Optibike, and it was adjusted for comfort.  They 
pedalled at 55-65 rpm for the duration of the exercise programme, with the 
resistance adjusting automatically as per the described programme. 
3.4 Outcome variables  
The aim was to achieve an increase of 1.5ml/kg/min in the Vo2 at AT ml.kg-
1.min-1.  This was deemed clinically significant based on previous work in 
patients undergoing hepatobiliary surgery (our target population) 34,43,49.  
Based on previous work34 such an improvement in our patient population 
! Duration! Wattage!
(as!a!percentage!of!workload!
achieved!at!anaerobic!threshold)!
Warm;up! 7!minutes! 50%!
Interval!
session!
30!minutes!
(6!x!5minute!cycles)!
High!intensity!–!120%!
Recovery!intensity!–!50%!
Recovery! 3!minutes! 60%!
 
 
 
 
!
Length!of!high!intensity!
portion!of!interval!!
(seconds)!
Length!of!recovery!
portion!of!interval!
(seconds)!
Session!1+2! 120! 180!
Session!4+5! 130! 170!
Session!6+7! 140! 160!
Session!8+9! 150! 150!
Session!10+11! 160! 140!
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would potentially transfer 30% towards routine ward care following surgery, 
as opposed to automatic critical care admission.  
Secondary endpoints included other CPET variables identified as potentially 
predictive of perioperative outcome 216,217. 
3.4.1 Assessment of fitness 
All candidates underwent fitness assessment using CPET performed in a 
similar manner to our preoperative CPET programme, as discussed below34.   
3.4.2 CPET Testing 
3.4.2.1 CPET equipment 
CPET was conducted using an electromagnetically braked cycle ergometer 
(Ergoline 2000). A flow sensor (Geratherm Respiratory GmbH) was used to 
measure differences in flow stream pressures, which allowed a gas analyser 
to assess concentrations of O2 and CO2.  The analysis was conducted using 
computer software (Blue Cherry version 1.1.4.0 – Geratherm Respiratory 
GmbH). Ambient temperature, pressure and humidity were recorded in real 
time (Ambi Stick - Geratherm Respiratory GmbH) and used within the 
computer software to aid in analysis.  
The flow sensor was calibrated for flow (l/s) with a standard 3L syringe prior 
to each test.  Two point gas calibrations for O2 and CO2, were also performed 
prior to each test, using standard, gravimetrically weighed, bottled calibration 
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gas of know concentrations (BOC gases). A typical CPET set-up is shown in 
figure 3-1.  
Figure 3-1 Standard CPET setup 
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3.4.2.2 CPET Contraindications  
Recommendations by CPET followed the American Thoracic Society/ 
American College of Chest Physicians recommendations 218  and by Jones 
and colleagues219 were followed. All subjects were assessed for CPET 
contraindications (Table 3-3)218. 
Table 3-3 Contraindications to CPET 
 
 
Absolute Contraindications Relative Contraindications 
Acute myocardial infarction Left main coronary stenosis 
Unstable angina Moderate stenotic valvular heart disease 
Uncontrolled arrhythmias causing 
symptoms or haemodynamic 
compromise 
Severe untreated arterial hypertension at 
rest (systolic > 200mmHg, 120mm Hg 
diastolic) 
Syncope Tachyarrhythmia or brady-arrhythmia 
Active endocarditis Hypertrophic cardiomyopathy 
Acute myocarditis or pericarditis Significant pulmonary hypertension 
Uncontrolled heart failure Advanced or complicated pregnancy 
Thrombosis of lower extremity Electrolyte abnormalities 
Suspected dissecting aneurysm  
Uncontrolled asthma  
Pulmonary oedema  
Room air desaturation at rest <85% if no 
known lung pathologies 
 
Respiratory failure  
Acute non-cardiopulmonary disorder 
that may affect exercise performance  
 
Mental impairment leading to inability 
to co-operate 
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3.4.2.3 CPET conduct 
Patient demographics including name, date of birth, hospital identification, 
study number, gender, height (cms), and weight (kg) were entered into the 
software. Electrocardiography electrodes were placed in 12-lead positions 
and attached to the ECG analyser (AMEDTEC).  
The ergometer position was adjusted according to patient preference.  
An airtight seal around the facemask was achieved. A non-invasive blood 
pressure (BP) cuff was fitted, and an automated BP was measured at rest, 
and every 2 minutes during the test. Subjects were also monitored with 
continuous pulse oximetry. 
Standard spirometry was performed before conduction of each test within the 
Blue cherry software. 
The CPET test protocol has been published previously but is reported briefly 
below34.  The ramp incremental protocol was determined for each patient by 
using the formula by Wasserman and colleagues32.  Subjects were instructed 
to pedal between 55 and 65 rpm for the duration of the test. The test protocol 
included four phases; an initial rest phase (three minutes), three minutes of 
unloaded cycling (zero watts), a subsequent ramp protocol (ideally 6-10 
minutes), and 3-minute recovery period. The recovery period was extended 
as necessary to allow physiological parameters to return close to baseline 
levels, and exercise induced ECG changes to resolve. 
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The incremental exercise phase continued to volitional termination or until the 
below criteria were met: 
• The subject stopped pedalling due to leg fatigue, dyspnoea, pain or 
light headedness 
• The subject failed to maintain an RPM of greater than 40 RPM for 
more than 1 minute and does not respond to encouragement. 
• Subject developed angina or the following ECG changes  
• Development of 2mm ST depression if symptomatic or 4mm if 
asymptomatic or > 1mm ST elevation 
• Development of a significant arrhythmias 
• A fall in systolic pressure > 20mmHg from the highest value recorded 
during the test. 
• Hypertension > 250mm Hg systolic; > 120 mm Hg diastolic 
• Severe desaturation: SpO2 < 80% accompanied by limiting 
hypoxaemia 
• Or if a subject developed any of the following symptoms 
• Sudden pallor 
• Loss of coordination  
• Mental confusion 
Ideally the exercise component of the test was 6-10 minutes. Following the 
exercise component there was a 5 minute recovery component during which 
the subject was observed until physiological variables including heart rate, 
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blood pressure, ventilation, and oxygen saturation, returned close to the 
baseline levels, and exercise induced ECG changes had resolved.  
3.4.2.4 CPET evaluation and reporting 
The clinician supervising the CPET, who was independent of the study, 
reported the test.  Subsequently, the tests were re-evaluated by a 
physiologist blinded to clinical data including the time point at which the test 
was conducted.  When interpreting the test the physiologist was informed of 
current medication that may affect the interpretation, including the use of beta 
blockade.  
The estimated anaerobic threshold was determined using the V-slope 
method by 2 independent blinded assessors220. 
3.4.3 CPET variables and definitions 
A number of important physiological variables are recorded during CPET.  
Some definitions are included in the following table.  Other variables 
recorded during a CPET include: heart rate (HR), blood pressure (BP), and 
oxygen saturation (SaO2).  All definitions are based on the work of 
Wasserman et al. 32  Subjects were considered sedentary if they took part in 
no formal exercise during a typical week; formal exercise included 
commuting to work by bike. 
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Table 3-4 Cardiopulmonary exercise test definitions 
 
 
Estimated Lactate 
Threshold  
( L) 
The exercise o2 above which anaerobic high-energy 
phosphate production supplements aerobic high-
energy phosphate production, Exercise above the L 
is reflected in the muscle effluent and central blood by 
an increase in lactate concentration, L/P ratio and 
metabolic acidosis.  
Oxygen Pulse  
(02 pulse) 
The oxygen uptake divided by the heart rate. This 
represents the amount of oxygen extracted by the 
tissues from the O2 carried in each stroke volume. Can 
be calculated at L and at peak exercise. 
Oxygen Uptake  
( o2) 
The amount of oxygen extracted from the inspired gas 
in a given period of time, expressed in ml or L per 
minute.  This can often be expressed relative to the 
weight of an individual undergoing the test. 
Peak Oxygen 
Uptake  
( o2 at peak) 
The highest oxygen uptake achieved during a 
maximum work rate test, calculated as the average 
o2 in the last 30 seconds of exercise. 
o2 max The o2 at which there is a plateau in the o2 despite increasing workload.  A physiological maximum often 
not achieved in the patient population. 
Work rate  The rate at which work is preformed in Watts.  
Ventilatory 
Equivalents for CO2 
and O2 ( E/ CO2 
and E/ O2) 
The ventilatory equivalents for CO2 and O2 are 
measurements of the ventilatory requirement for a 
given metabolic rate. Both can be calculated at L and 
at peak exercise. 
Minute Ventilation 
(VE) 
The volume of gas exhaled divided by the time of 
collection in minutes. 
Forced Expiratory 
Volume in 1 Second 
(FEV1) 
Volume that has been exhaled at the end of the first 
second of forced expiration 
Forced Vital 
Capacity (FVC) 
The determination of the vital capacity from a 
maximally forced expiratory effort 
FEV1/FVC A calculated ratio of the proportion of a person’s vital 
capacity that they are able to expire over one second 
 
θˆ
V!
θˆ
θˆ
V!
V! V!
V! V
! V!
V! V!
V! V!
θˆ
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3.4.1 Measurement of o2 kinetics 
Measurement of o2 kinetics was performed at the 3rd and 12th exercise 
sessions.  This involved 3 bouts of 15 minutes of light intensity exercise.  
Initially cycling unloaded (0 watts) for 3 minutes before a workload of 60% 
wattage achieved at the anaerobic threshold was applied for 6 minutes, with 
a subsequent period of 6 minutes unloaded cycling (0 watts). 
This was all done connected to the standard CPET equipment. 
These data have not been analysed or included in this thesis. It was felt they 
would not add to the value of the research given the findings achieved.  
These sessions were predominantly utilised as recovery exercise sessions. 
3.4.2 Study Recruitment 
Volunteer subjects were recruited from University Hospital Aintree.  An open 
invitation was provided to staff across the Digestive Diseases Directorate 
(Gastroenterology and General surgery). No volunteers were excluded.  The 
study was closed to recruitment once eleven volunteers had been recruited. 
3.4.3 Statistical analysis 
This was carried out using SPSS (Version 20, IBM 2011).  The majority of the 
analysis utilized paired t-tests, based on the assumption that response to a 
prehabilitation programme across a population is likely to follow a normal 
distribution.    
V!
V!
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3.5 Results 
3.5.1 Study Cohort 
Eleven volunteer subjects were recruited with a median age of 54 years (IQR 
44-56).  The median BMI was 29.0 (IQR 28-32, and range 25.5-39.2).  There 
were nine females and 2 males.  Two subjects were current smokers, 2 ex 
smokers and 7 non-smokers. Other baseline characteristics are summarised 
in Table 3-5. 
Table 3-5 Candidate demographics 
 
Subject( Age( Sex( BMI(
Smoking(
Status(
PMH( Medication(
Normal(
activity(level(
1( 40( M( 26.9(
Non(
smoker(
Nil( Nil( Sedentary(
2( 54( F( 39.2(
Non(
smoker(
Nil( Nil( Sedentary(
3( 56( F( 31.2(
Non(
smoker(
Nil( Nil( Sedentary(
4( 38( F( 28.6(
Non(
smoker(
Nil( Nil( Sedentary(
5( 56( M( 32.9( Smoker( Nil( Nil( Sedentary(
6( 46( F( 28.6(
Non(
smoker(
Nil( Nil(
2I3(times(a(
week(
7( 42( F( 25.5(
Non(
smoker(
Nil( Nil(
2I3(times(a(
week(
8( 46( F( 37.0(
Non(
smoker(
Nil( Nil( Sedentary(
9( 59( F( 26.7( X(smoker( Nil( Nil(
2I3(times(a(
week(
10( 53( F( 29.0(
Non(
smoker(
Hypertension( Propanalol( Sedentary(
11( 60( F( 32.0( Smoker( COPD( Nil( Sedentary(
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3.5.2 Adherence 
All eleven subjects completed the baseline and final CPET.  Attendance at 
the exercise sessions was 96%, with 9 of the 11 subjects completing all of 
the exercise sessions.   
3.5.3 Primary Outcome measure 
There was a mean improvement in the relative O2 uptake at the AT of 1.5 
ml.kg-1.min-1 (95% CI 0.7 ml.kg-1.min-1 to -2.3 ml.kg-1.min-1) (p<0.01).  Six 
subjects achieved improvements of greater than 2 ml/kg/min, with one patient 
achieving an improvement of 3.5 ml.kg-1.min-1.  The remaining 5 subjects had 
differences of less than 1 ml.kg-1.min-1, with only one subject having a drop in 
the relative uptake at the anaerobic threshold. The changes in the relative O2 
uptake at the AT for all candidates are shown in Table 3-6. 
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Table 3-6 Changes in the anaerobic threshold 
 
3.5.4 Effect on other variables 
There was no significant change in the weight or BMI of subjects over the 
study period.  The effect on other CPET variables is summarised in Table 
3-7. There was a reduction in mean resting VO2 of 1.4 ml.kg-1.min-1 (95% CI 
0.3: 2.2 ml.kg-1.min-1) (p=0.014) representing approximately a 29% reduction 
in resting oxygen uptake. The increased VO2 uptake at the anaerobic 
threshold was accompanied by a mean increase in the work rate at the AT of 
19 watts (95% CI 12:26 watts) p<0.01).  There was no significant change in 
heart rate at rest, anaerobic threshold or peak activity. There was an 
increase in peak VO2 uptake of 1.8 ml.kg-1.min-1 (95% 0.6:3.0 ml.kg-1.min-1). 
There was no significant change in peak wattage.  Given the significant 
Subject(
AT(pre(
(ml/kg/min)(
AT(post(
(ml/kg/min)(
Change(
(ml/kg/min)(
%(change(
1( 9.6( 11.9( 2.3( 24(
2( 11.2( 13.4( 2.2( 20(
3( 10.5( 12.6( 2.1( 20(
4( 10( 12.3( 2.3( 23(
5( 12.1( 12.9( 0.8( 7(
6( 18.6( 19.5( 0.9( 5(
7( 18.2( 17.8( G0.4( G2(
8( 8.8( 9.6( 0.8( 9(
9( 18( 20.2( 2.2( 12(
10( 10.1( 10.2( 0.1( 1(
11( 9.8( 13.3( 3.5( 36(
Overall( 12.4( 14.0(
1.5(
(95%(CI(0.7:2.3)(
12(
(95%(CI(6:19)(
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improvement in the mean oxygen uptake, it is not unsurprising that the O2 
pulse at both anaerobic threshold and peak activity improved given it is a 
derived variable. 
Table 3-7 Changes in other CPET variables 
 
Variable(
Pre(
Training(
Post(
Training(
Change(
ml/kg/min((95%(
CI)(
Mean((
Change
%(
Significance(
(
Anaerobic(Threshold(
(ml/kg/min)(
12.4( 14.0( 1.5((0.7:2.3)( +13%( 0.001(
Peak(VO2(
(ml/kg/min)(
18.5( 20.3( 1.8((0.6:3.0)( +10%( 0.008(
Resting(VO2(
(ml/kg/min)(
4.5( 3.2( N1.3((N0.3:N0.4)( N29%( 0.014(
O2(Pulse(at(AT( 9.1( 10.1( 1.0((0.7:1.4)( +11%( 0.000(
Peak(O2(Pulse( 10.6( 11.7( 1.1((N0.2:1.7)( +10%( 0.001(
Workload(at(AT(
(Watts)(
73( 92( 19((12:(26)( +26%( 0.000(
Peak(Workload((
(Watts)(
138( 148( 10((N5:24)( +7%( 0.17(
Resting(HR(
(BPM)(
85( 79( N6.2((N13:1)( N7.3%( 0.224(
HR(at(AT(
(BPM)(
114( 114( 0((N8:7)( 0%( 0.938(
Peak(HR(
(BPM)(
142( 146( 4((N6:14)( 2.5%( 0.439(
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3.6 Discussion 
This exercise programme delivered improvements in a variety of CPET 
variables in just 4 weeks.  These improvements may be related to the high 
adherence achieved within this study, but also may in part be due to the lack 
of an underling cancer diagnosis.  This exercise programme is standardised 
and can be calculated based on the initial CPET, making it easily adaptable 
to the preoperative setting.   
If this level of improvement in the anaerobic threshold could be achieved 
within the patient population it could represent a shift of 30% from a CPET 
assessed “high risk” (VO2 uptake at AT of <11 ml.kg-1.min-1) to a “low risk” 
group35,36.   This has the potential to reduce postoperative costs, and 
possibly perioperative morbidity. 
The adherence of 96% achieved in this study was high in comparison to 
other studies, and this is likely to have contributed to the success of the 
programme162,168,171,207.  The underlying reason for this high adherence is 
likely to be multi-factorial.  All subjects volunteered to partake in the exercise 
programme and consequently represent a highly motivated group.  Some of 
the contribution for the high adherence may stem from the design of the 
exercise programme, as interval-based training programmes have been 
shown to have higher ratings of perceived enjoyment than constant load 
programmes221.  The underlying mechanism for this is difficult to distinguish 
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but is likely to relate to a combination of the varied exercise profile with the 
direct effects of high intensity exercise.  Finally the study participants were 
without major health problems, and we would expect higher adherence in 
these healthy volunteers than the future intended preoperative cancer patient 
population.  
The study has demonstrated that it is possible to devise a successful 
exercise programme referenced to a baseline CPET which is simple to 
calculate and easy to deliver. The use of the anaerobic threshold detected 
during cardiopulmonary exercise testing, is key to the designs for a number 
of reasons. All target patients undergoing major cancer resections are 
routinely assessed with CPET, and the AT derived is used to stratify the 
postoperative care. The AT has also been shown to correlate well with 
endurance capacity, and is detectable in most patients and thus is an 
attractive variable on which to base a standardised exercise programme30,45. 
The exercise programme has been based on the power produced at the 
anaerobic threshold.  Power training has been suggested as a superior 
method of cycle training for elite athletes and with the advent of widely 
available power metres has become commonplace222,223.   Using power at 
the anaerobic threshold is an attractive value to base a training programme 
on owing to the ease with which a programme can be calculated, and 
delivered using pre-programmable cards.  It removes the need for heart rate 
monitors, formerly a standard technique for assessing exercise intensity224. 
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This exercise programme delivered clinically significant improvements in 
fitness in just 4-weeks.  In the preoperative setting two four-week 
programmes failed to deliver clinically significant improvements in CPET 
variables162,171. These studies were of a higher frequency and both utilised 
home-based programmes, and both suggested adherence as a potential 
reason for failure.  The success of the current programme is likely 
multifactorial including the high adherence, the interval nature of the 
programme, and the supervised nature of the exercise programme.  
These findings are yet to be validated in a cancer patient population, but 
certainly provide cause for optimism.  However, this must be tempered by the 
limitations of this study. This improvement was achieved in a population with 
an average fitness levels similar to the target patient population, however it 
must be noted there are a number of significant differing demographic 
variables which may prove significant when translating these findings into our 
target population.  The study population here was younger, with a higher rate 
of female participants.  None of the subjects had an underlying cancer 
diagnosis, with neither the associated paraneoplastic effects nor the 
concurrent treatment this may incur.  This study also lacked a control arm, 
and it may be that fitness improvements seen within this cohort related to 
activity outside the prehabilitation programme, as there were no specific 
limitations placed on participants.  
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3.7 Conclusions 
A standardised exercise programme based around the anaerobic threshold 
can deliver meaningful improvements in cardiopulmonary fitness. The 
feasibility of this training programme needs to be validated in the 
preoperative cancer population prior to randomised clinical trial assessing its 
impact on outcomes. 
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Chapter 4: Prehabilitation Trial  
4.1 Introduction 
Patients with lower CPET assessed oxygen uptake at the anaerobic 
threshold have been shown to have higher mortality, higher morbidity and 
longer hospital stay when undergoing major surgery40,43,49. Specifically in 
HPB surgery, patients with lower fitness as assessed by CPET have higher 
rates of complications 48,49,225.   
In cancer patients, postoperative rehabilitative exercise therapy has been 
shown to improve physical function, peak oxygen consumption and quality of 
life (QoL). There are, however, limitations. Following surgery, individuals may 
be fatigued, worried about the effects of exercise on the healing process, or 
anxious whilst awaiting adjuvant treatments226,227. Postoperative 
rehabilitation also fails to add any of the benefits of exercise therapy to the 
immediate perioperative period 164.  Preoperative exercise intervention, or 
prehabilitation, has been proposed as a more timely intervention in a 
patient’s management pathway, as it may bring the benefits of exercise 
therapy to bear on the intended operative intervention162,164. 
Fitness is often considered as a static concept by the medical profession. It 
has, however, been demonstrated that many preoperative interventions have 
a detrimental effect on preoperative CPET. Preoperative chemotherapy in 
patients undergoing upper GI cancer resections led to a significant drop in 
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the anaerobic threshold, which in turn was associated with early mortality228. 
In colorectal cancer preoperative chemo-radiotherapy has been shown to be 
associated with significant reductions in CPET variables229.  Indeed just a 
cancer diagnosis alone may be enough to precipitate a significant 
deterioration in fitness as suggested by the underlying mechanisms of cancer 
related fatigue syndrome161. 
Prehabilitation aims to counter the negative impact of an underlying cancer 
and any neoadjuvant treatment, thereby improving preoperative fitness.  
Currently no randomized study of prehabilitation has delivered improved 
preoperative fitness in a cancer population. The largest randomized trial of 
prehabilitation to date failed to demonstrate an advantage with a home-based 
exercise programme over a control arm of walking and breathing 
exercises162.  A number of non-randomized studies have demonstrated that 
supervised exercise programmes of typically 6 weeks or more could deliver 
clinically relevant improvements in fitness168,172,207.  However, this delay is 
not always feasible when treating malignant disease. This randomized 
controlled study therefore sought to assess the feasibility of a 4-week 
supervised preoperative exercise programme in patients awaiting surgery for 
CRLM, assessing the impact on preoperative fitness and QoL. 
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4.2 Methods 
4.2.1 Ethical approval 
This prospective interventional randomized trial was conducted with full 
ethical approval that was granted by the Liverpool Central Research Ethics 
service with the registration number 11/H1005/3 (REC number) on the 12th 
April 2011(IRAS ID: 65982) (Appendix 1.1). 
The study had Local Research approval and NHS sponsorship granted on 
the 12th April 2011 using the above listed REC number. 
The study was listed on the open access clinical trials registry 
clinicaltrials.gov with the registration number NCT01523353.  
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4.2.2 Trial design 
The study is summarised in the flow diagram below 
Figure 4-1 Study Flow Diagram 
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4.2.3 Participants 
All patients with CRLM being referred to the tertiary hepatobiliary service at 
Aintree University Hospital, Liverpool, UK were screened for potential 
eligibility.  Eligibility criteria are summarized in Table 4-1.  Potentially eligible 
candidates were given details of the study at the first clinic consultation 
(Patient Information leaflet Appendix 1.2).  Patients were only then invited to 
participate once a decision to proceed to surgery had been made, and full 
informed consent was obtained.  Ethical approval stipulated that recruitment 
to the study was not allowed to lead to a delay in surgical care. Consequently 
patients were only potentially eligible if the provisional operative date allowed 
at least 4 weeks for prehabilitation.  
Table 4-1 Eligibility criteria 
Inclusion Criteria 
1 Resectable CRLM 
2 Age>18 
3 Able to complete a cycle based exercise programme 
4 Able to give informed consent 
5 Adequate preoperative time to complete a cycle based exercise 
programme 
Exclusion Criteria 
1 Known pre-existing chronic liver disease  
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4.2.4 Randomisation 
Candidates were randomized to either a prehabilitation exercise programme 
or to standard care using a random number block randomization list created 
at trial outset, using Microsoft Excel 2010 (Microsoft, Washington).   An 
individual independent of the study held this list.  They were contacted via 
email to provide randomisation. 
4.2.5 Primary outcome measure 
The primary outcome measure of the study was change in the preoperative 
oxygen uptake at the anaerobic threshold following prehabilitation or 
standard care. An improvement of 1.5ml.kg-1.min-1 was considered 
achievable 168 and clinically relevant. If delivered across a patient population 
112 this could reduce the patients considered high risk  (Vo2 at AT <11 ml.kg-
1.min-1 ) by 30%35. 
4.2.6 Secondary outcome measures 
Secondary outcome measures included changes in the other preoperative 
CPET measures, and changes in QoL score, and Dukes activity Index (as 
discussed below). Data was also collected on operative intervention, 
perioperative outcomes, and subsequent postoperative progress.  The study 
was not statistically powered to formally assess differences in perioperative 
or long-term outcome and these data are descriptive. 
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4.2.6.1 Quality of Life Assessment 
Quality of life assessment was assessed using the RAND 36 – Short Form 
Health Survey 230 (RAND Corporation, Santa Monica, USA)(Appendix 1.5.1 
page 230), and the EORTC QLQ-C30 questionnaire (Appendix 1.5.2 page 
234) with the LMC-21(Appendix 1.5.3 page 235) bolt on questionnaire 
(EORTC, Brussels, Belgium).  Patients completed questionnaires 
independently, with researchers available to explain any questions not fully 
understood by the candidates.  
4.2.6.2 Activity Assessment 
Activity was assessed using the Dukes Activity Index questionnaire 
(Appendix 1.5.4  page 237) 231.  Candidates completed questionnaires 
independently, with researchers available for assistance as necessary. 
4.2.7 Blinding 
Clinicians providing care were blinded to the intervention patients received, 
and blinded to the results of all but the baseline CPET test.  This blinding 
included anaesthetists, surgeons, nurses and staff reporting the CPET tests. 
4.2.8 Sample size 
Preliminary data suggested that the target population had a mean oxygen 
uptake of 12.0 ml.kg-1.min-1 (SD 2.04). To demonstrate an increase of 1.5 
ml.kg-1.min-1, with a power of 0.8, and a type I error probability of 0.05, 30 
subjects randomised equally to either prehabilitation or standard care 
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required. Assuming an attrition rate of 25%207, a total recruitment of 38 
patients was calculated.  Analysis was conducted on an intention to treat 
basis. 
4.2.9 Interventions 
The prehabilitation programme is described in detail earlier (Chapter 3.3.1 
page 64). Briefly it consisted of 12 interval exercise sessions over a 4-week 
period232..  The sessions included a warm up and warm down, and 30 
minutes of interval training alternating between moderate (<60% VO2peak) and 
vigorous intensity exercise (>90% VO2peak)233. The sessions were delivered 
using a cycle ergometer (Optibike Ergoline GmbH, Bitz, Germany).  The 
exercise programme was personalized to candidates following a 
standardized equation based on their work rate at their anaerobic threshold 
on the baseline CPET test.   
No restrictions were placed on candidates in either arm of the study, and they 
were encouraged to follow clinical advice on exercise prior to surgery. 
4.2.10 Cardiopulmonary Exercise Testing 
The methodology for performing cardiopulmonary exercise test assessment 
has been previously described in Chapter 3 34,216.  
Evaluation of anaerobic threshold, AT, was undertaken independently by two 
experienced assessors, blinded to each other’s assessments, with 
disagreement resolved by a third assessor.  
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Patient were considered high risk if their Vo2 at AT was less than 11 ml.kg-
1.min-1 35. High risk patients were routinely admitted to critical care 
postoperatively, and had increased intraoperative monitoring and support148. 
4.2.11 Blood tests 
Blood was collected at each assessment and processed under standard 
clinical laboratory conditions within the clinical laboratories at University 
Hospital Aintree.  This was to exclude the presence of significant anaemia, or 
overt hepatic dysfunction that may affect CPET variables. 
4.2.12 Activity 
Activity levels were assessed with the Dukes Activity Status Index. 231 
4.2.13 Statistical methods 
Continuous normal data was analysed using a t-test, and the Mann-Whitney 
was used for continuous data with a non-normal distribution.  Categorical 
data was analysed using the X2 test, or Fischer’s exact as appropriate.  All 
statistical tests were conducted using SPSS (version 20.0, IBM, 2011).   
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4.3 Results 
4.3.1 Study conduct 
4.3.1.1 Study time period 
The study opened to recruitment on the 1st July 2011, recruiting the first 
patient on the 14th July 2011. The study recruited its 38th patient on the 18th 
February 2013 and closed to recruitment at that point.  Active follow up was 
completed on the 20th June 2013. Surveillance for recurrence and survival 
from the date of liver surgery is on going and will be for 10 years, as per the 
current clinical standard of colorectal liver metastasis follow-up. 
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4.3.1.2 Study recruitment and preoperative progress 
The recruitment and study progress is summarised in the consort diagram 
(Figure 4-2). 
Figure 4-2 Consort diagram showing study recruitment 
 
Prehabilitation before liver resection
Excluded n = 77
 Clinician did not approach n = 11
 Too far from centre n = 44
 Patient declined n = 5
 Not enough time n = 7
 Not interested n = 2
 Dislikes CPET n = 1
 No response n = 7
Excluded n = 78
 Hepatectomy not indicated n = 32
 Unfit for surgery n = 2
 Unable to complete CPET n = 6
 Insufficient time n = 38
Randomized n = 38
Preoperative exercise n = 20
 Completed exercise programme n = 19
 Did not complete exercise programme n = 1
 Concurrent oral cancer n = 1
Standard care n = 18
 Completed standard care n = 16
 Study withdrawal n = 2
 Withdrew as not exercising n = 1
 Arthritis, declined CPET n = 1
Underwent hepatectomy n = 16
No hepatectomy n = 3
 Peritoneal disease n = 2
 Chemotherapy-induced liver injury n = 1
Underwent hepatectomy n = 13
No hepatectomy n = 3
 Peritoneal disease n = 1
 Hepatic progression n = 2
Analysed n = 19
Excluded from analysis n = 1
 Did not complete two CPETs n = 1
Analysed n = 16
Excluded from analysis n = 2
 Did not complete two CPETs n = 2
Assessed for eligibility n = 193
Eligible to participate n = 115
Fig. 1 CONSORT diagram for the study. CPET, cardiopulmonary exercise testing
Evaluation of AT was undertaken independently by two
experienced assessors, blinded to each other’s assessments,
with disagreement resolved by a third assessor.
Patients were considered high-risk if their baseline VO2
at ATwas less than 11ml per kg permin.High-risk patients
were admitted routinely to critical care after surgery, and
had increased intraoperative monitoring and support14 .
Primary outcome measure
The primary aim of the study was to improve preoperative
VO2 at the AT by 1⋅5ml per kg per min. This was consid-
ered achievable and clinically relevant. If delivered across
a patient population14, it could reduce the proportion of
patients considered high-risk (VO2 at AT of less than 11ml
per kg per min) by 30 per cent.
Secondary outcome measures
Secondary outcome measures included changes in the
other preoperative CPET measures, and changes in the
preoperative QoL score, assessed using the Short Form
36 (SF-36®; QualityMetric, Lincoln, Rhode Island, USA)
questionnaire15. Data were also collected on operative
intervention, perioperative outcomes and subsequent post-
operative progress. The study was not statistically powered
for formal assessment of differences in perioperative or
long-term outcome, and these data are descriptive.
Blinding
Clinicians providing care were blinded to the intervention
received by patients, and to the results of all but the baseline
CPET values. This blinding included anaesthetists, sur-
geons, ward staff and staff reporting the CPET results.
Sample size
Preliminary data suggested that the target population had
a mean(s.d.) VO2 of 12⋅0(2⋅0)ml per kg per min. To
© 2016 BJS Society Ltd www.bjs.co.uk BJS
Published by John Wiley & Sons Ltd
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4.3.1.3 Reasons for ineligibility 
Consecutive patients referred to supra-regional MDT with CRLM were 
screened for eligibility.  Of the 193 patients screened for eligibility, only 115 
were deemed potentially eligible. In 38 patients there was insufficient time to 
complete an exercise intervention before a provisional operation date.  Other 
reasons are listed in Table 4-2. 
Table 4-2 Reasons for study ineligibility at screening 
Hepatectomy not appropriate treatment   32 
 Rapidly progressive disease on chemotherapy 7  
 Percutaneous ablation 3  
 SIRT 1  
 No evidence of metastases 6 
 Palliative DEB-Tace 1 
 Declined surgery 2 
 Irresectable disease at assessment 12 
   
Insufficient time to deliver prehabilitation  38 
   
Unfit for surgery  2 
   
Unable to perform CPET  6 
 Severe Arthritis 4 
 Recent pulmonary embolism 1 
 Necrotic wound post APR 1 
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4.3.1.4 Reasons for failure to recruit  
There were 11 potentially eligible patients identified through screening who 
were not approached to join the study. This was predominantly in the early to 
mid portion of the study, and solely related to one clinician within the unit who 
failed to mention the study to patients at first consultation.  
Of the 104 approached 66 declined to partake in the study.  Of these 66, 44 
patients (66.7%) declined the study due to the distance and travelling 
involved.  Other reasons included 5 (7.5%) with anxiety, 7 (10.6%) with 
limited time due to work commitments, 2 (3%) with no interest in exercise, 
and 1 who did not want to undertake further CPET due to claustrophobia 
from the CPET mask. In 7 patients (10.6%) no reason was given.  
4.3.1.5 Randomisation and subsequent withdrawal 
Thirty-eight patients were consented and randomised into the study.  Twenty 
patients were randomised to the prehabilitation intervention, and 18 to 
standard care.  One patient randomised to standard care withdrew from the 
study 2 hours following recruitment.  This was before the results of 
randomisation were available and before completion of baseline quality of life 
questionnaires and blood tests.  This was due to the development of arthritic 
pain hours after the completion of preoperative CPET and the desire to avoid 
further CPET assessment.  Due to an incomplete baseline assessment, and 
subsequent withdrawal from the entire study, this patient was excluded from 
the study and not included in any analysis. 
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Two other patients withdrew from the study, one in each arm.  One patient in 
the prehabilitation arm was diagnosed with concurrent oral cancer, and 
underwent urgent radical neck dissection.  One patient on the standard care 
arm withdrew as a direct result of being randomised to standard care.  Both 
these patients are included in the baseline demographic analysis, but 
excluded from the analysis beyond this. 
One further patient in the standard care arm completed the preoperative 
component of the study but did not undergo any surgical intervention.  This 
was as a result of a scan arranged following completion of the preoperative 
component due to worsening abdominal pain demonstrating rapidly 
progressive hepatic disease with new extrahepatic disease.  They were 
referred for second line palliative chemotherapy. 
4.3.1.6 Surgical intervention and follow-up 
Overall 34 of 37 patients who underwent initial assessment had surgical 
intervention.   Laparotomy only was carried out in 5 patients (3 Prehabilitation 
2 Standard care) for the reasons shown in Figure 4-2. This was not 
significantly different between study arms.  This rate of futile laparotomy in 
study patients (14.7%) was higher than seen in the overall cohort of patients 
undergoing resection of CRLM during the study period (4.4%) (p < 0.05) 234.  
Hepatectomy was performed in 16 patients in the prehabilitation arm, and 13 
in the standard care arm. The number of patients undergoing surgical 
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intervention, and subsequent follow-up assessment is summarised in Figure 
4-3. 
There was no significant difference in attendance rates at either the first or 
second postoperative visit between the study arms.  Of the 34 patients who 
underwent surgery, 31 attended the 1st postoperative visit (17 Prehab, 14 
Standard Care). Of the 31 patients who attended their 1st post-operative visit 
22 attended the 2nd visit at 12 weeks. 
In patients attending the visits, there was no significant difference in the 
desire to undergo postoperative CPET  (26 at 1st postoperative visit, 16 at 
second postoperative visit).  
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Figure 4-3 Study flow for patients undergoing surgical intervention 
 
Improving the perioperative management of resectable colorectal liver metastases 
 
99 
 
4.3.2 Study cohort characteristics 
4.3.2.1 Patient characteristics  
The individual patient characteristics are summarised in the appendix 
(Appendix 1.4 page 226).  The overall demographics for the study group are 
summarised in table 4-3.  There was no significant difference in 
characteristics across the two groups but the median age of patients 
recruited into the study is lower than would typically be seen in our patient 
group, illustrated by the publication of study units data (Appendix 1.6 page 
238)112. 
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Table 4-3 Demographics of study cohort 
 
 Study 
cohort 
(37) 
Prehab 
 
(20) 
Standard 
Care 
(17) 
P 
value 
Median Age (IQR)     
 At cancer diagnosis* 60(53-69) 60(55-64) 60(51-70) 0.918 
 At study recruitment 62(54-69) 61(56-66) 62(53-72) 0.916 
Sex     
 Male 26 13 13 
0.495  Female 11 7 4 
Recruitment BMI** 29.5(4.1) 29.7(4.2) 29.3(4.2) 0.748 
Smoking Status     
 Smoker 6 2 3 
0.75  X-smoker 6 3 3 
 Non smoker 25 15 11 
Comorbidities     
 Cardiovascular 18 10 8 1.00 
 Respiratory 7 3 4 0.68 
 Diabetes 4 2 2 1.00 
 Renal Disease 1 1 0 1.00 
 CNS 5 2 3 0.64 
 Musculoskeletal 6 4 2 0.67 
 Depression 2 1 1 1.00 
 Prior cancer 
diagnosis 7 5 2 0.42 
 Prior cancer surgery 5 4 1 0.35 
 None 4 1 3 0.33 
Medication     
 Cardiovascular 16 8 8 0.75 
 Diabetic 2 1 1 1.00 
 Anticoagulation 11 7 4 0.50 
 Respiratory 2 2 0 0.50 
 Nil 5 1 4 0.16 
*median(IQR) 
**mean(standard deviation) 
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4.3.2.2 Primary presentation and treatment 
The details of the primary presentation and treatment are summarised below. 
There were no significant differences between cohorts. 
Table 4-4 Primary presentation and management of study cohort 
 
	 	 Study	cohort	(37)	 Prehab	(20)	 Standard	Care	(17)	 P	value	Primary	Site	 	 	 	 		 Right		 6	 2	 4	 0.58		 Left	 9	 6	 5		 Rectal	 21	 12	 8	Emergency	presentation	 	 	 	 		 Yes	 9	 3	 6	 0.251		 No	 28	 17	 11	Presenting	Symptoms	 	 	 	 		 Obstruction	 4	 0	 4	
0.251	
	 Rectal	Bleeding	 9	 5	 4		 Anaemia	 7	 4	 3		 Change	in	Bowel	habit	 12	 8	 4		 Bowel	Cancer	Screening	 4	 3	 1		 Other	symptoms	 4	 2	 2		 Unavailable	 1	 0	 1	Synchronous	presentation	 	 	 	 		 Yes	 18	 8	 10	 0.330		 No	 19	 12	 7	Surgical	strategy	for	synchronous	presentations	 	 	 	 		 Colorectal	surgery	first	 12	 5	 7	 0.330		 Liver	surgery	first	 5	 2	 3		 Joint	resection	 1	 1	 0	Perioperative	treatment	 	 	 	 		 None		 16	 7	 9	 0.51		 Adjuvant	radiotherapy	 1	 0	 1	 1.00		 Long	course	Chemo-radiotherapy	 9	 6	 3	 0.46		 Neoadjuvant	systemic	chemotherapy	 6	 4	 2	 0.67		 Adjuvant	chemotherapy	 9	 5	 4	 1.00		
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4.3.2.3 Primary surgery and outcomes 
The surgical treatment of the primary malignancy and complications of 
treatment are summarised below. There were no significant differences 
between groups. 
Table 4-5 Primary surgery and outcome 
  
 Study 
cohort 
(37) 
Prehab 
(20) 
Standard 
Care 
(17) 
P 
value 
Primary Surgery      
 Right hemicolectomy  6 2 4 
0.91 
 Left hemicolectomy 5 2 3 
 Sigmoid colectomy 5 5 0 
 Anterior resection 16 8 8 
 APR 1 1 0 
 Other resection 3 1 2 
 Primary unresected 1 1 0 
Covering ileostomy 9 4 6 0.45 
Laparoscopic approach     
 Yes 6 3 3 
0.56  No 27 15 12 
 Converted 3 1 2 
En-bloc resection of other metastatic 
colorectal disease 2 2 0 0.49 
Post operative Complications     
 Yes 15 8 7 
0.99  No  16 9 8 
 Unknown 4 2 2 
Re-operation     
 Yes 1 1 0 1.00 
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4.3.2.4 Primary Histology 
The histology of the primary tumours is summarised in Table 4-6. Again there 
were no significant differences between groups. 
Table 4-6 Primary histology 
 
	 	 Study	cohort	(37)	 Prehab	(20)	 Standard	Care	(17)	 P	value	Dukes	Stage	 	 	 	 		 A	 2	 2*	 0	 		 B	 9	 4	 4	 		 C1	 16	 7	 9	 0.33		 C2	 6	 5	 1	 		 Unavailable	 6	 3	 3	 	T	stage	 	 	 	 		 1	 0	 0	 0	 		 2	 8	 5	 3	 		 3	 16	 8	 8	 0.25		 4	 8	 6	 2	 		 Unavailable	 5	 1	 4	 	N	stage	 	 	 	 		 0	 10	 6	 4	 		 1		 9	 4	 5	 0.51		 2	 12	 8	 4	 		 Unavailable	 6	 2	 4	 	Differentiation		 	 	 	 	None		 Well	 1	 1	 0	 		 Well/Moderate	 8	 3	 5	 		 Moderate	 11	 7	 4	 0.66		 Poor	 3	 2	 1	 		 Unavailable	 12	 6	 6	 	Mucinous	tumour	 2	 1	 1	 1.00	3Vascular	invasion	 	 	 	 		 Yes	 12	 7	 5	 		 No	 14	 8	 6	 0.79		 Unavailable	 11	 5	 6	 	K	ras	status	 	 	 	 		 Wild-type	 11	 6	 5	 		 Mutant	 4	 2	 2	 1.00		 Unavailable/Not	done	 22	 12	 10	 	*	One	post	conversion	neoadjuvant	chemotherapy	for	liver	synchronous	disease,	and	one	post	rectal	radiotherapy.	
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4.3.2.5 Metastatic presentation 
The patient characteristics surrounding the metastatic presentation are 
summarised in Table 4-7.  There was a trend towards lower disease free 
interval within the Standard Care Arm (Log Rank significance 0.09) (Figure 
4-4).  Primarily this was powered by a greater proportion of patients 
presenting synchronously within the standard care arm (8 of 17 standard 
care versus 7 of 20 prehabilitation) 
Figure 4-4 Chart showing difference in time to metastasis detection. 
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Table 4-7 Summary of metastatic presentation 
 
 Study 
cohort 
(37) 
Prehab 
(20) 
Standard 
Care 
(17) 
P 
value 
Time from primary to metastases     
 Synchronous 15 7 8 
N/A 
 >0-12 months 3 2 1 
 >12-36 months 7 4 3 
 >36-60 months 4 2 2 
 >60 months 8 5 3 
Mode of detection     
 Staging CT 17 7 10* 
0.21 
 Surveillance CT 16 9 7 
 Climbing CEA 3 3 0 
 Incidental on ultrasound  1 1 0 
Previous metastatic disease/local 
recurrence treatment     
 Lung resection 1 1 0 
N/A 
 Anastomotic recurrence 1 1 0 
 Hepatectomy 2 1 1 
 Prior primary colorectal cancer 1 0 1 
Other concurrent metastatic disease 
on presentation scans     
 Lung 4 1 3 
N/A 
 Pelvic recurrence 2 1 1 
 Splenic 1 0 1 
 Ovarian 1 0 1 
 Wound 2 1 1 
 Portal node 1 0 1 
Preoperative hepatic disease      
 Bilobar metastases 13 5 8 0.19 
 Isolated metastases 9 5 4 
0.16 
 2-3 metastases 8 5 3 
 4-6 metastases 9 2 7 
 7 or more 3 3 0 
 Maximum size >5cm 13 7 6 1.00 
 Maximum size >10cm 0 0 1 1.00 
* One on staging for secondary primary colorectal cancer.  
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4.3.3 Baseline outcome variable comparisons 
This section describes the baseline scores of the variables to be used as 
outcomes within the study. 
4.3.3.1 Baseline CPET variable comparison 
Baseline CPET characteristics were similar in both the prehabilitation group 
and standard care group (Table 4-8).  The only difference between cohorts 
was a lower ventilatory equivalent of oxygen at peak exercise, in the 
prehabilitation group. 
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Table 4-8 Baseline CPET variable comparison.  Values shown as mean (standard 
deviation). P value shown for comparison between cohorts. 
 
CPET variable Overall Prehab Standard Care 
P 
value 
Patients included in 
analysis 37 20 17 N/A 
FEV1 3.00 (0.8) 2.91 (0.78) 3.10 (0.88) 0.50 
FVC 4.14 (1.03) 3.99 (0.99) 4.32 (1.09) 0.34 
FEV1/FVC 72.4 (7.8) 72.8 (6.9) 72.1 (9.0) 0.81 
Resting relative O2 
uptake (ml/kg/min) 3.6 (0.6) 3.6 (0.6) 3.6 (0.8) 0.96 
Resting absolute O2 
consumption (l/min) 
0.306 
(0.070) 
0.305 
(0.062) 
0.308 
(0.081) 0.91 
Resting HR (bpm) 85 (16) 87 (17) 81 (15) 0.26 
Relative O2 uptake at AT 
(ml/kg/min) 11.3 (1.6) 11.3 (1.5) 11.4 (1.8) 0.74 
Absolute O2 uptake at AT 
(l/m) 
0.965 
(0.231) 
0.953 
(0.220) 
0.979 
(0.249) 0.74 
O2 Pulse at AT 9.1 (2.8) 8.7 (2.5) 9.6 (3.1) 0.34 
Ventilatory equivalent of 
O2 at AT 
28.1 (4.6) 26.7 (3.8) 29.6 (5.1) 0.06 
Ventilatory equivalent of 
CO2 at AT 
30.1 (4.3) 30.0 (4.0) 31.8 (4.6) 0.22 
Work rate at AT (watts) 65 (16) 64 (16) 66 (16) 0.68 
HR at AT (bpm) 109 (18) 113 (20) 105 (15) 0.20 
Relative O2 uptake at 
peak 18.0 (3.1) 17.6 (2.3) 18.6 (3.9) 0.37 
Absolute O2 uptake at 
peak (l/min) 
1.535 
(0.402) 
1.491 
(0.349) 
1.587 
(0.464) 0.48 
O2 Pulse at peak 11.2 (3.4) 10.7 (3.0) 11.8 (3.8) 0.37 
Ventilatory equivalent of 
O2 at peak 
41.0 (7.2) 38.7 (6.3) 43.7 (7.4) 0.03 
Ventilatory equivalent of 
CO2 at peak 
33.6 (4.4) 32.4 (4.1) 35.0 (4.3) 0.08 
Work rate at peak (watts) 131 (33) 124 (27) 139 (39) 0.19 
HR at peak (bpm) 141 (23) 143 (22) 138 (24) 0.50 
HR response to AT(bpm) 25 (11) 26 (12) 24 (9) 0.67 
HR reserve (bpm) 56 (17) 56 (18) 57 (18) 0.87 
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4.3.3.2 Baseline quality of life score comparison 
The quality of life scores based on SF36 are summarised in Table 4-9, with 
those from EORTC (with Liver Metastasis Component (LMC) addition) 
summarised in Table 4-10.  At baseline there were no statistically different 
findings between cohorts.  
Table 4-9 Baseline SF 36 values 
 
 
  
  
Study 
cohort 
(37) 
Prehab 
(20) 
Standard 
Care 
(17) 
Cohort 
Diff. 
95% 
Confidence 
Interval Sig. 
lower upper 
Physical 
Function 76	 70	 84	 +13	 -3	 29	 0.10	
Role-Physical 47	 46	 49	 +2	 -26	 31	 0.87	
Body Pain 70	 65	 77	 +12	 -8	 30	 0.21	
General Health 63	 63	 63	 +1	 -13	 +14	 0.93	
Vitality 55	 52	 59	 +7	 -10	 23	 0.44	
Social 
Functioning 72	 65	 80	 +16	 -3	 34	 0.09	
Role 
Emotional 72	 70	 74	 +4	 -21	 30	 0.73	
Mental Health 78	 75	 82	 +7	 -5	 18	 0.22	
Overall 
Physical 
Health 
62	 59	 66	 +7	 -9	 23	 0.37	
Overall Mental 
Health 68	 64	 72	 +7	 -7	 21	 0.31	
TOTAL SF36 
Score 67	 63	 71	 +7	 -7	 22	 0.29	
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Table 4-10 Baseline EORTC (including LMC bolt on) Values 
 
Global	Health	Status	
Study 
cohort 
(37)	
Prehab 
(20)	
Standard 
Care 
(17)	
Cohort 
Diff 	
95%  
Confidence 
Interval	 P	value	
lower	 upper	
Global	Health	Status	 66	 70	 60	 -10	 -26	 5	 0.19	
Physical	Functioning	 86	 84	 88	 4	 -10	 17	 0.59	
Role	Functioning	 81	 83	 77	 -6	 -25	 13	 0.51	
Emotional	Functioning	 84	 84	 84	 0	 -13	 12	 0.96	
Cognitive	Functioning	 88	 84	 91	 6	 -9	 22	 0.39	
Social	Functioning	 81	 81	 82	 2	 -16	 20	 0.86	
Fatigue	 26	 25	 31	 5	 -13	 23	 0.54	
Nausea	and	vomiting	 6	 8	 3	 -5	 -14	 4	 0.30	
Pain	 18	 21	 14	 -8	 -24	 9	 0.37	
Dyspnoea	 10	 9	 10	 2	 -16	 19	 0.85	
Insomnia	 25	 26	 27	 1	 -21	 23	 0.94	
Appetite	loss	 10	 14	 13	 -2	 -20	 17	 0.87	
Constipation	 7	 5	 8	 3	 -8	 14	 0.57	
Diarrhoea	 11	 5	 19	 13	 -2	 29	 0.08	
Financial	Difficulties	 16	 19	 10	 -9	 -28	 10	 0.34	
LMC	Eating	 6	 5	 9	 4	 -6	 15	 0.44	
LMC	Pain	 15	 15	 14	 -1	 -13	 10	 0.82	
LMC	Fatigue	 31	 30	 35	 4	 -18	 27	 0.70	
LMC	Social	 15	 16	 13	 -4	 -18	 11	 0.59	
LMC	Anxiety	 34	 32	 39	 7	 -12	 26	 0.47	
LMC	Weight-loss	 6	 7	 10	 3	 -12	 19	 0.65	
LMC	taste	 13	 16	 17	 1	 -21	 23	 0.94	
LMC	dry	mouth	 24	 21	 27	 6	 -17	 29	 0.60	
LMC	neuropathy	 29	 25	 31	 7	 -15	 29	 0.54	
LMC	Jaundice	 2	 0	 4	 4	 -4	 12	 0.28	
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4.3.3.3 Baseline activity  
Baseline activity was assessed using the Dukes activity status index 
(Appendix 1.5.4  page 237) 231. 
4.3.3.3.1 Baseline Dukes activity questionnaire 
At recruitment there was a difference in the number of people reporting an 
inability to run a short distance with a greater proportion of the standard care 
arm reporting being capable of running a short distance (16 of 17 (94%) of 
standard care versus 12 of 20 (60%) Prehab) (p-0.02).  Other than this the 
overall activity status was largely similar across the groups, including the 
overall Dukes activity score. 
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Table 4-11 Baseline comparison of Dukes activity index with percentage capable of 
achieving questioned activity 
 
 
 Overall 
Prehab 
(20) 
Standar
d Care  
(17) 
P 
value* 
Eat dress, bathe or use the toilet 100 100 100 ns 
Walk indoors, such as around their 
house 100 100 100 ns 
Walk 200 yards on level ground 95 90 100 0.49 
Climb a flight of stairs or walk up a hill 97 95 100 1.00 
Run a short distance?  76 60 94 0.02 
Do light work around the house like 
dusting or washing dishes 100 100 100 ns 
Do moderate work around the house 
like vacuuming sweeping floors or 
carrying groceries? 
97 95 100 1.00 
Do heavy work around the house like 
scrubbing floors or lifting or moving 
heavy furniture? 
78 70 88 0.24 
Do yard work like raking leaves, 
weeding or pushing a power mower? 84 85 82 1.00 
Have sexual relations?  62 60 65 1.00 
Participate in moderate recreational 
activities like golf, bowling, dancing, 
doubles tennis, or throwing a ball? 
70 65 76 0.50 
Participate in strenuous sports like 
swimming, singles tennis, football, 
basketball or skiing? 
49 55 41 0.52 
Overall Dukes score** 46 44 (16.5) 
48 
 (10.4) 0.32 
*Fisher’s exact test 
** Independent t test (Standard Dev) 
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4.3.4 Exercise programme compliance 
Adherence to the exercise programme was excellent with 18 of 19 patients 
who completed the programme completing 100% of exercise sessions.  One 
patient missed 2 exercise sessions when they developed large bowel 
obstruction due to their primary tumour and spent 4 days in hospital 
undergoing colonic stenting.  Overall adherence to the exercise programme 
was 99.1%. 
One patient in the exercise arm discontinued smoking as they felt it was 
making them more “short of breath” during the exercise sessions.  They have 
remained abstinent in the postoperative period. 
4.3.5 Effect of prehabilitation on CPET variables 
4.3.5.1 Single arm analysis of change in CPET variables within 
prehabilitation group 
One patient was excluded from the analysis, as they did not complete a 
second CPET test.  This left 19 patients included in the analysis, which is 
summarised in Table 4-12.  Within the group there was a significant 
improvement in the O2 pulse at the AT, the relative and absolute O2 uptake at 
peak, the peak work rate, the heart rate reserve AT.  There were also a trend 
towards improved values in resting HR, relative O2 uptake at the AT, absolute 
O2 uptake at the AT, work rate at the AT, and peak O2 pulse.  
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Response to the training programme was variable, which can be seen by the 
generalised widening of the standard deviations for a variety of the CPET 
variables.  For example the relative O2 uptake at the AT increased by an 
average of 1 ml.kg-1.min-1, however this ranged from a -3.7 ml.kg-1.min-1 
(26% decrease) to a 6.7 ml.kg-1.min-1 (70%) increase. Overall, 7 patients 
increased by 1.5 ml.kg-1.min-1or more, 1 decreased by 1.5 ml.kg-1.min-1 or 
more, and 11 patients either increased or decreased by less than 1.5 ml.kg-
1.min-1.  Similar variation in response to the prehabilitation programme was 
seen in a series of other key variables, and these are summarised in Table 
4-13. 
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Table 4-12 Single arm comparison of CPET variables in prehabilitation group.  Shown 
as mean (standard deviation), and mean change (95% CI for mean) 
 
CPET variable Baseline (19) 
Post Prehab 
(19) 
Change 
(95% CI) 
P 
value 
FEV1 2.95 (0.76) 2.95 (0.76) 0.00 (-0.16:0.16) 0.97 
FVC 4.05 (0.98) 4.10 (0.95) 0.048 (-0.17:0.27) 0.67 
FEV1/FVC 72.5 (7.0) 71.9 (7.7) -0.6 (-2.3:1.2) 0.51 
Resting Relative O2 uptake 
(ml.kg-1.min-1) 3.6 (0.58) 3.6 (0.55) 
-0.0 
(-0.3:0.2) 0.74 
Resting absolute O2 
consumption (l/min) 
0.309 
(0.061) 0.308 (0.078) 
-0.002 
(-0.027:0.024) 0.90 
Resting HR (bpm) 88 (17) 84 (16) -4 (-8:1) 0.09 
Relative O2 uptake at AT 
(ml.kg-1.min-1) 11.2 (1.5) 12.2 (2.4) 
1.0 
(-0.2:2.1) 0.09 
Absolute O2 uptake at AT 
(l/m) 
0.964 
(0.220) 
1.06  
(0.328) 
0.098 
(-0.009:0.205) 0.07 
O2 Pulse at AT 8.8 (2.5) 9.6 (2.9) 0.8 (0.1:0.5) 0.03 
Ventilatory equivalent of 
O2 at AT 
26.8 (3.9) 27.0 (4.0) 0.1 (-1.5:1.7) 0.87 
Ventilatory equivalent of 
CO2 at AT 
29.8 (4.0) 30.0 (4.0) 0.1 (-1.0:1.2) 0.82 
Work rate at AT (watts) 65 (16) 73 (23) 8 (-1:16) 0.08 
HR at AT (bpm) 114 (21) 112 (17) -1 (-6:4) 0.61 
Relative O2 uptake at peak 
(ml.kg-1.min-1) 17.6 (2.3) 19.4 (3.8) 
2.0 
(0.4:3.6) 0.02 
Absolute O2 uptake at 
peak (l/min) 
1.507 
(0.351) 1.683 (0.490) 
0.177 
(0.031:0.322) 0.02 
O2 Pulse at peak 10.7 (3.0) 11.6 (3.0) 0.8 (-0.1:1.7) 0.08 
Ventilatory equivalent of 
O2 at peak 
38.7 (6.5) 38.4 (5.8) -0.2 (-1.9:1.4) 0.76 
Ventilatory equivalent of 
CO2 at peak 
32.2 (4.2) 32.3 (3.6) 0.1 (-1.0:1.1) 0.91 
Work rate at peak (watts) 125 (26) 138 (35) 13 (7:19) 0.00 
HR at peak (bpm) 144 (22) 146 (22) 2 (-2:6) 0.31 
HR response to AT(bpm) 26 (13) 28 (12) 2 (-2:6) 0.26 
HR reserve (bpm) 56 (18) 62 (20) 6(1:10) 0.03 
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Table 4-13 Summarising variation in response of key CPET variables in prehabilitation 
group 
 
 
4.3.5.2 Single arm comparison of CPET variables within the standard 
care group 
One patient was excluded from the analysis, as they did not complete a 
second CPET test.  This left 16 patients included in the analysis, which is 
summarised in Table 4-14.   
Other than a minor reduction in the FEV1 (-0.08 litres), and heart rate at the 
anaerobic threshold (3 bpm) there was no statistically significant difference 
between CPET variables pre and post conduction of standard care.  There 
was a trend towards a lower anaerobic (both relative and absolute) threshold 
following standard care.  
There was not the same variation in outcome seen in the prehabilitation arm, 
as evidenced by the largely similar standard deviations pre and post standard 
 Mean Std. 
Deviation 
Min Max Range 
Relative O2 uptake at AT 
(ml.kg-1.min-1) 1.00 2.46 -3.70 6.70 10.40 
Relative O2 uptake at 
peak (ml/kg/min) 2.0 3.3 -2.6 10.8 13.4 
O2 Pulse at AT 0.8 1.4 -1.5 3.8 5.3 
O2 Pulse at peak 0.8 2.0 -2.5 5.2 7.7 
Work rate at AT (watts) 8 18 -18 48 66 
Work rate at peak 
(watts) 13 14 -2 50 52 
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care (Table 4-15).  Focusing on the relative O2 uptake at the anaerobic 
threshold, no patient improved by 1.5 ml.kg-1.min-1or greater, 4 patients 
deteriorated by 1.5 ml.kg-1.min-1or more, and 12 patients changed their AT by 
less than 1.5 ml.kg-1.min-1.  
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Table 4-14 Single arm comparison of CPET variables in standard care group.  Shown 
as mean (standard deviation), and mean change (95% CI for mean change) 
 
CPET variable 
Baseline 
(16) 
Post Standard 
Care 
(16) 
Change 
(95% CI) 
P 
value 
FEV1 3.10 (0.88) 3.12 (0.83) 
-0.08 (-0.15:-
0.00) 0.04 
FVC 4.32 (1.01) 4.31 (1.01) -0.11 (-0.26:0.04) 0.15 
FEV1/FVC 72.1 (9.0) 72.6 (9.6) -0.1 (-1.9:1.7) 0.94 
Resting Relative O2 
uptake (ml.kg-1.min-1) 3.6 (0.8) 3.8 (0.8) 
0.1 
(-0.4:0.6) 0.65 
Resting absolute O2 
consumption (l/min) .308 (0.81) .319 (0.73) 
.008 
(-0.036:0.051) 0.72 
Resting HR (bpm) 81 (15) 79 (19) -2 (-6:3) 0.40 
Relative O2 uptake at 
AT (ml.kg-1.min-1) 11.4 (1.8) 11.0 (2.1) 
-0.5 
(-1.2:0.1) 0.09 
Absolute O2 uptake at 
AT (l/m) 
.979 
(0.249) 0.942 (0.262) 
-0.038 
(-0.090:0.014) 0.14 
O2 Pulse at AT 9.6 (3.1) 9.6 (3.3) -0.1 (-0.7:0.5) 0.77 
Ventilatory equivalent of 
O2 at AT 
29.6 (5.1) 28.8 (4.2) -0.8 (-2.2:0.6) 0.26 
Ventilatory equivalent of 
CO2 at AT 
31.8 (4.6) 31.4 (3.4) -0.3 (-1.8:1.1) 0.63 
Work rate at AT (watts) 66 (16) 64 (19) -3 (-10:4) 0.42 
HR at AT (bpm) 105 (15) 101 (17) -3 (-6:-1) 0.02 
Relative O2 uptake at 
peak (ml.kg-1.min-1) 18.6 (3.9) 18.7 (4.1) 
0.0 
(-1.3:1.2) 0.96 
Absolute O2 uptake at 
peak (l/min) 
1.587 
(0.464) 1.603 (0.464) 
0.006 
(-0.107:0.118) 0.91 
O2 Pulse at peak 11.8 (3.8) 12.1 (3.8) 0.2 (-0.6:0.9) 0.64 
Ventilatory equivalent of 
O2 at peak 
43.7 (7.4) 42.7 (8.0) -1.1(-3.5:1.2) 0.32 
Ventilatory equivalent of 
CO2 at peak 
34.9 (4.3) 34.5 (4.7) -0.5 (-2.4:1.4) 0.57 
Work rate at peak 
(watts) 138 (39) 140 (39) 0 (-5:6) 0.92 
HR at peak (bpm) 138 (24) 136 (26) -2 (-7:3) 0.41 
HR response to 
AT(bpm) 
24 (9) 22 (9) -2 (-5:2) 0.34 
HR reserve (bpm) 57 (18) 57 (17) 0 (-4:4) 0.87 
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Table 4-15 Summarising variation in response of key CPET variables in standard care 
group 
 
 
4.3.5.3 The effect of prehabilitation on CPET variables: comparison 
between study arms.  
The differences achieved in key CPET variables are summarised in Table 
4-16.  The primary outcome is highlighted in red, and demonstrates that a 
four-week cycle based interval-training programme is capable of delivering a 
1.5 ml.kg-1.min-1 shift in the anaerobic threshold (p-0.023).  This represents a 
14% shift from the baseline value, and just short of one standard deviation for 
our patient population.   This shift was accompanied by a significant 
improvement in the absolute O2 uptake at the anaerobic threshold of 0.136 
litres (14%) (p-0.024), and an improvement of 13 watts (10%) at peak 
exercise (p-0.005). 
 Mean Std. Deviation Min Max Range 
Relative O2 uptake at 
AT (ml.kg-1.min-1) -0.5 1.2 -2.5 1.3 
3.8 
 
Relative O2 uptake at 
peak (ml.kg-1.min-1) 
-0.3 2.4 -5.3 4.5 9.8 
O2 Pulse at AT -0.1 1.1 -1.7 1.9 3.6 
O2 Pulse at peak 0.2 1.4 -3.3 2.7 6.0 
Work rate at AT (watts) -3 13 -30 22 52 
Work rate at peak 
(watts) 0 11 -26 14 40 
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There were also a number of non-significant trends in favour of the 
prehabilitation group including a 10% improvement in O2 pulse at the AT (p-
0.05), a 15% improvement in the work rate at AT (p-0.06), an 11% 
improvement in the relative O2 uptake at peak (p-0.05), a 11% improvement 
in the absolute O2 uptake at peak (p=0.07), and a 3 bpm (5%) improvement 
in the HR reserve.  
There was no change in the FEV1, FVC, resting O2 uptake, resting HR, or 
ventilatory equivalents of CO2 and O2. 
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Table 4-16 Summary of differences in change of CPET variables between cohorts 
following intervention. Primary outcome variable highlighted (Red) 
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4.3.6 Effect of exercise intervention on quality of life 
As described earlier, one candidate in each study arm was excluded from the 
analysis, as they had only baseline quality of life assessments. The SF-36 
questionnaire, must be interpreted by considering that a shift of 10 points is 
needed to be deemed clinically relevant.  Thus meaning that statistically 
significant shifts may occur that are not deemed clinically relevant. 
4.3.6.1 SF-36 single arm analysis 
When considering changes in the quality of life assessed by the SF-36 
questionnaire, first it is worth considering the arms in isolation to establish 
whether significant changes have occurred. The results are summarised in 
tables 4-17 and 4-18.  Within the prehabilitation arm a clinically relevant 
positive change was seen in 5 of the eight domains, of which “Role-physical”, 
“Vitality”, “Social functioning” and “Role-emotional” were statistically 
significant (table 4-17). Clinically relevant and statistically significant positive 
differences were found in the overall physical health, overall mental health, 
and overall SF-36 score (table 4-17). Overall, there were positive shifts in all 
domains with the exception of the “general health” domain that remained 
unchanged. 
In the standard care arm no clinically relevant changes in scores were 
observed, and the only statistically significant change was a negative shift in 
the “mental health” domain (Table 4-18) this approached clinical relevance.  
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Though this change failed to reach the shift of a score of 10 deemed clinically 
significant. 
Table 4-17 Change in SF 36 values prehabilitation (Paired T test)  
 
 
 
 
  
  
  Baseline (19) 
Post 
Prehab 
(19) 
Change 
95% Confidence 
Interval Sig. 
lower upper 
Physical Function 73	 81	 8	 2	 14	 0.014	
Role-Physical 49	 68	 20	 1	 38	 0.039	
Body Pain 68	 80	 12	 -1	 26	 0.077	
General Health 64	 66	 2	 -6	 10	 0.616	
Vitality 54	 66	 12	 4	 20	 0.005	
Social Functioning 66	 83	 17	 6	 28	 0.005	
Role Emotional 70	 89	 19	 0	 38	 0.045	
Mental Health 76	 83	 7	 2	 12	 0.009	
Overall Physical 
Health 61	 72	 11	 4	 17	 0.003	
Overall Mental 
Health 66	 77	 11	 5	 18	 0.003	
TOTAL SF36 Score 65	 77	 12	 5	 19	 0.002	
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Table 4-18 Change in SF 36 vales post-standard care (Paired t test) 
  
  Baseline (16) 
Post 
Standard 
Care 
(16) 
Change 
95% Confidence 
Interval Sig. 
lower upper 
Physical Function 83	 85	 2	 -5	 10	 0.535	
Role-Physical 47	 48	 2	 -21	 25	 0.887	
Body Pain 75	 78	 3	 -5	 11	 0.475	
General Health 65	 67	 3	 -5	 11	 0.493	
Vitality 58	 64	 6	 -3	 16	 0.175	
Social Functioning 79	 80	 1	 -16	 18	 0.926	
Role Emotional 77	 73	 -4	 -24	 16	 0.672	
Mental Health 83	 77	 -6	 -11	 0	 0.049	
Overall Physical 
Health 65	 68	 3	 -4	 10	 0.360	
Overall Mental 
Health 72	 72	 0	 -9	 9	 0.989	
TOTAL SF36 Score 71	 72	 1	 -7	 9	 0.828	
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4.3.6.2 SF-36 Prehabilitation versus standard care comparison 
The results of a comparison between the two study arms are summarised in 
table 4.19.  Clinically relevant changes in favour of prehabilitation were 
observed in 4 of the 8 domains (“Role-physical”, “Social Functioning”, Role-
emotional” and “mental health”), though only the changes observed in the 
mental health domain was statistically significant.  
Clinically relevant changes were also observed in the overall mental health 
and overall SF-36 score, with the prehabilitation arm contributing to an 11% 
improvement in overall SF-36 score (p–0.028).  
Across all the 8 SF-36 domains prehabilitation seemed to consistently 
contribute to improvements in Qol, though statistical significance was not 
observed.  A larger study would be needed to confirm if prehabilitation can 
deliver improvements in these domains.  
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Table 4-19 Difference in SF36 scores across the two cohorts following exercise 
intervention or standard care 
  
  Prehab (19) 
Standard 
Care 
(16) 
Difference 
95% Confidence 
Interval Sig. 
lower upper 
Physical Function 8	 2	 5	 -3	 14	 0.223	
Role-Physical 20	 2	 18	 -10	 46	 0.199	
Body Pain 12	 3	 10	 -7	 26	 0.240	
General Health 2	 3	 -1	 -12	 11	 0.902	
Vitality 12	 6	 6	 -6	 17	 0.333	
Social Functioning 17	 1	 17	 -2	 36	 0.085	
Role Emotional 19	 -4	 23	 -3	 50	 0.083	
Mental Health 7	 -6	 12	 5	 20	 0.001	
Overall Physical 
Health 11	 3	 8	 -2	 17	 0.103	
Overall Mental 
Health 11	 0	 12	 1	 22	 0.037	
TOTAL SF36 Score 12	 1	 11	 1	 21	 0.030	
 
4.3.6.3 Single arm comparison of EORTC and LMC scores 
In a similar manner to the SF-36 analysis, first each arm was considered in 
isolation (tables 4.20 & 4.21).   
Globally there were minimal changes in the EORTC scores. Improvements 
were seen in the prehabilitation arm in the physical functioning domain, and 
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both fatigue domains.  There were also trends towards improved scores in 
the domains global health status, pain, appetite loss, and dry mouth.  
In the standard care arm there was an improvement in the domain global 
health status. However, there was deterioration in the domain cognitive 
functioning.  There were a number of trends towards improvements in the 
domains fatigue, dyspnoea, and financial difficulties.  
4.3.6.4  EORTC prehabilitation versus standard care comparison 
The results of a comparison between the two study arms are summarised in 
Table 4-22.  This summarises the difference from baseline to post 
prehabilitation or standard care, and also gives the overall difference 
between the two study arms given that positive and negative changes 
occurred. There were no statistically significant differences between the two 
study arms.  
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Table 4-20 Differences in the EORTC score (including LMC bolt on component) for the 
patients undergoing prehabilitation 
 
 
  
  Baseline (19) 
Post 
Prehab 
(19) 
Change 
95% Confidence 
Interval Sig. 
lower upper 
Global	Health	Status 70	 76	 6	 -1	 13	 0.069	
Physical	Functioning 84	 90	 6	 0	 13	 0.049	
Role	Functioning 83	 87	 4	 -6	 13	 0.448	
Emotional	
Functioning 84	 80	 -4	 -15	 7	 0.447	
Cognitive	
Functioning 84	 89	 4	 -7	 16	 0.426	
Social	Functioning 81	 86	 5	 -8	 19	 0.420	
Fatigue 25	 15	 -11	 -21	 0	 0.049	
Nausea	and	vomiting 8	 4	 -4	 -11	 4	 0.331	
Pain 21	 14	 -7	 -15	 1	 0.088	
Dyspnoea 9	 7	 -2	 -15	 12	 0.79	
Insomnia 26	 18	 -9	 -21	 3	 0.135	
Appetite	loss 14	 4	 -11	 -21	 0	 0.055	
Constipation 5	 2	 -4	 -9	 2	 0.163	
Diarrhoea 5	 2	 -4	 -11	 4	 0.331	
Financial	Difficulties 19	 11	 -9	 -22	 4	 0.172	
LMC	Eating 5	 3	 -3	 -11	 6	 0.506	
LMC	Pain 15	 12	 -4	 -12	 5	 0.420	
LMC	Fatigue	 30	 19	 -12	 -22	 -2	 0.023	
LMC	Social	 16	 11	 -6	 -16	 4	 0.235	
LMC	Anxiety	 32	 29	 -3	 -13	 7	 0.529	
LMC	Weight-loss	 7	 4	 -4	 -13	 6	 0.429	
LMC	taste	 16	 7	 -9	 -21	 3	 0.135	
LMC	dry	mouth	 21	 11	 -11	 -21	 0	 0.055	
LMC	neuropathy	 25	 21	 -4	 -19	 12	 0.650	
LMC	Jaundice	 0	 0	 0	 n/a	 n/a	 n/a	
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Table 4-21 Differences in the EORTC score (including LMC bolt on component) for the 
patients undergoing standard care 
 
  
  
  Baseline (16) 
Post 
Standard 
Care 
(16) 
Change 
95% Confidence 
Interval Sig. 
lower upper 
Global	Health	Status 62	 69	 7	 0	 14	 0.048	
Physical	Functioning 88	 88	 0	 -11	 11	 1	
Role	Functioning 80	 84	 4	 -7	 16	 0.433	
Emotional	
Functioning 84	 84	 1	 -8	 9	 0.885	
Cognitive	
Functioning 92	 88	 -4	 -9	 0	 0.041	
Social	Functioning 83	 88	 4	 -1	 10	 0.104	
Fatigue 27	 21	 -7	 -14	 0	 0.057	
Nausea	and	vomiting 3	 4	 1	 -1	 3	 0.334	
Pain 14	 19	 4	 -5	 14	 0.334	
Dyspnoea 11	 4	 -7	 -14	 1	 0.082	
Insomnia 22	 20	 -2	 -20	 16	 0.792	
Appetite	loss 7	 2	 -4	 -14	 5	 0.334	
Constipation 9	 2	 -7	 -17	 4	 0.189	
Diarrhoea 20	 13	 -7	 -24	 11	 0.424	
Financial	Difficulties 11	 4	 -7	 -14	 1	 0.082	
LMC	Eating 7	 4	 -2	 -7	 3	 0.334	
LMC	Pain 15	 12	 -3	 -9	 3	 0.301	
LMC	Fatigue	 32	 21	 -10	 -22	 2	 0.084	
LMC	Social	 32	 5	 -7	 -15	 1	 0.095	
LMC	Anxiety	 38	 31	 -7	 -21	 6	 0.266	
LMC	Weight-loss	 4	 7	 2	 -3	 7	 0.334	
LMC	taste	 11	 4	 -7	 -23	 9	 0.384	
LMC	dry	mouth	 29	 24	 -4	 -18	 9	 0.499	
LMC	neuropathy	 33	 29	 -4	 -21	 12	 0.582	
LMC	Jaundice	 4	 0	 -4	 -14	 5	 0.334	
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Table 4-22 Difference in EORTC (including LMC bolt on) scores across the two 
cohorts following exercise intervention or standard care 
 
 
  
  Prehab (19) 
Standard 
Care 
(16) 
Diff. 
95% Confidence 
Interval Sig. 
lower upper 
Global	Health	Status 6	 5	 1	 -9	 12	 0.776	
Physical	Functioning 6	 0	 6	 -5	 18	 0.284	
Role	Functioning 4	 2	 1	 -13	 16	 0.843	
Emotional	
Functioning -4	 -5	 1	 -16	 17	 0.927	
Cognitive	
Functioning 4	 -8	 13	 -2	 27	 0.081	
Social	Functioning 5	 0	 5	 -12	 22	 0.533	
Fatigue -11	 -11	 1	 -14	 16	 0.937	
Nausea	and	vomiting -4	 1	 -5	 -13	 3	 0.258	
Pain -7	 4	 -11	 -23	 0	 0.059	
Dyspnoea -2	 -6	 4	 -11	 20	 0.564	
Insomnia -9	 -8	 0	 -23	 22	 0.968	
Appetite	loss -11	 -10	 0	 -18	 18	 0.99	
Constipation -4	 -6	 3	 -7	 13	 0.581	
Diarrhoea -4	 -6	 3	 -13	 19	 0.732	
Financial	Difficulties -9	 -6	 -3	 -18	 13	 0.735	
LMC	Eating -3	 -5	 3	 -8	 14	 0.636	
LMC	Pain -4	 -3	 -1	 -11	 10	 0.889	
LMC	Fatigue	 -12	 -15	 3	 -13	 19	 0.72	
LMC	Social	 -6	 -8	 2	 -11	 14	 0.773	
LMC	Anxiety	 -3	 -10	 7	 -9	 23	 0.391	
LMC	Weight-loss	 -4	 -4	 1	 -15	 16	 0.933	
LMC	taste	 -9	 -13	 4	 -17	 25	 0.72	
LMC	dry	mouth	 -11	 -4	 -6	 -22	 10	 0.423	
LMC	neuropathy	 -4	 -4	 1	 -21	 22	 0.951	
LMC	Jaundice	 0	 -4	 4	 -4	 12	 0.282	
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4.3.7 Effect of prehabilitation on activity  
4.3.7.1 Effect of prehabilitation on Dukes activity status index 
The changes in Duke’s activity index comparing baseline to post 
prehabilitation or standard care are summarised in tables 4.23 and 4.24. 
Within the prehabilitation arm there was very little change, with only a trend 
towards an increased belief that study participants could undertake moderate 
recreational activity and greater Dukes score. In the standard care arm there 
was again little difference. Given the findings of the single arm analysis more 
detailed analysis was not undertaken. 
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Table 4-23 Prehabilitation arm changes in Dukes activity index from baseline to post 
intervention (19 patients).  
	 Baseline	
Post	
Prehab		 change		 Sig.	
Eat dress, bathe or use the toilet 19	 19	 0	 N/A	*	
Walk indoors, such as around their 
house 19	 19	 0	 N/A	*	
Walk 200 yards on level ground 18	 18	 0	 N/A	*	
Climb a flight of stairs or walk up a hill 19	 19	 0	 N/A	*	
Run a short distance?  12	 15	 +3	 0.25*	
Do light work around the house like 
dusting or washing dishes 19	 19	 0	 N/A	*	
Do moderate work around the house 
like vacuuming sweeping floors or 
carrying groceries? 
19	 19	 0	 N/A	*	
Do heavy work around the house like 
scrubbing floors or lifting or moving 
heavy furniture? 
14	 14	 0	 N/A	* 
Do yard work like raking leaves, 
weeding or pushing a power mower? 17	 19	 +2	 0.50*	
Have sexual relations?  12	 14	 +2	 0.61*	
Participate in moderate recreational 
activities like golf, bowling, dancing, 
doubles tennis, or throwing a ball? 
13	 18	 +5	 0.07*	
Participate in strenuous sports like 
swimming, singles tennis, football, 
basketball or skiing? 
11	 13	 +2	 0.72*	
Overall Dukes score** 45.6	(14.5)	
51.0	
(11.9)	
4.8		
***	
(-1.6:	11.2)	
0.13 
*Mcnemar test 
** Independent t test (Standard Dev) 
*** 95% Confidence Interval 
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Table 4-24 Standard care arm changes in Dukes activity index from baseline to 
immediately before surgery (16 patients) 
	 Baseline	
Post	
Prehab		 change		
P	
value*	
Eat dress, bathe or use the toilet 16	 16	 0	 N/A	
Walk indoors, such as around their 
house 16	 16	 0	 N/A	
Walk 200 yards on level ground 16	 16	 0	 N/A	
Climb a flight of stairs or walk up a hill 16	 16	 0	 N/A	
Run a short distance?  15	 15	 0	 N/A	
Do light work around the house like 
dusting or washing dishes 16	 16	 0	 N/A	
Do moderate work around the house 
like vacuuming sweeping floors or 
carrying groceries? 
16	 16	 0	 N/A	
Do heavy work around the house like 
scrubbing floors or lifting or moving 
heavy furniture? 
14	 14	 0	 N/A 
Do yard work like raking leaves, 
weeding or pushing a power mower? 13	 14	 +1	 1.00	
Have sexual relations?  10	 13	 +3	 0.25	
Participate in moderate recreational 
activities like golf, bowling, dancing, 
doubles tennis, or throwing a ball? 
13	 13	 0	 N/A	
Participate in strenuous sports like 
swimming, singles tennis, football, 
basketball or skiing? 
8	 8	 0	 N/A	
Overall Dukes score** 48.5	(10.7)	
50.3	
(9.9)	
+1.7	
(-4.2	:	7.7)	 0.550 
*Mcnemar test 
** Independent t test (Standard Dev) 
*** 95% Confidence Interval 
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4.3.8 High risk cohort subset analysis 
An unplanned subset analysis was carried out to consider changes occurring 
in patients deemed “high risk” with an oxygen uptake at the anaerobic 
threshold of <11 ml.kg-1.min-1. 
4.3.8.1 Changes In CPET values in the high risk cohort 
Within the high-risk cohort there were significant changes in the CPET 
values.  This is despite limited patient numbers (9 prehabilitation, 7 standard 
care).  Prehabilitation was associated with a significant improvement in both 
the relative and absolute oxygen uptake at the AT.  There was also an 
increase in the work rate at the AT, and improved ventilatory equivalents of 
both oxygen and carbon dioxide at peak exercise (Table 4-25). 
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Table 4-25 CPET changes in high-risk cohort 
 
CPET variable 
Mean difference after 
intervention Difference 
between cohorts 
(95% CI)  
P value 
Prehab 
(9) 
Standard 
Care 
(7) 
FEV1 0.09	 -0.33	 0.42	(-0.28	:	1.12)	 0.22	
FVC 0.137	 -0.547	 0.684	(-0.308	:	1.676)	 0.16	
FEV1/FVC 0.2	 -9.1	 9.4	(-9.7	:	28.4)	 0.31	
Resting Relative O2 
uptake (ml.kg-1.min-1) 
0.1	 0.3	 -0.1	(-0.6	:		0.4)	 0.56	
Resting absolute O2 
consumption (l/min) 
0.010	 0.026	 -0.016		(-0.058	:	0.027)	 0.44	
Resting HR (bpm) -4	 -2	 -2	(-12	:	9)	 0.75	
Relative O2 uptake at AT 
(ml.kg-1.min-1) 
1.9	 -0.4	 2.3	(0.3:	4.2)	 0.03	
Absolute O2 uptake at AT 
(l/m) 
0.151	 -0.024	 0.175		(0.015	:	0.335)	 0.03	
O2 Pulse at AT 1.2	 0.0	 1.2	(-0.1	:	2.4)	 0.06	
Ventilatory equivalent of 
O2 at AT 
1.3	 -1.3	 2.5	(-0.5	:	5.6)	 0.10	
Ventilatory equivalent of 
CO2 at AT 
0.4	 -0.8	 1.2	(-1.1	:	3.5)	 0.29	
Work rate at AT (watts) 13	 -6	 19	(5	:	33)	 0.01	
HR at AT (bpm) 1	 -4	 5	(-4	:	13)	 0.23	
Relative O2 uptake at 
peak (ml.kg-1.min-1) 
2.8	 0.3	 2.5	(-1.3	:	6.2)	 0.18	
Absolute O2 uptake at 
peak (l/min) 
0.234	 0.037	 0.197	(-0.124	:	0.519)	 0.21	
O2 Pulse at peak 1.4	 0.5	 0.8	(-0.9	:	2.6)	 0.31	
Ventilatory equivalent of 
O2 at peak 
0.3	 -4.2	 4.6	(0.3	:	8.9)	 0.04	
Ventilatory equivalent of 
CO2 at peak 
0.9	 -2.7	 3.6	(1.1	:	6.0)	 0.01	
Work rate at peak (watts) 13	 -1	 14	(-1	:	30)	 0.07	
HR at peak (bpm) 1	 -5	 6	(-4	:	15)	 0.20	
HR response to AT(bpm) 5	 -2	 7	(-2	:	15)	 0.13	
HR reserve (bpm) 4	 -3	 7	(-2	:	17)	 0.12	
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4.3.8.2 Changes in Quality of Life in the high risk cohort 
When comparing the SF-36 values between cohorts there was a clinically 
relevant improvement in the mental health domain of 10 (95% CI 8:29) in 
favour of prehabilitation (p<0.01) (Table 4-26).  There was also trend towards 
improved role-physical (+36 (95% CI -2:74).  Though confidence intervals are 
very wide for the role–physical domain, so caution must be exercised in the 
interpretation. 
Table 4-26 Changes in SF 36 values within high-risk cohort 
  
  Prehab (9) 
Standard 
Care 
(7) 
Difference 
95% Confidence 
Interval Sig. 
lower upper 
Physical Function 8	 3	 5	 -12	 23	 0.51	
Role-Physical 25	 -11	 36	 -2	 74	 0.06	
Body Pain 17	 9	 8	 -26	 41	 0.63	
General Health 4	 3	 2	 -16	 19	 0.85	
Vitality 11	 10	 1	 -17	 18	 0.95	
Social Functioning 17	 -6	 22	 -16	 60	 0.23	
Role Emotional 19	 5	 14	 -33	 60	 0.54	
Mental Health 8	 -10	 18	 8	 29	 0.00	
Overall Physical 
Health 13	 3	 10	 -5	 24	 0.16	
Overall Mental 
Health 12	 0	 11	 -9	 31	 0.25	
TOTAL SF36 Score 13	 1	 13	 -5	 30	 0.14	
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4.3.9 Perioperative outcomes 
4.3.9.1 Surgical interventions 
The surgical interventions undertaken are summarised in Table 4-27.  There 
were no statistically significant differences between the cohorts.  Specifically 
there was no difference between the incidence of major hepatectomy, or 
minor hepatectomy (prehab 38%, standard care 31%), those cases where 
additional non-hepatic procedures were undertaken (prehab 16%, standard 
care 13%), or the number of lesions undergoing treatment (median 3 in both 
groups).   
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Table 4-27 Extent of surgical intervention 
 
  Prehab 
(19) 
Standard 
Care 
(17) 
P 
value 
Hepatic Procedure    
 No surgery 0 4  
 Open and Close 3 2  
 No hepatic intervention 1 0  
 Right Hemihepatectomy 1 2  
 Left hemihepatectomy 2 0  
 Right hemihepatectomy + multiple 
metastectomy 2 1 N/A 
 Left hemihepatectomy + multiple 
hepatectomy 0 1  
 Left lateral sectionectomy 0 1  
 Metastectomy 4 4  
 Multiple metastectomy 5 1  
 Multiple metastectomy + Ablation 1 1  
 Extended right hemihepatectomy + 
caudate lobectomy 1 0  
Hepatectomy Extent    
 Major 6 4 
0.90  Minor 10 9 
Additional Procedure    
 Yes 3 2  
 No 16 13 1.00 
Additional Procedures (excluding gallbladder)    
 Bile Duct reconstruction 1 0 
N/A 
 Right hemicolectomy 1 0 
 Incisional hernia repair  1 
 Excision of wound metastasis 1 1 
 Portal vein ligation  1 
Segments involved in treatment* 3 (1:5) 3 (1:4) 0.682 
Lesions Treated* 3 (1:4.25) 3 (1:7) 0.693 
*Median and IQR 
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4.3.9.2 Comparison of perioperative outcomes between study arms  
The main perioperative outcomes analysed by group are summarised in 
Table 4-28.  Whilst statistically there is no significant difference in 
perioperative outcomes across the cohorts, all the patients who suffered a 
readmission were part of the prehabilitation group (4 vs 0; 21% vs 0%).  The 
reasons for readmission included 1 abdominal dehiscence, 2 patients 
developed bilomas requiring percutaneous drainage, and one patient 
developed significant hepatic insufficiency and pedal oedema. 
Table 4-28 Comparison of perioperative outcomes across cohorts 
  Study 
cohort 
(34) 
Prehab 
(19) 
Standard 
Care 
(15) 
P 
value 
Critical Care Admission * 12 (36%) 8 (42%) 4 (27%) 0.48 
Complication*     
 All Grades 15 (44%) 9 (47%) 6 (40%) 0.47 
 Grade 3&4 4 (12%) 3 (16%) 1 (7%) 0.40 
Complications     
 Total 26 10 13  
 Bile Leak/Biloma 2 2 0  
 Hepatic Insufficiency 4 1 3  
 Atrial fibrillation 1 1 0  
 Pacemaker malfunction 1 1 0  
 Respiratory Infection 4 1 3  
 Wound Infection 2 2 0  
 Ileus 1 0 1  
 Renal Impairment 1 1 0  
 Abdominal Dehiscience 1 1 0  
 Postoperative confusion 2 0 2  
 Nausea and vomiting 2 0 2  
 UTI 1 0 1  
 Thrombocytopenia 1 0 1  
Critical care length of stay** 1 (1:2) 1 (1:2) 1.5 (1:2) 1.00 
Length of stay** 5 (4:6.5) 5 (4:6) 5 (4.5:7) 0.584 
Readmission* 4 (12%) 4 (21%) 0 (0%) 0.113 
* Shown as median and percentage ** Shown as median and IQR 
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4.3.10 Assessments post surgery  
Exploratory data were collected for patients post operatively.  Unfortunately 
the data is confounded by varied surgical interventions, varied postoperative 
course and limited numbers.  This means beyond attendance data, 
meaningful conclusions cannot be drawn.  Consequently this data is not 
presented. 
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4.4 Discussion 
4.4.1 Preoperative CPET values 
The study met its primary objective of detecting a difference ≥ 1.5 ml.kg-
1.min-1in the Vo2 at AT when comparing a prehabilitation programme to 
standard care.  
The significant difference seen in the study is in part due to an unexpected 
deterioration in CPET values in the standard care arm.  In the standard care 
arm no patient had a significant improvement in Vo2 at AT (ml.kg-1.min-1) and 
4 had deterioration in excess of 1.5 ml.kg-1.min-1.    Overall there was a non-
significant trend towards worse Vo2 at AT (ml.kg-1.min-1) (p=0.09).  This would 
be in keeping with the literature on cancer related fatigue syndrome 
suggesting deteriorating physical conditioning is a key contributor to that 
syndrome161.    
This is a previously unpublished finding, and raises the question about timing 
of any preoperative CPET test.  Many of the large series examining CPET 
tests fail to report the timing of the CPET test in relation to surgery 34,43,49,229, 
and given that we have seen significant deterioration in CPET values in just 4 
weeks of standard care adds another potential confounding factor to the 
literature.   It may be that a CPET test conducted 4 weeks prior to surgery 
suggesting a patient is low risk, may in fact be inaccurate by the time of 
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surgery, meaning a patient gets inappropriately labelled as low risk and 
managed as such. 
The improvements in the workloads achieved at both the AT and peak 
exercise suggest improvements in skeletal muscle mass. Nearly 20% of 
patients undergoing colorectal liver metastasis resection are identified as 
having sarcopenia, a factor associated with higher complications, higher cost 
and earlier cancer recurrence127,235,236.   If prehabilitation could attenuate this, 
it could lead to lower costs of surgery, with better long term outcomes and 
disease free survival, vastly improving the cost efficacy of our treatments.   
Unfortunately this was not explored in this study and would be a focus for 
future research. 
The variation in response to the standardised exercise programme is 
interesting and in keeping with the theory of “responder/non responder” 
based on genetic markers237.  It should not be suggested that an absence of 
a VO2 response means that the exercise has failed to yield benefit.  In the 
prehabilitation arm nearly 40% of patients responded to the exercise 
programme in terms of the Vo2 at AT, but looking at the “non-responders” it 
may be that if they were left without prehabilitation their Vo2 values would 
have deteriorated, as was seen in a number of patients on standard care.   
Interestingly the group deemed high risk, appeared to have arguably some of 
the biggest improvements in CPET Values.  This would suggest that this 
group, at highest risk have the most to gain from prehabilitation.  In the era of 
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limited health resource these patients should form the focus of further 
research and intervention. 
Other benefits of exercise including improved muscle bulk, improved insulin 
resistance and improved preoperative psychological status238-241.  All can 
contribute to an improved perioperative outcome.  These were not studied in 
this thesis and would warrant further exploration. 
4.4.1 Preoperative QoL  
Clinically and statistically significant improvements in quality of life were 
detected using the SF-36 questionnaire.  This was not anticipated at the 
outset of the study as it was not possible to power the study on available 
data, and the absence of any correlating results in the EORTC 
questionnaires probably represents an under-powering for that particular 
outcome measure. 
The improvement in quality of life was in part related to improved physical 
functioning but the majority of the improvement was in improved mental 
health, in particular emotional and social functioning.  This finding of 
improved emotional and social functioning is in keeping with other studies of 
exercise in cancer sufferers242,243.  It is however interesting that a four week 
programme of just 12 sessions can achieve similar improvements to 
programmes typically of much longer duration. 
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The improvements in QoL are almost certainly related to the actual 
participation in the exercise programme.  In comparison to the CPET values 
that deteriorated across the control arm, the QoL (SF-36) values were largely 
unchanged, suggesting that the QoL was independent of physical fitness.  
This would suggest that improvements in physical fitness do not necessarily 
correlate with improved QoL but participation in the exercise programme 
itself seemed to be key.  This is similar to previous work244, but the 
mechanism for this improvement is not clear and remains a focus for further 
work.   Perhaps this could be examined by a study comparing prehabilitation 
against a sham arm of social interaction alone.  
Prehabilitation offers an opportunity to improve the preoperative education 
that could have multifactorial benefits beyond that of the improved physical 
fitness alone.  Preoperative exercise intervention provides an opportunity to 
educate patients. The exercise was supervised by a number of staff with 
differing levels of knowledge of the surgical intervention proposed.  Staff 
were allowed to answer patient questions, and it may be that some of the 
improved QoL seen is due to improved preoperative education and reduced 
anxiety levels. Lower preoperative anxiety, is associated with better 
postoperative gut motility and improved wound healing139,245-248.   
Life expectancy for patients with colorectal liver metastasis is increasing with 
a reported 5-year survival of 10% in patients treated with only palliative 
intent249.  Consequently, quality of life and not just length of life is becoming 
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ever more important.  The improvement in preoperative quality of life in this 
study should be seen as a significant achievement, given this is often a 
challenging time for patients.  However the longer-term effect was not 
explored and this would need to be assessed, as this may be a short-lived 
change.  
Prehabilitation fits well with the principals of living with and beyond cancer 
(LWBC), a concept of trying to improve quality of life and both physical and 
social functioning for patients undergoing cancer treatment, and in their life 
after treatment 250.  Exercise has been seen to be a key component of 
LWBC, with poor exercise levels identified and seen as a major focus for 
improving outcomes 250-252. 
The presence of preoperative psychological disturbance may be associated 
with poorer long-term survival in colorectal cancer159. In our study we found 
significant improvements were achieved in particular in the mental health of 
patients undergoing prehabilitation.  The impact of this on long-term life 
expectancy could be examined in future studies.  
4.4.2 Recruitment 
The recruitment rate was lower than seen in previous prehabilitation studies 
168,170,173, distance to travel being the greatest barrier to recruitment.  This 
barrier became apparent during the trial and was in part due to the tertiary 
nature of the disease.  This meant asking patients to travel for up to 3 hours 
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three times a week in addition to hospital appointments, with no funding for 
travel expenses incurred. Accepting this barrier, recruitment was acceptable, 
with a number of patients willing to travelling 90 minutes each way to attend 
exercise sessions and assessments.  In future studies making prehabilitation 
accessible locally would likely improve recruitment and make it applicable to 
the majority of patients. 
The cohort recruited to the trial were younger than a typical demographic of 
patients with CRLM 112. This clearly demonstrates a recruitment bias in 
favour of younger patients. Younger patients are reported to have more 
advanced disease at presentation and higher recurrence rates so this may 
have contributed to the selection of a cohort with biologically aggressive 
disease 253. 
Interestingly, two factors anticipated to be significant barriers to recruitment 
did not materialise at the level expected.  Around 12% of patients were 
excluded purely on the basis of inadequate time to deliver the exercise 
programme before the provisional surgery date, suggesting that the exercise 
programme in use in this study could be delivered within current UK cancer 
pathways.  Given that much of the population presenting with liver 
metastases are elderly, few could not participate as a result of being 
physically unable to cycle.  This absence of physical limitation as a barrier 
would fit with our previous experience of CPET in the population 34. 
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4.4.3 Study Cohort 
Whilst importantly there were no differences in any baseline characteristics 
between study arms, it is worth considering the effect recruitment bias may 
have had on the overall cohort within the study. 
The presence of a cohort with more aggressive tumour biology is supported 
by baseline characteristics with nearly half of patients presenting with 
synchronous disease, and 6 patients having a colorectal primary in situ 
during the trial. This is higher than would be expected in a typical cohort of 
patients presenting with liver metastases160.  A number of candidates had 
already undergone resection of other site disease, and several had multi-site 
disease.  The patients also had a greater preponderance to an advanced 
primary than seen in other studies160. 
Patients with a metachronous presentation had an unexpectedly high rate of 
complications following their primary surgery at approximately 50%. This high 
complication rate is not explainable by emergency presentations as the rates 
of emergency presentations are fairly typical in our study cohort142.  
Complications have been implicated in disease recurrence following 
colorectal resection and hepatectomy for CRLM238,254.  This relationship 
warrants further exploration. 
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4.4.4 Preoperative study progress 
Study completion and attendance was high in comparison to other studies 
162,169,173,207. In particular the adherence of 99.1% is excellent, suggesting that 
the exercise intervention is acceptable to the recruited patient group; and that 
the study cohort were highly motivated.   This given the relatively low 
recruitment rate raises the question of selection bias, and may temper the 
results, and mean the results do not translate in wider practice.  
Other contributory factors to the high adherence include the supervised 
nature of the exercise, and the interval nature of training. Other supervised 
exercise programmes have been successful168,172,207 in comparison to home 
based prehabilitation programmes which have failed to yield significant 
fitness improvements162,171.. Interval-based training programmes have been 
shown to have higher ratings of perceived enjoyment than constant load 
programmes; meaning adherence is likely to be higher. 221 
There was a relatively high rate of failure to progress to hepatectomy, with 5 
patients being irresectable at laparotomy, 3 for peritoneal disease, 1 for 
advancing hepatic disease, and one for extensive chemotherapy induced 
liver injury (patient required 70% hepatectomy).   This is much higher than 
expected given our own published data234.  Whilst given the small numbers 
this could be chance, it could also suggest that the overall cohort had 
aggressive tumour biology. 
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4.4.4.1 Preoperative Activity 
Activity did not objectively increase in the prehabilitation group compared 
with the standard care group. It may be that the Dukes activity index was not 
an adequate tool to evaluate activity, and that with the proliferation of 
electronic activity monitors this could be better assessed in future studies. 
4.4.5 Perioperative outcomes 
There is no statistically significant difference in perioperative outcomes or 
complication rates between the study arms.  This however is limited by the 
small numbers and confounded by the differing extent of surgical 
intervention.  
There was no difference in length of stay, however there were three 
readmissions with complications from the prehabilitation study arm.  A larger 
study would be needed to assess any differences observed, but given that in 
large series of hepatectomy using ERAS the median length of stay is already 
reduced to 6 days any benefit would be limited112. 
4.4.6 Postoperative study progress 
Due to a multitude of factors there was a relatively high attrition rate following 
the active study period, which has limited conclusions drawn from the 
postoperative period. In particular 3 patients failed to undergo any surgical 
intervention, and then a further 5 patients did not undergo hepatectomy.  
These patients undergoing a laparotomy only were not excluded from the 
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study, and were eligible to partake in follow-up.  By the second postoperative 
visit a number of patients had started to undergo further treatment including 
surgery (3 patients), and chemotherapy (8 patients), this limited attendance 
and completion of CPET tests, and could have confounded QoL measures. 
Reassuringly the vast majority of patients attending the 6-week visit were 
physically capable of completing a CPET test.  This was a point of concern 
during trial design, with clinicians involved in the trial design concerned that 
patients were unlikely to be physically capable. The high compliance rate 
suggests that if anything we underestimate the capacity of patients to recover 
from major surgery.  A larger study could utilise tests from 6 weeks to 
measure how quickly patients recover following surgery. 
4.5 Conclusions  
This randomized study has demonstrated that in patients prior to 
hepatectomy for CRLM, prehabilitation appears to be feasible.  It leads to a 
significant improvement in preoperative relative oxygen uptake at the 
anaerobic threshold, and a variety of other CPET variables.  It also improves 
preoperative quality of life.  This study was not powered to assess the affect 
of prehabilitation on postoperative outcome, and now its feasibility can be 
demonstrated future studies should be constructed to explore this further. 
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Chapter 5: Human liver slices as a model of 
hepatic function 
5.1 Introduction 
Patients with impaired hepatic function (cirrhosis), have poorer post surgical 
outcomes188. Given that patients with better cardiopulmonary fitness have 
better post surgical outcomes, it could be postulated that patients with better 
CPET fitness have better hepatic function.  Being able to correlate these 
factors would help allow tailoring of intervention and therapy. This could help 
reduce PHLF, thereby improving the safety profile of hepatectomy for CRLM. 
There is some evidence to support this correlation in animals, possibly 
mediated by an improvement in gluconeogenic capacity179. Unfortunately due 
to inaccessibility and limitations in the current models of hepatic functioning 
this relationship has not been adequately explored in humans182.   A number 
of different models of hepatic functioning have been developed197.   The most 
common of these is primary human hepatocyte collection and incubation, 
which is often seen as the gold standard for toxicology studies197.   This 
technique has a number of limitations, most notably the absence of other 
cells and the hepatic matrix, which is important for cellular function. One 
alternative method of hepatic function study is the use of human liver slices.  
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These have the advantage of containing all hepatic cells within the structure 
of the liver58. 
Human liver slices are not a widely used model of study, primarily due to 
limited access to hepatic tissue, and their relatively time consuming 
production255,256.  The prime source of liver for hepatic slicing is from rejected 
transplant specimens, or from the edge of resected liver.  Both of these 
sources are associated with prolonged time to slicing, which in conjunction 
with a variable operative trauma, contributes to the variability of function seen 
in samples256.  This variability has also contributed to a failure in widespread 
uptake of the technique. 
Liverpool University is home to the MRC Centre for Drug Safety Science, and 
the Liverpool Hepatobiliary Centre.  The Liverpool Hepatobiliary Centre is a 
high volume, internationally recognised cancer resectional centre.  The MRC 
Centre for Drug Safety Science is the UK’s leading centre for investigation of 
drug safety science.  A close collaboration between the centres has already 
led to a system for collection of primary hepatocytes from liver resection 
specimens 257. 
Liver slices are seen as a potential solution to the reducing frequency of 
samples large enough for primary hepatocytes, primarily as a result of 
increasing parenchymal preserving surgery.  Human liver slices can be 
collected from the margin even of metastectomy samples. 
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The aims of this component of the thesis are to develop a model of hepatic 
function based on human liver slices and demonstrate it is feasible at the 
University of Liverpool.    
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5.2 Methods 
5.2.1 Consent 
The research was performed with full ethical approval (Appendix 1.1), and all 
candidates were consented for donation of tissue samples. 
5.2.2 Sample Collection 
5.2.2.1 Liver sample collection 
Following appropriate patient information and informed consent, hepatic 
tissue cores were produced within the operating theatre to minimise warm 
ischemia time.  Following removal from the abdomen the hepatic resection 
specimen was immediately placed on a sterile surface.  Cores of tissue 
(diameter - 8mm) were collected manually using the technique described by 
Fischer et al 1995258. These were placed in ice cold pre-oxygenated Krebs-
Henislett Buffer than had been pre-oxygenated with 95%O2/5%CO2 and 
transported to the laboratory. 
Separately a sample of liver tissue and tumour tissue was collected using a 
scalpel from the resection specimen.  These were placed in separate 
Eppendorf tubes and immediately frozen in liquid nitrogen before transfer to  
-80°C freezer (Sanyo Upright ultra low freezer MDFU72VC). 
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5.2.2.2 Muscle 
The operating surgeon collected a small sample of skeletal muscle (2-4g) 
from the anterior abdominal wall.  This was immediately snap frozen in liquid 
nitrogen, before transfer to a -80°C freezer (Sanyo Upright ultra low freezer 
MDFU72VC). 
5.2.2.3 Serum 
Blood was taken using standard phlebotomy technique at all study time 
points (baseline, post prehab/standard care, post op visit 1, post of visit 2).  
This was spun at 4°C, 13,000 rpm for 10 minutes, following which the serum 
was removed using a pipette and placed in an Eppendorf tube and stored at         
-80°C. 
5.2.1 Production of hepatic slices 
The ideal thickness of liver slices to facilitate uptake of oxygen and 
substrates during incubation has previously been established as 240 µm259-
261. 
The Krumdieck MD6000 slicer (Alabama Research and Development, 
Munford, USA)(Figure 5-1) was used to generate hepatic slices using the 
method described by De Graaf et al with the slicer set to 240 µm58. 
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Figure 5-1 Krumdiek MD6000slicer in use. 
 
5.2.2 Incubation 
All culture and media changes were conducted under sterile conditions. 
Slices for incubation were immediately transferred to 12 well plates 
containing 1.5 ml of the incubation medium, as per Dogterom 1993262.    This 
was pre-incubated for 90 minutes to allow for cells traumatised during the 
slicing period to die, and other cells to restore potassium and ATP levels260.   
At this point slices were transferred using fine forceps to pre-warmed, pre-
prepared 12 well plates containing 1.5ml of incubation medium at 37°C.  
Media changes were conducted at 24 hours as per deGraff58.   Slices were 
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harvested at baseline, immediately following pre-incubation, then following 
pre-incubation at 1,2,4,12,24,48, and 72 hours. 
5.2.3 Viability assessment 
Viability was assessed with ATP and mitochondrial function. 
5.2.3.1 ATP assessment 
 Samples were placed in round-bottomed 2ml Eppendorfs containing ATP 
collection solution.  These were snap frozen in liquid nitrogen until time of 
ATP analysis. 
Samples were defrosted on ice, before tissue disruption with a microbead 
beater and centrifuged at 13,000 rpm, for 3 minutes at 4°C to form a pellet 
cell debris and a supernatant.  The pellet was then dissolved in 1ml of 0.5 M 
NaOH (> 2h, 60°C), for subsequent protein estimation  
ATP analysis was carried out using the CellTiter-Glo Luminescent Cell 
viability assay (Promega, Madison, USA).  The ATP standards were 
prepared using Adenosine 5’-triphosphate disodium salt, (Sigma-Aldrich, 
Gillingham, UK). All values were expressed in relation to the protein content 
of the slice. 
5.2.3.2 Mitochondrial activity assessment 
Mitochondrial activity was measured on the day of the incubationby the  
Resazurin test A 12 well plate for conduct of the assay was made up and 
placed in an incubator prior to the experiment. Each well contained 1350 µL 
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of Krebs buffer, which was allowed to equalise with the incubator 
temperature prior to the assay.  
At the selected time point a slice was transferred into one of the wells on the 
assay plate, and 150 µL (10% of total well volume) of Resazurin solution 
(Sigma-Aldrich, Gillingham, UK) was added.. The plate was incubated for 90 
minutes, following which  the slice was placed in a round-bottomed 2ml 
Eppendorf and snap frozen in liquid nitrogen for future estimation of protein 
content.  
To measure fluorescence, 100 µL of the study solution was added to a 96-
well black plate, running samples in triplicate.  A plate reader at 560nm then 
read this. 
5.2.3.3 Protein assessment 
Total protein concentration was determined using the method described by 
Lowry et al (1951)263. 
5.2.4 Functional assessment 
5.2.4.1 Albumin production 
Following a 4-hour incubation, albumin concentration in the incubation 
medium was assessed using the Human ELISA Quantification Kit (Bethyl 
Laboratories, Cambridge Bioscience, Cambridge UK).  
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5.2.4.2 Glucose Production 
Slices were removed from incubation media and incubated in Krebs-
Henseleit Buffer (KHB) without Glucose.  At 90 minutes supernatant was 
removed and glucose concentration estimated using the Glucose Oxidase 
estimation kit (Sigma-Aldrich, Gillingham, UK). 
5.2.1 Solutions used in laboratory analysis 
There are a number of solutions used within the study and their production 
methodology and composition is described below. 
5.2.1.1 Liver collection and transport media 
Cores of Liver tissue were collected using 1x HEPES solution (Fisher 
Scientific UK, Loughborough). 
5.2.1.2 Incubation media 
This was made up using phenol-free Williams E media (Sigma-Aldrich, 
Gillingham, UK) supplemented with 2 mM glutamine (Sigma-Aldrich, 
Gillingham, UK)), penicillin-streptomycin (100 U/mL penicillin; 100 µg/mL 
streptomycin; invitrogen), 100 nM dexamethasone (Sigma-Aldrich, 
Gillingham, UK) and 1 X soln. ITG-S (Life-Technologies, Carlsbad, USA). All 
concentrations are final concentrations.  
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5.2.1.3 Standard Krebs-Henseleit Buffer 
A 10× concentrated KHB stock solution (10× KHB) was produced.  First 3.67 
g CaCl2·2H2O was dissolved in 0.5 litres of ultrapure water. Then 3.73 g KCl, 
69 g NaCl, 2.71 g MgSO4·7H2O and 1.63 g KH2PO4 were dissolved in a 
separate 0.5 litres of ultrapure water. Subsequently, the 2 solutions were 
mixed together and stored at 4 °C (stable for 6 months)58. 
On the day of the slice experiment, 2 litres of KHB was prepared by 
dissolving 4.2 g NaHCO3, 9.9 g d-glucose monohydrate and 4.76 g HEPES in 
about 0.8 litres of ultrapure water at 4 °C. Following this 200 ml 10× KHB, 
and 1 litre of ultrapure water at 4 °C were mixed.  This was kept at 0–4 °C on 
melting ice, and oxygenated with 95% O2/5% CO2 for at least 30 minutes 
before use. The pH was measured and standardised to pH 7.4.  
5.2.1.4 Krebs-Henseleit Buffer without Glucose 
KHB buffer without glucose was prepared in a similar manner to standard 
KHB (Chapter 5.2.1.3), except that instead of d-glucose monohydrate, l-
lactate (Sigma-Aldrich, Gillingham, UK) was added to a final concentration of 
20mM/l. 
5.2.1.5 ATP collection 
To prepare 500 ml of the ATP collection solution, 0.372 g EDTA was 
dissolved in 100 ml of ultrapure water.  The pH was adjusted with 5 M NaOH 
to obtain a pH of 10.9. Ultrapure water was added to the solution to obtain a 
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volume of 130 ml. This was supplemented with 370 ml ethanol (96%). This 
solution can be stored at 4 °C for approximately 3 months. 
5.2.1.6 ATP dilution solution 
To prepare 1 litre of the ATP dilution solution, 900ml of ultrapure water was 
combined with 100 ml of the ATP collection solution.   This can be stored for 
1 month at 4 °C. 
5.2.2 Histological analysis 
Slices were stored in 10% neutral buffered formalin solution (Sigma-Aldrich, 
Gillingham, UK).  One patient who underwent full 72-hour culture was 
randomly selected for analysis. 
The slices were processed and paraffin embedded by trained pathology staff 
at Leahurst School of Veterinary Science, Neston, UK. 
 Slices were then sent to a histopathologist for analysis using standard 
techniques. 
5.2.3 Study conduct 
Samples were analysed from a variety of different time points.  The overall 
pathway is summarised in Figure 5-2. 
There was limited quantity of available tissue from patient 3 which curtailed 
the experiments that could be performed.  
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Figure 5-2 Tissue collection points 
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5.3 Results 
5.3.1 Patient Demographics 
After method development six patient samples underwent hepatic slicing.  
The slices obtained were used for a variety of experiments. Patient 
demographics are summarised in Table 5-1. There were three men and three 
women, aged 47 – 76. Three had undergone prior chemotherapy, two as 
neo-adjuvant for their hepatic resection; this was completed at 44 weeks, 20 
weeks and 7 weeks respectively prior to hepatic resection. All 3 received a 
standard chemotherapy regimen with oxaliplatin and capecitabine. Five of the 
patients had underlying metastatic colorectal cancer, and one had 
hepatocellular carcinoma without evidence of cirrhosis.  Patients had little 
comorbidity, though patients 5 and 6 self reported poor (patient’s subjective 
assessment) recent activity levels, with patient 5 struggling for many months 
with chronic pelvic sepsis, and patient 6 suffering from chronic fatigue 
syndrome. 
Steatosis was present in all patients histologically. Patient 4 had evidence of 
sinusoidal obstruction, thought to relate to the size of his hepatic tumour 
(13cm HCC).  No patients had any chronic liver disease or cirrhosis. 
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Table 5-1 Demographics of patients undergoing slicing 
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5.3.1.1 Preoperative blood tests 
Preoperative blood results are summarised in Table 5-2. No patient was 
anaemic. Patient two had an elevated platelet count, thought to be a post 
inflammatory response to an episode of bowel obstruction, treated by the 
insertion of a colonic stent two weeks prior to hepatic resection. No patient 
had biochemical evidence of renal impairment or hepatic impairment.  
Table 5-2 Preoperative blood tests of patients 
 
Variable Patient 
1 2 3 4 5 6 
Hb (g/dL) 13.3 13.5 14.9 14.3 13.0 12.7 
WCC (10*9/L) 12.6 11.2 6.9 7.2 5.9 8.4 
Plt (10*9/L) 238 561 225 346 197 402 
Urea (mmol/L) 5.1 5.0 5.1 4.4 6.6 4.4 
Creatinine 
(umol/L) 97 68 107 66 76 67 
Albumin (g/L) 44 45 49 47 46 44 
Bilirubin (umol/L) 30 4 9 7 5 5 
ALT (u/L) 16 23 22 15 22 20 
Alkaline 
Phosphatase 
(u/L) 
72 119 93 138 176 151 
INR 1.0 1.0 1.0 1.1 1.0 1.1 
Prothrombin 
Time (seconds) 10.9 10.9 10.8 11.3 10.9 11.4 
APPT (seconds) 27.9 N/A 28.9 N/A 25.3 N/A 
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5.3.1.2 Patient CPET values 
All patients had undergone cardiopulmonary exercise testing and their results 
are summarised in Table 5-3.  Patients 4, 5 and 6 were of lower fitness levels 
(AT <11 than patients 1, 2 and 3 (AT >11). All CPET variables for these 
patients were markedly depressed throughout.  
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Table 5-3 CPET values 
 
*Developed AF at peak exercise, patient also on beta-blockade. 
  
!
Candidate!
1! 2! 3! 4! 5! 6!
Days!before!surgery!of!test! 9! 1! 55! 69! 50! 9!
Height!(cm)! 182! 165! 165! 176! 160! 166!
Weight!(kg)! 104! 64! 81! 83! 53! 77!
BMI!(kg/m2)! 31.6! 23.5! 29.8! 26.9! 20.9! 27.9!
REST!
VO2/KG!(ml/kg/min)! 3.2! 3.8! 4.0! 4.0! 4.6! 3.1!
Absolute!VO2!l/min! 0.33! 0.24! 0.32! 0.33! 0.25! 0.24!
o2!pulse! 3.5! 3.0! 3.5! 5.0! 2.5! 2.3!
VE/Vo2! 28.7! 33.8! 34.7! 33.5! 35.4! 42.3!
VE/VCO2! 38.9! 35.2! 37.8! 39.8! 40.8! 39.6!
HR! 93! 81! 92! 67! 98! 102!
RER! 0.74! 0.96! 0.92! 0.84! 0.87! 1.04!
AT!
VO2/KG!(ml/kg/min)! 11.6! 12.4! 12.0! 8.8! 9.6! 6.1!
Absolute!VO2!l/min! 1.21! 0.79! 0.97! 0.73! 0.51! 0.47!
o2!pulse! 10.5! 7.0! 8.4! 8.6! 4.9! 4.5!
VE/Vo2! 28.4! 29.6! 31.7! 32.3! 35.4! 27.4!
VE/VCO2! 34.1! 30.0! 34.4! 36.4! 37.9! 29.1!
Wattage! 70! 60! 58! 62! 20! 32!
HR! 115! 114! 116! 87! 105! 105!
RER! 0.83! 0.99! 0.90! 0.88! 0.94! 0.94!
VO2!
peak!
VO2/KG!(ml/kg/min)! 15.9! 19.4! 16.8! 11.3! 14.8! 14.0!
Absolute!VO2!l/min! 1.65! 1.24! 1.36! 0.94! 0.79! 1.08!
o2!pulse! 11.5! 7.9! 9.8! 11.0! 6.2! 7.5!
VE/Vo2! 38.1! 50.6! 38.3! 32.5! 36.8! 39.8!
VE/VCO2! 33.2! 36.0! 34.8! 36.5! 31.9! 31.7!
Wattage! 166! 108! 104! 76! 68! 116!
HR! 144! 158! 139! 84! 127! 144!
RER! 1.15! 1.41! 1.10! 0.89! 1.16! 1.26!
Delta!
HR1!
HR!response!to!AT!
(bpm)! 22! 33! 24! 20! 7! 3!
Delta!!
HR!2!
HR!reserve!
(bpm)! 51! 77! 47! *! 29! 42!
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5.3.2 Histological analysis 
Histological analysis of slices was conducted on one patient (patient 4) over 
a full time course.    
5.3.2.1 Initial histological analysis 
All three slices demonstrated liver tissue with portal tracts. The hepatocytes 
were normal, with lightly eosinophilic finely granular cytoplasm and minimal 
nuclear pleomorphism. There was no evidence of steatosis or cholestasis.  
Slight sinusoidal congestion; in keeping obstruction due to tumour, was 
evident. The portal tracts were normal. 
Figure 5-3. H+E stain of liver slice at x110 magnification demonstrating normal hepatic 
structure with slight sinusoidal congestion. 
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5.3.2.2 Post pre-incubation until 4 hours 
Following pre-incubation the slices all retain normal architecture, with no 
histological change.  By one hour there are very occasional acidophilic 
hepatocytes (represents dying hepatocytes)(<1 per x4 field), which gradually 
increase in frequency to 4 hours.  By 4 hours acidophilic hepatocytes are 
counted at 2-6 per x10 field.  By 2 hours there is very slight enlargement of 
some hepatocytes, which is similar up until 4 hours.  Sinusoidal dilatation 
starts to develop at 2 hours.  In one of the slices at 4 hours this has 
progressed to sinusoidal congestion.  This is the slice with the most evidence 
of other inflammatory change including acidophilic hepatocytes. At four hours 
there is evidence of increasing eosinophilic granular change to the cytoplasm 
in all slices. 
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Figure 5-4 H+E stain of liver slice 4 hours post incubation at x110 magnification, 
demonstrating increasing eosinophilic granular change. 
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5.3.2.3 12-24 hours following pre-incubation 
At 12 hours there is significant histological change with a loss of 
cohesiveness of hepatocytes, and evidence of nuclear pyknosis.  There is 
evidence of individual hepatocyte necrosis/apoptosis.   These changes are 
progressive by 24 hours, with zones of enlarged vacuolated hepatocytes 
developing.  These hepatocytes contain enlarged nuclei.  These changes 
occur mainly in the peri-portal areas. In non-portal areas cellular morphology 
is preserved with minimal cytoplasmic and nuclear changes. 
Figure 5-5 +E stain of liver slice 24 hours post incubation at x110 magnification 
demonstrating some peri-portal hepatocyte necrosis but preservation of cellular 
morphology elsewhere. 
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5.3.2.4 48-72 hours post pre-incubation 
At 48 hours the inflammatory changes seen at 24 hours have progressed, 
with increasing numbers of necrotic hepatocytes.  There are, however, still 
sections of viable hepatocytes, though within these sections there are 
occasional ballooned hepatocytes.  The necrotic changes are predominantly 
centred around the portal tracts.  These changes are progressive at 72 hours 
with increasing necrotic hepatocytes, though even at 72 hours there remain 
sections of viable hepatocytes. 
Figure 5-6 +E stain of liver slice 72 hours post incubation at x110 magnification 
demonstrating preservation of viable hepatocytes. 
 
Improving the perioperative management of resectable colorectal liver metastases 
 
172 
 
5.3.2.5 Histological assessment of intracellular matrix 
The cellular matrix was assessed using reticulin staining.  This demonstrated 
good preservation of the extracellular matrix. 
Figure 5-7 Reticulin staining of initial slice (Top) at x90 magnification and at 72 hours 
(Lower) at x50 magnification demonstrating good preservation of the extracellular 
matrix. 
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5.3.2.6 Ki 67 Staining 
Cellular proliferation was assessed using Ki 67 and Vimentin staining.  There 
was little demonstrable increase in cellular proliferation during the course of 
the incubation.  The Ki67 stains are shown below to illustrate this. 
Figure 5-8 Vimentin staining of liver slices at x225 magnification demonstrating no 
increase in Ki-67 over the course of the incubation.  
 
!A!–!Initial,!B!–!24!hours,!C!–!72!hours!!
A!
B!
C!
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5.3.3 Viability Assays 
5.3.3.1 ATP 
ATP was measured at baseline, immediately following pre-incubation, and 
then at 1, 2, 4,12, 24, 48 and 72 hours following pre-incubation. Patients 1 
and 2 only had one slice run at time points baseline, following pre-incubation, 
and at 4 hours.  Patient 3 had 3 slices taken at time-points baseline, following 
pre-incubation, and then at 4 and 24 hours.  Patients 4 - 6 had 3 slices run at 
each time point.  Results are expressed relative to the protein content of the 
slices, as nanomoles ATP per mg protein.  An ATP ratio of 2 nanomoles per 
mg of protein has previously been reported as representing viability58.  Mean 
ATP at baseline was 2.72nm/mg (SD 1.23), Patients 1-4 had values typically 
in excess of 2nm/mg. Patients 5 and 6 had values significantly below this 
threshold, with a mean ATP content of 1.48 nm/mg protein (SD 0.52 nm/mg 
protein).  Despite this suggested non-viability, as can be seen from the other 
assays, these slices appeared to retain viability and preservation of function 
through to 72 hours.  
ATP content was preserved throughout the incubation period, with no 
discernable reduction relative to protein content (Figure 5-9 & Table 5-4).  
This suggests preservation of viable cells during the time-course. 
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Table 5-4 ATP content of slices, expressed relative to protein in nanomoles per mg of 
protein. 
Time	Point	 Patient	
1	 2	 3	 4	 5	 6	
initial	
Slice	1	 3.81	 2.59	 3.24	 4.06	 1.61	 1.14	
Slice	2	 	 	 2.04	 4.21	 2.14	 0.74	
Slice	3	 	 	 2.34	 4.95	 1.95	 1.28	
Post	Pre	Incubation	
Slice	1	 3.88	 3.16	 1.47	 3.84	 1.81	 2.68	
Slice	2	 	 	 1.64	 4.18	 1.55	 1.83	
Slice	3	 	 	 1.29	 3.15	 0.94	 1.15	
1	HR	
Slice	1	 	 	 	 3.35	 1.76	 2.29	
Slice	2	 	 	 	 3.49	 1.33	 3.61	
Slice	3	 	 	 	 2.39	 3.18	 3.42	
2HR	
Slice	1	 	 	 	 2.34	 0.98	 1.47	
Slice	2	 	 	 	 1.03	 1.76	 2.28	
Slice	3	 	 	 	 2.39	 1.46	 1.76	
4	HR	
Slice	1	 4.05	 1.78	 1.59	 2.84	 1.17	 1.05	
Slice	2	 	 	 1.63	 1.05	 0.88	 1.29	
Slice	3	 	 	 2.10	 1.90	 0.96	 1.76	
12	HR	
Slice	1	 	 	 	 4.07	 2.11	 2.27	
Slice	2	 	 	 	 2.02	 1.78	 2.17	
Slice	3	 	 	 	 2.47	 1.61	 2.33	
24	HR	
Slice	1	 	 	 1.89	 2.24	 2.40	 1.61	
Slice	2	 	 	 2.01	 2.96	 1.70	 1.41	
Slice	3	 	 	 2.00	 1.59	 1.57	 1.86	
48	HR	
Slice	1	 	 	 	 5.24	 1.90	 3.16	
Slice	2	 	 	 	 2.70	 1.48	 3.05	
Slice	3	 	 	 	 7.12	 2.36	 3.34	
72	HR	
Slice	1	 	 	 	 3.03	 2.46	 1.96	
Slice	2	 	 	 	 9.12	 2.28	 2.22	
Slice	3	 	 	 	 4.26	 2.30	 2.22	
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Figure 5-9 Graph showing ATP content over time, expressed per mg of protein 
 
5.3.3.2 Protein content 
Mean protein content per slice at baseline ranged from 1.37mg to 3.26mg 
(Table 5-5), however the intra-patient variability was small suggesting that 
slices from patients were similar, with the variability reflecting physical 
differences between the hepatic tissue of patients. 
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Table 5-5 Mean protein content of slices per patient, expressed in mg 
 
Over time there was a drop in the protein content of slices.  By 4 hours the 
reduction was between 8-30% of the initial weight, and by 72 hours the slices 
had lost between 23-52% of their initial protein content.  There appeared to 
be an initial drop in protein content after pre-incubation followed by a 
recovery (Figure 5-10). This may be a reflection of the failure to take slices 
!
Mean!protein!content!mg!
(Standard!deviation)!!
Patient!
1! 2! 3! 4! 5! 6!
Initial! 1.37!(0.07)!
1.96!
(0.06)!
1.50!
(0.19)!
1.85!
(0.31)!
3.26!
(0.11)!
2.30!
(0.09)!
Post!!
PreBincubation!
1.29!
(0.03)!
1.51!
(0.39)!
1.66!
(0.04)!
0.98!
(0.06)!
2.91!
(0.09)!
1.85!
(0.13)!
1!HR! ! ! !
1.38!
(0.46)!
2.65!
(0.32)!
1.52!
(0.28)!
2HR! ! ! !
1.30!
(0.33)!
2.48!
(0.04)!
2.03!
(0.16)!
4!HR! 0.96!(0.27)!
1.62!
(0.04)!
1.39!
(0.18)!
1.69!
(0.18)!
2.65!
(0.25)!
1.94!
(0.19)!
12HR! ! ! !
1.23!
(0.16)!
1.73!
(0.21)!
1.55!
(0.18)!
24!HR! ! !
1.18!
(0.04)!
1.34!
(0.32)!
1.85!
(0.13)!
1.52!
(0.06)!
48!HR! ! ! !
0.95!
(0.57)!
1.64!
(0.13)!
1.38!
(0.06)!
72!HR! ! ! !
0.89!
(0.38)!
1.63!
(0.01)!
1.77!
(0.10)!
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from patients 1-3 at 1 and 2 hours, but could also represent the theoretical 
shedding of damaged cells on the cut surfaces during the pre-incubation 
period followed by a recovery of cellular protein. 
Figure 5-10 Protein content change over time (mg) 
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5.3.4 Functional Assays 
5.3.4.1 Mitochondrial Activity 
Mitochondrial activity was measured for all patients with the exception of 
patient 3 where tissue was limited and it was elected to pursue other assays 
as a priority.  Mitochondrial activity was available corrected for the protein 
content of the slice for patients 4-6, through to 72 hours.  In patients 1 and 2 
mitochondrial activity was not corrected for the protein content of the slices 
used for the study and protein content was estimated using the slices 
obtained for ATP content, thus allowing comparison of all 5 patients studied.  
Patients 1 and 2 only had mitochondrial activity measured through to 4 hours. 
There was a consistent pattern in mitochondrial activity with a peak activity 
observed at 12 hours (Table 5-6 and Figure 5-11).  Activity then levelled out 
at a level similar to that observed at 4 hours, and remained constant over the 
72-hour incubation. 
There was limited inter, and intra patient variability.  The variations that were 
seen likely reflect variation in slice quality, incubation success and trauma 
sustained during collection and slicing.   
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Table 5-6 Mitochondrial Activity expressed relative to slice protein content (standard 
deviation) 
 
Figure 5-11 Chart demonstrating average mitochondrial activity relative to protein 
content for all slices. 
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5.3.4.2 Albumin Production 
Albumin production was measured in two patients (1 and 2).  Albumin 
concentration in the supernatant after a 4-hour incubation is summarised in 
Table 5-7, and Figure 5-12.  All slices demonstrated the ability to release 
albumin into the supernatant. There was a narrow range of albumin 
concentrations at 4 hours (498ng/ml +/- 37ng/ml), this is regardless of the 
slice protein content.   
Table 5-7 Mean albumin concentration in supernatant after a four-hour incubation 
	
Albumin	concentration	ng/ml	
(Standard	deviation)	
Albumin	concentration	per	
mg	of	slice	protein	(ng/ml)	
(Standard	deviation)	
Patient	1	 487	(+/-	40)	 527.08	(+/-	99)	
Patient	2	 510	(+/-	29)	 314.32	(+/-	19)	
Mean	 498	(+/-	37)	 420.70	(+/-	128)	
Figure 5-12 Graph depicting albumin concentration in the supernatant following a 
four-hour incubation 
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5.3.4.3 Glucose production 
Glucose production into the supernatant was measured in 3 patients (4-6) 
(Table 5-8 and Figure 5-13).  Patients 4 and 5 underwent culture to 72 hours, 
with patient 6 undergoing culture to 12 hours.  The reduction in culture time 
was due to a rapid drop of glucose concentration in the media by 24 hours. 
The glucose concentration was not related to protein content of individual 
slices.  Glucose concentration in the supernatant went from 0 mcg/ml at 
baseline to a maximum of 63 mcg/ml by 12 hours.  The drop in glucose 
concentration by 24-72 hours was likely related to the culture media being 
inadequate for long cultures, and the absence of any prophylaxis to infection.    
Table 5-8 Glucose concentration of supernatant 
	
Mean	Glucose	concentration	of	supernatant		(mcg/ml)	
Time	(Hours)	 Patient	4	 Patient	5	 Patient	6	 Average	
0	 0.00	 0.00	 0.00	 0.00	
1	 38.85	 50.08	 54.97	 47.97	
2	 36.24	 51.18	 56.34	 47.92	
4	 49.92	 72.74	 67.02	 63.23	
12	 48.71	 66.92	 47.01	 54.21	
24	 53.74	 21.70	 N/A	 37.72	
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Figure 5-13 Graph showing glucose concentration in supernatant 
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5.4 Conclusions 
This chapter has demonstrates the success of our human liver slice model, 
with viable tissue at 72 hours post resection.   
The results obtained in this study are difficult to compare to previously 
published work on PCLS264.  Primarily this is due to the relative infrequency 
of using human tissue in such models.  A comprehensive review of the 
characteristics and pharmaco-toxicology of PCLS identified only a handful of 
studies utilising human tissue264.  None of the human studies used the ATP 
measure.  
De Graaf et al suggested that an ATP of less than 2nmol mg-1 protein in a 
liver slice was non viable58.  We utilised slightly different methodology, and 
consequently our results are not directly comparable.  However we achieved 
levels of ATP in keeping with their results, but our results suggests that an 
ATP of less than 2 mmol mg-1 protein does not necessarily indicate non-
viability. 
It is reported that typically have a wet weight of 20-30mg, with a protein 
content of 1-2mg, which would be in keeping with our results (Table 5-5)264.  
Owing to different methodological approaches, the albumin production, 
glucose production, and mitochondrial function assays are not directly 
comparable, but serve to underline the functional viability of our liver slice 
model 264. 
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Working closely with the clinical teams meant that samples could be 
collected and placed in the collection fluid within the operating department.  
This will have minimised the warm ischaemia time of the tissues, and 
contributed to the preserved viability.  Typically ATP levels are depressed 
and the period of pre-incubation serves to allow recover of the slices before 
utilising them in experimentation265.  Within this model there was little 
depression and recovery of ATP levels suggesting that pre-incubation trauma 
(and consumption of ATP) had been minimised (Figure 5-10).   
There was little variation in results from slices taken from the same patients, 
suggesting that the methodology for both incubation and reporting has been 
consistent, and that the variation arises from the patients themselves, and 
the operative trauma preceding collection. Access to patient level data may 
allow some explanation of the variation seen within the hepatic slices, 
although conclusions are limited by the small sample size.   
When examining the ATP levels it is noted that patients 5 and 6 had the 
lowest levels of ATP. Both of these patients had limited aerobic capacity.  
This could suggest a correlation between hepatic ATP and aerobic capacity. 
However patient 4 also had depressed aerobic capacity but had high ATP 
levels.  Patient 4 is however a relative anomaly within the series, given the 
underlying diagnosis of HCC.  This HCC may reflect an underlying problem 
with hepatic tissue, as HCC in non-cirrhotic patients often evolves in part as a 
result of potentially harmful carcinogens266.  Despite the very low numbers it 
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may be worth further investigating the correlation between aerobic capacity 
and hepatic ATP. 
A number of alterations in the methodology as suggested by de Graff et al 
were adopted and may have affected our results accordingly58.  Primarily 
these adaptions were made owing to available resources.  Firstly the liver 
tissue was not flushed or stored with University of Wisconsin preservation 
fluid, in part due to cost restrictions, but primarily due to the variability of the 
size of preserved tissue.  Whilst our technique is used by others in similar 
circumstances it may have led to a reduction in viability267.  The second 
major variation from their methodology was the absence of a circulating 
coolant in the Krumdiek liver slicer.  Given the relatively few slices prepared 
over a short time in ice cold KHB it is unlikely to have impaired viability 
significantly.    
The last major variation in the methodology is the variation in the incubation 
method.  Slices were incubated in a standard incubation with a 5% CO2/95% 
air environment in 12 well plates on an orbital shaker (Orbit LS, Labnet, 
Appleton Woods).  Whilst the use of a 95%O2/5%CO2 atmosphere has been 
suggested to help preserve viability a number of studies have utilised the 
incubation environment used in this study with success264. Indeed some 
comparative studies have found little or no benefit of a high oxygen 
environment when culturing slices268,269. 
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This component of my thesis demonstrates a viable model of hepatic function 
that has a number of potential advantages over currently established primary 
hepatocyte models206,255,270,271.  
As this model is utilised further, it should allow exploration of the hypothesis 
that patients with greater cardiopulmonary fitness have improved hepatic 
function.  It should also allow exploration of the affect that neoadjuvant 
chemotherapy has on hepatic functional capacity.  If this hypothesis were 
proven, it could allow cardiopulmonary exercise testing to be utilized to 
estimate the volume of hepatic tissue that can be safely resected, and the 
volumes at which a patient is at higher perioperative risk.  
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Chapter 6: Discussion 
6.1 Introduction 
This thesis focuses on the surgical management of colorectal liver 
metastases with particular emphasis on prehabilitation and the potential links 
between hepatic function and physical fitness. 
The management of CRLM is constantly evolving. The number of treatments 
available has increased greatly over the last 20 years8,24,123,272. Local, loco-
regional and systemic therapies have been developed to improve efficacy 
and patient suitability24,123,273, and consequently many patients are surviving 
longer and undergoing increasingly complex multi-modal treatment 
pathways.  
Patients with CRLM are undergoing more treatments, and all of these 
treatments have associated morbidity. We can expect the cumulative effect 
of the associated morbidity to impair physical fitness. This poorer fitness is 
likely to cost patients in two ways, firstly in terms of a negative impact on their 
quality of life, and secondly the effect of poorer fitness on individual treatment 
outcome.  Poorer physical fitness has been implicated to cause greater 
perioperative morbidity 40,43,49,216,274. Perioperative morbidity has also been 
linked with poorer long-term survival135.  Greater morbidity and poorer 
survival lead to greater treatment cost (cost of complications) for poorer 
overall gain (reduced survival).  
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Prehabilitation is likely to become more important in the future as colorectal 
cancer is increasingly prevalent with age, and global populations are aging5.  
Advancing age is associated with greater frailty and comorbidity, so a 
successful prehabilitation programme may help mitigate the effects of 
advancing age on patient outcomes 5,116,117.  
6.2 Prehabilitation 
This thesis has developed and demonstrated that a four-week prehabilitation 
programme can improve the mean VO2 at the AT of patients 275. A low VO2 at 
AT is associated with increased complications, longer hospital length of stay, 
higher perioperative mortality, and poorer medium-term 
survival35,37,40,43,49,216,228,274,276,277. Prehabilitation also led to improved quality 
of life preoperatively, as measured by the SF-36 questionnaire 275.   
Prior to this research no programme of just 4 weeks has demonstrated 
improvements in preoperative fitness and none in a population with 
metastatic cancer. The improved preoperative quality of life has not 
previously been demonstrated in a randomised study, though small cohort 
studies have found similar results207. The high adherence seen in this 
programme suggests that it is acceptable to the patient population. 
At the commencement of this study no randomised trial had demonstrated 
the capacity of prehabilitation to significantly improve the mean VO2 at AT of 
cancer patients277. Even now as the research completes only 4 randomized 
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studies have been performed involving cancer patients162,171,173,278. The 
largest of these failed to deliver significant improvements in VO2 at AT over 
their control arm162. 
The prehabilitation programme achieved its primary objective to deliver a 1.5 
ml.kg-1.min-1 improvement in the Vo2 at AT, when compared to standard care.  
This is an important achievement given the failures of previous randomized 
studies of prehabilitation162,171.  Within the prehabilitation arm it can be seen 
that a variety of measures of preoperative fitness seen as potentially relevant 
to predicting outcome have also improved, or have trends towards 
improvement, such as the Vo2 at Peak (ml.kg-1.min-1), and the o2 pulse29,30.   
Both of these have been identified as factors closely tied to perioperative 
outcomes including morbidity, mortality and hospital length of stay40,43. 
The prior randomized studies in abdominal cancer surgery have had 
inconsistent results162,278-280.   The shortest programme, a supervised 2-4 
week programme (mean 5 sessions), demonstrated the feasibility of 
prehabilitation in a cancer population279.   The authors suggested improved 
respiratory muscle endurance following prehabilitation, when compared to 
exercise advice.  There was, however, no improvement in physical exercise 
capacity or quality of life.  The largest trial randomized 133 patients prior to 
colorectal resection to a home based exercise programme, or a sham control 
of walking and breathing exercises162.   The programme had a longer 
prehabilitation time (mean 43 days) but failed to demonstrate an 
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improvement in peak Vo2, or distance achieved in the 6-minute walk test. 
This was thought to relate to poor compliance in the home-based exercise 
programme. Recently a study randomized 77 patients to either rehabilitation 
or prehabilitation (plus rehabilitation) before colorectal resection173.   The 
prehabilitation took place at home and was similar timescale to the current 
study (mean 24.5 days).  The authors demonstrated that prehabilitation led to 
improved functional walking capacity, and a quicker return to baseline levels 
post-surgery. There were no differences in complications, or hospital length 
of stay. 
The non-randomized studies have consistently demonstrated that 
prehabilitation leads to improvements in Vo2 uptake at AT and Peak169,170,172.  
Some studies have also demonstrated improvements in the 6 minute walk 
capacity both pre and postoperatively, and an improved SF-36 mental health 
composite score 170. 
The general trend towards improved CPET variables when comparing 
prehabilitation with standard care supports the view that prehabilitation led to 
a global improvement in physical functioning.  Prehabilitation led to improved 
work rate at both peak exercise and the anaerobic threshold, and an increase 
in the heart rate reserve.  The heart rate at the anaerobic threshold and the 
heart rate reserve were identified as a variables of potential relevance to 
predicting postoperative outcome in the patients in this study and by 
Hightower et al34,281. The mechanism underpinning this relationship remains 
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unclear, but may relate to improvements in cardiac functioning.  This should 
be examined in future studies. 
The development and validation of a new exercise program has contributed 
to the success of the main study232. This development was not planned at the 
outset of the research, however it became evident that no suitable 
programme existed. The challenge was to design a program of short enough 
duration, and low enough frequency that it would fit around preoperative 
cancer pathways.  This programme needed to deliver clinically relevant 
improvements in preoperative fitness. Even defining the concept of “clinically 
relevant” improvements in fitness had to be conceptualized.  An improvement 
on 1.5 ml.kg-1.min-1, was felt to be clinically relevant, as if deliverable across 
our patient cohort would shift up to 30% of our patients out of the category 
“high risk” who were automatically admitted to critical care112.  Our 
institutional policy was based on the work by Older et al who identified “high 
risk” patients and managed them accordingly35,36. 
These “high-risk” patients were a group who had arguable the greatest 
benefit from prehabilitation. With an average improvement in the AT being 
greater than for the cohort as a whole 275.  These patients who are at higher 
risk of complications also consume greater healthcare spending. Focusing 
prehabilitation on these patients is likely to yield greatest benefit53.  A 
recently published randomised study in patients deemed high risk for surgery 
has shown that prehabilitation reduces complications by 50%, shortens 
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hospital and critical care stay278.  This study classified high risk as patients 
over the age or 70 or patients assessed as ASA 3 or 4.  The prehabilitation 
utilised in this study employed an exercise programme almost identical in 
nature to the programme utilised in this study, in addition nutritional and 
psychological interventions were employed278.   This trial adds weight to the 
suggestion that prehabilitation should be adopted into clinical practice, at 
least for those deemed high risk.   
Further studies should examine the cost efficacy of prehabilitation.  Work 
conducted in our centre has shown no association between Vo2 uptake at the 
AT and perioperative mortality, or morbidity34.  This was thought to reflect 
how the CPET was being used to delimitate perioperative care. This tailored 
care means that patients with poorer Vo2 uptake at the AT cost more to treat 
in the perioperative period even if they suffer no complications53.  Therefore 
even if prehabilitation failed to improve perioperative outcomes it may 
dramatically reduce the cost of care. 
Adherence to the exercise programme in the RCT component of the study 
was similar to that seen in the pilot study.  This is despite the population in 
the RCT having metastatic cancer and significant comorbidities 232,275. The 
adherence was high in comparison to other studies, and this will have 
contributed to the success of the programme162,168,171,207  This high 
adherence also suggests that the programme is appropriate to the target 
population.  
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The underlying reasons for this high adherence are likely to be multi-factorial.  
All patients volunteered to take part, knowing it could involve participation in 
an exercise programme.   Consequently they are likely to be a highly 
motivated group. In addition interval-based training programmes have been 
shown to have higher ratings of perceived enjoyment than constant load 
programmes221. The underlying mechanism for this is difficult to distinguish 
but is likely to relate to a combination of the varied exercise profile with the 
direct effects of high intensity exercise.  
Calculating the programme based on a baseline symptom limited CPET has 
significant advantages.  It allows patients to be screened for major risks when 
undertaking exercise, thus reducing any risks of the exercise programme 
itself.  Prehabilitation programmes utilising submaximal testing have seen 
significant adverse events during the exercise sessions168.  The ability to 
calculate the entire programme based on a baseline test minimises on-going 
management of the exercise programme, and should minimise cost if CPET 
is utilised when expanding to a service level provision.   The VO2 at AT, 
detected during cardiopulmonary exercise testing, was used to design the 
programme as it has been shown to correlate well with endurance capacity, 
and is detectable in most patients 30,45. 
An unexpected finding within this study was the marked deterioration in those 
patients randomized to standard care.  This finding has not been previously 
demonstrated though this may stem from an absence of true control arms in 
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the majority of studies.  West et al, utilised CPET in a non-randomised study 
and suggested a possible underlying trend, towards deteriorating Vo2 uptake 
at the AT in the control patients following chemo radiotherapy for primary 
rectal cancer172.  In West et al this deterioration could relate to progressive 
changes following the neoadjuvant treatment, rather than the disease 
process. However Gillis et al found that 36% of patients not partaking in 
prehabilitation (rehabilitation only arm) had a significant drop in the distance 
achieved in the 6-minute walk test173.  This would further support the view 
that without intervention patients are deteriorating prior to surgery.  
It had been established that there was heterogeneity in gains of the VO2max to 
endurance training ranging from 0-100%, and that some people lacked 
capacity to improve the aerobic capacity282-284.   The work by Timmons et al 
established a series of gene biomarkers that could account for 50% of the 
variation in VO2max response, though the exact mechanisms underpinning the 
role these gene markers play remains largely unclear237.   Their work also 
identified that around 20% of patients lack the capacity to increase the 
VO2max response, which is not dissimilar to the 30% (6 of 19) patients on the 
prehabilitation arm who had either unchanged or deteriorating VO2peak.  This 
is slightly higher than may have been expected in a general population, 
though low numbers and metastatic cancer represent potential explanations.  
We could expect greater benefit of prehabilitation in responders, however an 
absence of a VO2 response, may not represent a failure. Prehabilitation may 
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have prevented the deterioration in VO2 uptake seen in the control arm.  
Exercise is known to have other benefits which may have been accrued in 
the non - VO2 responders.  
Exercise is a known treatment for sarcopenia285-287.   Sarcopenia has been 
identified in around 20% of patient with CRLM and is associated with higher 
complications, poorer survival and higher treatment cost127,235,236.  Whilst it 
could be argued that sarcopenia is a marker of adverse disease biology, and 
that this is the reason for these findings there is evidence that sarcopenia is a 
significant predictor of adverse outcome in a variety of other settings.  It has 
been identified as a predictor of poor outcome following trauma, and also in 
the elderly hospitalised and non-hospitalised patient288-290.   Given this 
established role in the non-cancer setting, it may be postulated that the 
sarcopenia may not relate to the disease but the physical conditioning of the 
patients.  The improvements in the workloads achieved at both the AT and 
peak exercise suggests improvements in skeletal muscle mass.   
Prehabilitation may affected sarcopenia, and thus could impact on survival.  
This warrants further investigation. 
Insulin resistance develops as part of a series of homeostatic alterations 
leading to the development of a catabolic state as a normal response to any 
trauma, including surgery291.  This insulin resistance develops in a dose 
dependant manner correlating with the magnitude of surgery292.  It is 
predominantly related to extrahepatic modifications, but there is also a 
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significant increase in hepatic glucose production following surgery293.   The 
degree of insulin resistance has been shown to correlate with postoperative 
length of stay, and reducing insulin resistance has been a focus of 
research292,294.  Reduction of insulin resistance is thought to be a key 
mechanism of the success of ERAS programmes239. 
Exercise is known to be an effective strategy for diminishing insulin 
resistance295. The mechanisms underlying the exercise-induced 
improvement in whole body glucose tolerance are not fully understood.    
Established contributors are improved glucose disposal and enhanced insulin 
mediated cellular transport in skeletal muscle296.    The hyperglycaemia 
resultant from increased insulin resistance is known to be associated with 
poorer outcome in variety of setting including in critical care patients297.  
Interestingly aggressively treating the hyperglycaemia with insulin does not 
appear to be associated with improved outcomes298.   This would suggest 
that the hyperglycaemia is not the cause of the worse outcome but a 
symptom of the underlying mechanisms.  Whilst not investigated in this study 
prehabilitation may have affected these underlying mechanisms.  If 
prehabilitation could deliver reduced perioperative insulin resistance it may 
lead to improved perioperative outcomes regardless of the changes in 
aerobic capacity, and this should form a focus for further work. 
Interestingly Timmons et al identified that 30% of patients failed to improve 
insulin sensitivity in response to exercise, it would be useful to examine the 
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relationship between these patients, the patients who could not increase 
aerobic capacity and the incidence of sarcopenia127,237.   It would appear that 
the mechanisms of action of a variety of these pathways overlap, and it may 
be that a cohort of patients who will not benefit from exercise therapy exists. 
If these could be identified triage for patients who are unlikely to benefit from 
prehabilitation could be performed. 
Quality of life has been a major focus for this research.  In metastatic 
colorectal cancer survival has dramatically improved over the last 2 decades, 
meaning that quality is ever more important than just quantity.  In patients 
with resectable CRLM survival to 5 years is in the order of 50%24,78.   Even in 
patients with incurable metastatic disease undergoing palliative 
chemotherapy median survival has more than doubled to greater than 2 
years272.  Given this increasing survival, quality of life has become an 
increasingly important clinical outcome299. 
Prehabilitation led to improved quality of life preoperatively, as measured by 
the SF-36 questionnaire.  In contrast standard care did little to alter the 
quality of life. Interestingly when the quality of life was assessed with the 
EORTC questionnaire there was no statistically significant difference 
between the study arms.  However this may relate to an under powering for 
analysis using the EORTC questionnaire, particularly given the general shift 
in values in favour of prehabilitation. 
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No other randomized prehabilitation study in abdominal surgery has 
demonstrated significant improvements in quality of life162,278-280.  It was 
assessed in three of the four studies162,278,279.  One utilised the EORTC 
questionnaire and found similar results to this study, this may relate to under 
powering with only 87 patients randomised279.  The largest study, Carli et al, 
was largely affected by the apparent success of the “sham” control arm of 
breathing/walking162.  They found improvements in the hospital anxiety and 
depression scores300 in both study arms.  This would suggest that it is not 
necessarily the exercise that makes the difference, but perhaps the 
empowering the patients to feel like they can make a difference to their 
outcomes.  The recent study where high-risk patients underwent a 
prehabilitation programme utilized the SF-36 assessment. It found no 
significant differences in pre-surgical quality of life, no explanation for this 
variation was postulated, though it may reflect the variation in disease 
processes within the treatment population. 
In other prehabilitation studies utilising SF-36170,173  Gillis et al found a non-
significant trend towards improved mental health (p=0.085) in the 
prehabilitation arm, similar to our study173.   Li et al found prehabilitation 
improved a variety of SF-36 domains including Role Physical, Vitality, and 
mental health.  This study was, however, limited by a non-randomized 
historical control arm, and an absence of baseline SF-36 scores in this 
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cohort. These results are not surprising given the findings in lung resectional 
surgery suggesting that prehabilitation leads to improved quality of life207. 
The majority of SF-36 improvement was delivered by improvements in 
mental health, in particular emotional and social functioning.  This finding of 
improved emotional and social functioning is in keeping with other studies of 
exercise in cancer sufferers242,243.  It is however interesting that a four week 
programme of just 12 sessions can achieve similar improvements to 
programmes typically of much longer duration150.  In particular this trial 
suggests improved preoperative psychological status, a factor known to be 
associated with improved long-term survival in colorectal cancer159. 
Prehabilitation would appear to represent the natural progression for ERAS 
programmes that are now established in many surgical 
disciplines112,140,144,301,302.   These ERAS programmes have revolutionised 
surgical practice in the last decade leading to reduced morbidity, and 
healthcare cost139,140.  The suggested mechanisms of action underpinning 
prehabilitation are similar to those thought to underpin the benefits delivered 
by ERAS.  These include improved insulin sensitivity, better physical 
conditioning and an opportunity to improve the preoperative education a key 
pillar of ERAS139.  
Despite the success of the programme, there was no demonstrable 
difference in activity levels between the cohorts when assessed utilizing the 
Dukes activity questionnaire.  This is similar to previous studies utilising 
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activity questionnaires279. The activity questionnaire may not be sensitive 
enough to detect this.  Further research into this area may be aided by the 
widespread adoption of smart devices, and should be considered in future 
studies. 
6.2.1 Limitations  
The findings of this study offer interesting avenues for future development, 
but there are limitations that must be considered when interpreting the 
results. Importantly whilst this study demonstrates that it is possible to deliver 
significant improvements in CPET values, and it would appear logical to 
assume this will deliver the benefits associated with better fitness217, this 
requires confirmation in a larger trial. Future studies should be powered to 
detect differences in postoperative morbidity, alongside survival and quality 
of life benefits. 
There is a potential recruitment bias that may limit generalizability to a wider 
population overall. The cohort is younger than the typical patient group, 
suggesting an preoperative exercise intervention is more appealing to the 
younger patient population112.  Younger patients have been reported to have 
more aggressive disease, meaning the study population may have been 
more likely to have aggressive disease than the overall patient population253. 
These study patients also had a greater preponderance to an advanced 
primary than seen in other studies160.  The relatively high rate of failure to 
progress to hepatectomy is much higher than expected from the unit’s own 
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published data, and would support the assumption that the cohort had more 
aggressive tumour biology234.  
A final concern within the study is the difficulty presented within blinding.  All 
clinicians were blinded to the 2nd cardiopulmonary exercise test results, and 
the randomization of patients.  Despite this patients were prone to reveal 
their attendance at preoperative exercise programme.  The patients attending 
prehabilitation were immensely proud of their achievements.  Many had not 
partaken in exercise for a number of years before starting prehabilitation. In 
addition a number of patients within the prehabilitation arm had gone beyond 
the prehabilitation programme.  One of those achieving the greatest 
response had taken to cycling to and from the prehabilitation sessions, which 
was nearly a 20 mile round trip.  Whilst it could be argued that it was not the 
prehabilitation programme that achieved the improvement, there were no 
incidences of patients taking up exercise within the standard care arm. 
6.2.2 Future work 
This thesis has demonstrated that a short prehabilitation programme can 
deliver significant improvements in aerobic fitness, but has also identified a 
number of potential areas for future research.  Replicating the work by 
Barberan-Garcia et al in a hepatectomy cohort would be useful to confirm the 
positive effects of prehabilitation on perioperative outcome 278.   
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Selecting the appropriate endpoint to study in such a study is challenging. 
Numbers would be exceptionally high for assessing the effect on 
postoperative mortality given a published mortality of 0.3%112.  Other 
perioperative outcome measures that could be considered are postoperative 
morbidity, hospital length of stay, or treatment cost.   
The effect of prehabilitation on rates of postoperative complications is 
possibly not appropriate. Some complications are a result of technical failure, 
and prehabilitation is unlikely to influence a surgical team’s performance.  
Consequently it may be more appropriate to investigate the effect of 
prehabilitation on cardiorespiratory complications, as other studies have 
expllored303,304. However in liver surgery there is a significant interplay 
between surgical complications and cardiorespiratory complications, owing to 
the proximity of the liver to the diaphragm34. 
Hospital length of stay may be a more appropriate choice of outcome; given 
the relationship of CPET values to length of stay in blinded studies40,43.  
However following CRLM surgery length of stay is typically 5-6 days 
regardless of extent of hepatectomy, meaning such a trial may be require 
very high numbers to show differences112.  
Treatment cost could be considered though it would require un-blinding the 
clinical team to the intervention, and 2nd cardiopulmonary exercise test.  As 
without this it would not be able to affect the triage of care that goes on for 
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those patients deemed higher risk.  Any trial would therefore be subject to 
significant bias. 
Overall survival could be considered but there are a number of well-
documented problems with this endpoint305.  In particular the developments 
in colorectal cancer make powering any study challenging, and identifying the 
contribution a short prehabilitation programme had to survival is likely to be 
challenging.  
Quality of life is another potential endpoint to consider.  Unfortunately, the 
postoperative results suggested Qol was largely similar at 12 weeks (data not 
included in thesis).  Though this could in part relate to the aforementioned 
confounds, but it makes powering a future study difficult.  A future quality of 
life study should combine prehabilitation with rehabilitation. 
Given these difficulties and the findings in high-risk patients undergoing 
hepatectomy, these probably represent the group in which to focus a larger 
study.  The primary endpoint should probably be either quality of life or 
perioperative complications, as this has meaningful implications on cost, and 
disease recurrence53,135,306.  It should combine prehabilitation with 
rehabilitation. 
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The other challenging questions that future work should try and answer 
include:  
1. What is the most effective form of prehabilitation? 
2. Are there patients who gain no benefit from prehabilitation? 
 
6.2.2.1 What is the most effective form of prehabilitation? 
This study utilised a supervised interval exercise programme, alternating 
between severe and moderate intensities232.   This has likely contributed to 
the success of the programme given the limited success of previous 
unsupervised or constant load studies162,171,279.   Interval training is also the 
most effective way to achieve maximal aerobic capacity gain, and aerobic 
capacity has been identified as correlating with postoperative 
outcome40,43,48,49.  However there are other aspects of prehabilitation 
programmes to consider. 
Sarcopenia has been identified as correlating with post operative and long-
term outcomes, following a variety of surgical interventions127,235,236,290.  
Several studies have combined aerobic prehabilitation with resistance or 
strength training170,279,307,308.   Unfortunately these studies fail to address 
sarcopenia directly though this may stem from the difficulties this provides as 
an endpoint309.  Sarcopenia has a variety of definitions, and methods of 
assessment, which can be both costly and time consuming to measure.  
Given this there has been an increasing interest in utilising simple tests such 
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as hand grip tests279, and gait speed170,308.  The studies utilising some form 
of measurement of strength have suggested that prehabilitation could 
improve muscle strength, and the 6-minute walk capacity170,308. However 
Dronkers et al 279 found no difference in the timed “up and go test” 310, which 
has been correlated with sarcopenia309.  Future prehabilitation work should 
address sarcopenia utilising a measurement of muscle bulk, in combination 
with sarcopenia measurement on routine scans in the prehabilitation and 
follow-up period. 
Prehabilitation works on more than just the physical needs of a patient as 
seen by the reduced anxiety levels seen in this study.  This may in part be 
due to a feeling of an improved fitness level reducing the worry prior to 
surgical intervention. However it is likely that other factors contribute.  The 
act of prehabilitation empowers the patient to do something about their 
disease, giving them more control over a situation they have previously felt 
powerless within311.  Prehabilitation also allows time for patients ask 
questions about their upcoming intervention.  This improved understanding is 
likely to reduce anxiety311.   Preoperative education is a key component of 
ERAS139, and prehabilitation offers an ideal setting to maximise preoperative 
education.  Future prehabilitation programmes should make use of structured 
education programmes to enhance this aspect of care. 
A final area of interest is the combination of prehabilitation with rehabilitation. 
This has been done in patients with cirrhosis prior to hepatectomy for 
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HCC159.   In this study they found that at 6 months post-operatively patients 
who had undergone prehabilitation combined with rehabilitation had lower 
BMI, and body fat. Little data was provided about other parameters, though 
comment was made that those who performed exercise more frequently had 
greater benefit.  Given the established benefits of rehabilitative exercise, 
combining it with prehabilitation in future studies would seem logical, though 
it would make deciphering the benefit of prehabilitation from rehabilitation 
more difficult150. 
Given the evidence it is likely that a future prehabilitation programme would 
be multimodal, involving aerobic training, with strength work and preoperative 
education.  This should be combined with an active rehabilitation programme.   
6.2.2.2 Are there patients who gain no benefit from prehabilitation? 
The benefits of any prehabilitation programme are likely to be highly variable 
and work should be devoted to detecting from the outset those patients in 
whom no benefit is to be accrued so they can proceed directly to other 
therapy. 
Timmons et al identified that a cohort of people lack the genetic ability to 
improve aerobic capacity or reduce insulin resistance237. When approaching 
the subject of identifying those who are not going to get benefit, both the 
patients genetics and the biologically of the underlying disease should be 
considered.  
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Future work should involve assessment at baseline of both the patient 
genetics and the tumour to facilitate identifying those in whom resource could 
be better directed, and help facilitate personalized prehabilitation 
programmes to deliver maximal benefit to individual patients. 
6.3 Hepatic slicing 
The assessment of hepatic function is an on-going challenge for the research 
community197. It is possible to measure levels of hepatic functioning in 
humans using a variety of tests65,312-314. These tests, however, do not 
measure total capacity; rather they measure function at a point in time. 
Models of human hepatic function are all associated with limitations197.  The 
initial aim of investigating links between cardiopulmonary fitness and hepatic 
function was not feasible without a viable model of hepatic functioning. 
Establishing such a model of hepatic functioning has implications beyond this 
research including drug toxicity studies, physiological studies and also work 
on hepatic regeneration.  
Whilst few firm conclusions were drawn from the work on hepatic slicing 
(Chapter 5, page 154) it has establishes a viable model of hepatic functioning 
that has offered a variety of potential avenues for future research. 
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6.3.1 Optimizing slicing methodology and incubation. 
The quality of hepatic tissue has been identified as the major factor in in vitro 
studies256.  In resection specimens it would be useful to establish how much 
of the damage to hepatic tissue is created during the operative trauma.  This 
could easily be facilitated by slices taken from cores of tissue being taken 
from the intended resection specimen, immediately upon opening the 
abdomen, being compared slices generated from cores taken from the 
resected specimen. This would require intraoperative coring of the liver tissue 
by the operating surgeon. 
The collection buffer utilised in this study was ice cold KHB, in keeping with 
similar methodology underway at Maastricht University267.  However, a 
variety of groups propose perfusion of a specimen with UW solution prior to 
creating cores of tissue58,315.  It would be useful to investigate whether this 
has adversely affected the viability of our tissue, though reportedly in humans 
UW makes little difference as long as hypothermic incubation time is under 
18 hours206.  
In terms of optimising the methodology, of real interest would be incubation 
within a dynamic 3-D culture system197. A variety of technologies are already 
available.  Primarily these were designed to incubate primary hepatocytes 
within a 3–D culture system but it would be interesting to see the effect these 
have upon the preservation of viability in hepatic slices.  
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6.3.2 Hepatic function and exercise 
At the outset of this research there was a suggestion that the liver may play a 
role in fitness, or vice versa.  This was thought to be the case as the liver is 
intrinsically involved in metabolism and gluconeogenesis, and previous work 
has demonstrated an effect of exercise on this function, with significant inter-
patient variation27.  It has also been shown that during exercise, despite 
reduced blood delivery, the liver has an increased uptake of lactate and 
increased glucose output28.   Once the human liver slice collection and 
incubation methodology has been standardised correlations could be drawn 
with patients CPET results.  If there is a correlation between fitness and 
hepatic functioning this should become identifiable.  
6.3.3 Preoperative carbohydrate loading and preservation of 
hepatic function 
Poor hepatic function is an established predictor of poor outcome following 
surgery193. Liver resection associated hepatic insufficiency, where the 
residual liver is insufficient to meet the systemic needs, is a major cause of 
morbidity and the leading cause of mortality10,54,55. Furthermore a degree of 
hepatic insufficiency is almost universally observed following major 
hepatectomy316. Defining hepatic function has remained one of the 
challenges of liver surgery, and currently there is no universally accepted 
method to define liver function preoperatively 59,62. 
Improving the perioperative management of resectable colorectal liver metastases 
 
211 
 
Preoperative carbohydrate loading (PCL) has been purported to improve 
peri-operative outcome, as part of the ERAS139,142. However, evidence of 
individual benefit is limited, and very little is understood about the 
mechanism.  One suggested mechanism for PCL is via preservation of 
hepatic glycogen content, which has been demonstrated in patients given 
PCL before gallbladder removal317.  Preservation of glycogen content is 
thought to prevent inhibition of both liver and systemic metabolism, allowing 
the body to respond to increased energy demands following surgery318-320. 
Currently, however, evidence to support the preservation of liver function is 
limited, and has not been explored in humans. 
The liver slice model of hepatic functioning would serve as a useful model to 
investigate this further, and to that end a study protocol has been devised 
and we are currently exploring avenues for funding. 
6.3.4 Development of liver extracellular matrix  
Regenerative medicine has identified that tissue engineering requires a 
scaffold for optimal effectiveness. Appropriate scaffolds facilitate cells with a 
surface for adhesion and also space for growth321.  Utilization of extracellular 
matrices promotes cell adhesion, and expression of organ-specific functions 
and cell differentiation 322-324. Interestingly primary hepatocytes, cultured on 
organ-specific matrices sustain expression of organ-specific functions325,326.  
This had led to an interest in development of improved organ scaffolds.  
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There is currently an interest in developing a de-cellularized extracellular 
matrix from PCLS.  Such a model has a number of advantages over formal 
hepatic specimens.  Primarily they are more easily obtainable, and multiple 
slices of a similar size are easily produced. These slices could be made to an 
appropriate thickness, which could be thicker than the optimal 240μm utilized 
in culture. 
These extracellular matrices could then be utilized in the development of both 
3-D culture systems and bio-artificial livers, concepts that are currently a key 
goal of regenerative hepatic science196. 
6.3.5 Co-culture 
The concept of a cancer micro-environment is long established, and the 
interplay between normal cells and cancer cells is a key to both their 
progression and response to chemotherapy327.  Work from the University of 
Liverpool identified that the function of normal hepatic tissue was key to 
predicting response to irinotecan328. Culturing precision cut liver slices is a 
form of co-culture, given that all cell types are represented.   There is on-
going interest in the culture of cancer slices with PCLS hepatic tissue.  This 
should facilitate a greater understanding of the interplay of drug efficacy on 
differing cell types.  Ultimately it may offer an alternative method for ex vivo 
investigation of response to chemotherapy, particularly for drugs where 
hepatic metabolism is relevant329. 
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6.4 Conclusions 
The affects of a globally aging population mean that colorectal cancer is likely 
to become more prevalent, with older more comorbid patients presenting with 
the disease.  Advances in the chemotherapeutic and surgical armamentarium 
mean that patients with CRLM are undergoing more treatment in increasingly 
complex treatment pathways.  These pathways are associated with 
significant morbidity and hepatic injury.  
ERAS and better preoperative assessment of patients using CPET may help 
mitigate some the challenge of treating a more elderly co-morbid population. 
Significant challenges remain and methods to improve perioperative care are 
needed.  
This thesis has demonstrated that prehabilitation is feasible, deliverable 
within cancer pathways, and associated with improved preoperative aerobic 
fitness and quality of life 275.  The response to the prehabilitation programme 
was variable in keeping with prior work into the genetic response to aerobic 
exercise training.  Future prehabilitation work should examine if there is a 
cohort of patients in whom prehabilitation offers no benefit. 
The development of a PCLS model should allow investigation of the links 
between cardiopulmonary fitness and hepatic function.  It should also allow 
investigation into other areas of hepatic functioning including research into 
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hepatic regeneration and chemotherapy toxicity.  That may allow further 
improvements in our treatment of CRLM.  
Developing on the work contained within this thesis should involve a large 
trial focusing on clinical outcome as a primary endpoint, possibly quality of 
life. Research into the mechanisms underpinning prehabilitation including 
sarcopenia, and insulin resistance should be a priority.   
Prehabilitation represents the natural progression from enhanced recovery, 
which is now recommended as standard of care for patients undergoing 
hepatectomy for CRLM 148.  I would expect a form of prehabilitation to 
become a standard of care for all patients undergoing hepatectomy for CRLM 
in the future.  
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Appendix 1: Prehabilitation programme 
development  
1.1 Ethical Approval 
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Patient Information Sheet 
 
Preoperative Exercise Intervention in Liver Surgery 
 
 
Introduction 
 
You are currently undergoing investigations to see whether you are suitable for surgery to 
remove bowel cancer that has spread to your Liver. 
 
Once these investigations are complete, you may require surgery, in which case we will 
invite you to take part in our research project.  
 
Before you decide whether to take part in this research, we would like you to understand 
why the research is being done and what would be involved.  
 
One of our team will go through the information sheet with you and answer any 
questions you have. 
 
Please talk to others about the study if you wish. 
Ask a member of the team if there is anything that is not clear. 
 
Part 1: Explains the purpose of this study and what will happen to you if you take part.  
Part 2: Explains more detailed information about the conduct of the study.  
 
 
Part 1 
 
 
What is the purpose of the study?  
As part of the normal assessment to decide whether an operation on your Liver is the right 
treatment for you, we perform an exercise test.  This gives us measures of your fitness. 
Studies have shown that patients who are physically fitter have fewer complications and a 
shorter hospital stay after surgery.   
The Liver plays a crucial role in exercise as it recycles some products of exercise and helps 
produce energy.  Very little research has been done looking at the effect of exercise training 
on Liver function.  
We want to see if a short period of exercise training in the weeks before surgery can make 
people fitter, and whether this will reduce the number of complications patients suffer after 
surgery.  We also want to study the effect of exercise on the function of the Liver. 
 
Why have I been invited?  
Patients who have bowel cancer that has spread to the liver, who may benefit from an 
operation to remove part of the Liver, are being asked to take part in the study. The study 
will involve around 40 patients.  
 
 
Improving the perioperative management of resectable colorectal liver metastases 
 
217 
 
 
  
2 of 10 
Preoperative Exercise Intervention in Liver Surgery 
Patient Information Sheet  
Version 2.3      June 2012 
 
 
Do I have to take part?  
It is entirely up to you whether you join the study. We will describe the study and go through 
this information sheet. If you agree to take part, we will then ask you to sign a consent form. 
You are free to withdraw at any time, without giving a reason. This would not affect the 
standard of care you receive. 
 
 
What will happen to me if I take part?  
This is all summarised in the diagram on the page 4. 
 
 
Preoperative Assessment 
As part of your assessment for surgery you will undergo an exercise test, blood tests, and 
possibly other tests which your consultant feels are necessary.  Once these have been 
completed and you have decided to undergo surgery, then we will give you the option to be 
involved in this research project. 
 
 
Recruitment 
If you decide to take part in the research we will first talk you through the project, describing 
what is involved and ask you to sign a consent form.  We will then ask you to fill in three 
short questionnaires, asking you about your general fitness and how you feel.  This should 
take around 10-15 minutes.  We would then take a blood sample.  This should take about 5 
minutes. 
 
We are unsure of the benefits that a short exercise program before surgery may bring. To 
find out, we need to compare different groups. To try to make sure the groups are the same 
to start with, each patient is put into a group by chance (randomly).  This is done by 
computer putting you into one of two groups, a 50% chance of being in either group. 
 
Both groups will be asked to use an activity monitor for the next 3-5 days.  This is a band 
which sits round your upper arm and gathers information on your level of activity.  We 
would ask you to continue as normal when using this.  We would arrange for its return.   
 
 
Group 1 
In this group you would be completing an exercise program.  This would involve 3 visits to 
hospital each week for 4 weeks.  The exercise would be on an exercise bike and involve 
short bursts of quite hard effort with periods of recovery after.  It will probably make you feel 
a little out of breath at some points, but through the majority of the exercise you should be 
able to talk comfortably.  It will not make you as out of breath as your initial exercise test 
and should not be as hard. 
 
 
Group 2 
In this group we would ask you to continue as normal, following our standard advice before 
surgery. 
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Assessment: The week before Surgery 
In this week we would bring you back to the hospital.  We would go through the same 3 
questionnaires that you filled in at the start.  Before surgery you will need further blood tests 
as part of the normal assessment for surgery. While these are being taken we would take 
one further 3ml blood bottle for our study.   
 
We would also repeat the exercise test you had in the assessment for surgery, and 
afterwards give you an exercise monitor to take home again.  We would collect the activity 
monitor from you when you come for surgery. 
 
 
Your Operation 
Your operation will be carried out in exactly the same way, except that 2 samples of tissue 
and one blood bottle will be taken.  
 
The blood bottle would be taken whilst you are asleep from the drip lines that are put in as 
part of normal surgery, and would not bring any increased risk. 
 
When your consultant is making a cut in the abdomen he will cut through some of your 
abdominal muscles.  At this time a small sample of muscle will be taken for study, this 
carries no increased risk. 
 
The second tissue sample is from your Liver. Normally his will be taken from an area of 
normal Liver tissue that needs to be cut away during the operation, and would include a 
portion of the cancer.  This tissue would normally be discarded. This brings no increased 
risk to you. 
 
Occasionally the amount of liver tissue being taken away is very small, if this were the case 
we would take a small biopsy from the liver that is staying behind so that we could still 
measure the liver function.  This would pose no significant increase in risk. 
 
 
Follow-up after surgery 
After you are discharged from hospital you will be seen in the clinic around 1 month later, 
and then again at around 3 months later.  When you come for these clinic visits we would 
ask you to complete the same questionnaires done before surgery, and do an exercise test 
(the same as before surgery).  Normally at these visits your doctor would request blood 
tests, when these are taken we would take a further blood sample. 
 
 
Ongoing Follow-up 
After this your formal involvement in the study will finish.  As part of your normal care you 
will be followed up for a period of 10 years.  During this time we will keep our research data, 
so that we may analyse it again at intervals to see if the study has had an effect on your 
long term outcome. 
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Flow Diagram Summarising Study 
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Expenses and payments  
Unfortunately there is no money available to help with travel expenses incurred by the 
study, however all parking at Aintree Hospital in relation to the study would be free (In the 
multi-storey car park).  We are seeking additional funding to support travel costs and if this 
becomes available we will inform you. 
 
 
What will I have to do?  
We would expect you to attend all clinic appointments, and both exercise tests before 
surgery.  After surgery we would like to repeat the exercise tests, however this would only 
be if you felt you had recovered enough.  
 
If you are unable to attend some of the exercise sessions it would not exclude you from the 
study, however we think it is likely that the more sessions you attend the more likely we are 
to see improvements in your fitness. 
 
Other than the involvement in the sessions, we would expect you to continue as normal 
following the standard advice given to you by your surgeon in the run up to surgery. 
 
 
What are the alternatives for diagnosis or treatment? 
Currently there are no standardised exercise programs in use before surgery at Aintree. 
 
 
What are the possible disadvantages and risks of taking part? 
The risks associated with taking part are minimal.   
 
 
Risks of the Exercise test 
This is the test you would normally undergo. There is a very small risk of problems with 
breathing or your heart associated with this.  We will repeat the test as part of the study a 
further 3 times. We would not expect any problems in the repeat tests, we would expect if 
you were going to have a problem it would be on the first test (the one you normally have 
as part of the workup for surgery). 
 
 
Risks of the exercise program 
As you would have had a full fitness assessment we would not expect any problems during 
the exercise test.  During the exercise program we would not exercise you as hard as in the 
original test.  
 
 
Disadvantages of taking part 
The project will require extra visits to the hospital, particularly for those who are allocated to 
the exercise group. This will involve time and the costs of transport to the hospital.  Parking 
will be free.  
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What are the side effects of taking part?  
If you do not normally exercise regularly then it is likely that your legs will ache a little 
following the initial exercise; these side effects should disappear over the course of the 
training program.   
 
If you do not ride a bike regularly before taking part in the study, you may get some mild 
discomfort on the bottom from sitting on the cycle seat towards the end of the exercise.  
This could be reduced through using padded cycling shorts.  This should also improve over 
the course of the training program. 
 
We would not expect any other side effects.  If you have other concerns you can always 
contact the lead researcher or their deputy. 
 
 
CONTACT NUMBERS AT END OF INFORMATION LEAFLET 
 
 
What are the possible benefits of taking part?  
In both groups you will be able to undergo fitness tests 3 further times in comparison to our 
normal practice.  This will give you extra information on your fitness.   
 
Within the exercise group, you will be given advice and training on how to improve your 
fitness.  This may increase your fitness before surgery, though this has not been proven. If 
we can improve your fitness this means you are at a lower risk for complications during 
surgery, and it may help you recover after surgery, and shorten your hospital stay.  
 
Exercise programs have also shown improvements in the feeling of general wellbeing, so it 
may be that you also feel better.   
 
 
What happens when the research study stops?  
Once the research stops we will continue to follow you up as we would in our normal 
practice. Currently this is ongoing for 10 years.  We will continue to collect follow up data 
and will look for long term benefits from the study. 
 
 
What if there is a problem?  
Any complaint about the way you have been dealt with during the study or any possible 
harm you might suffer will be addressed. The detailed information on this is given in Part 2.  
 
 
Will my taking part in the study be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will be handled 
in confidence. The details are included in Part 2. 
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Part 2 
 
What if relevant new information becomes available? 
Sometimes we get new information about the treatment being studied. If this happens, your 
research doctor will tell you and discuss whether you should continue in the study. If you 
decide not to carry on, your research doctor will make arrangements for your care to 
continue. 
 
What will happen if I don’t want to carry on with the study? 
If you don’t wish to continue in the study you may withdraw at any time, and your treatment 
will not be affected.  We would be grateful if you would let the lead researcher know, 
through the contacts available at the end of this information leaflet, or though your specialist 
nurse or consultant, so that your ongoing care can be arranged. 
 
If you decide not to continue in the project and you wish your samples and any data 
collected to be destroyed, then please contact the lead researcher so that this can be 
arranged.   
 
What if I have a complaint about the study? 
If you are not happy with the general care and treatment you receive during the study, 
please speak first to your study doctor who will try to resolve the problem. They can tell you 
about the hospital’s standard complaints procedure in case you wish to take the matter 
further.  
 
Complaints can also be directed to:  
Mr Stephen Fenwick 
Hepatobiliary Unit              
  Aintree Hospital                           
  Lower Lane                                  
  Fazakerly                                  
  Liverpool                                      
  L9 7AL                                         
 
  0151 529 2740 / 0151 529 8578 
 
When you call or write about a concern, please give as much information as you can. 
Include the name of the study leader and details about the problem. This will help officials 
look into your concern. When reporting a concern, you do not have to give your name. 
 
Will my taking part in this study be kept confidential? 
Your data and samples will be stored on secure NHS and university computers with your 
name and date of birth removed.  The lead researcher and the clinical team will be able to 
access a secure list which would allow your data to be retrieved should the need arise. 
It will be used only for this study and other studies that subsequently may be ethically 
approved by the local ethics committee.  
 
Will my GP be involved?  
We would inform your GP that you were taking part in the research project, but there will 
not be direct involvement from your GP.  We will not be sending copies of the research data 
to your GP. 
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What will happen to my samples? 
Your samples will be given to the University of Liverpool, where researchers will perform 
studies trying to assess Liver function.   If there is any tissue or samples left at the end of 
this study they will be stored.  Any further tests on the samples will only be done with full 
ethical approval. 
 
How will my sample be anonymised? 
When your sample is transferred from Aintree Hospital to the University of Liverpool it will 
be labelled with a unique code. The only person who knows this code will be the lead 
researcher in this study.  Scientists using your cells will not be able to find out who they are 
from, and any medical information linked to your sample will be anonymised. The link 
between your sample and your code will be kept on a password protected database in 
Aintree Hospital. It will only be accessible by the lead researcher. This link means that your 
specimen can be identified, but only indirectly.  
 
What will happen to the results of the research study? 
The result of the study as a whole will be published in medical literature. If there are results 
relevant to the general public then we will endeavour to disseminate these results through 
the local and national media. Any published results will not include any identifiable data.  If 
there are any results that the researchers feel pertinent to yourself these will be given to 
you during your follow-up appointments at the Aintree Hepatobiliary unit. 
 
Who has reviewed this study?  
All research in the NHS is looked at by an independent group of people, called a Research 
Ethics Committee, to protect your interests. This study has been reviewed and given 
favourable opinion by Liverpool Central Research Ethics Committee.  
 
Who is organising and funding the research?  
The study has been organised by the Aintree Hepatobiliary unit in conjunction with the 
University of Liverpool and the Liverpool School of surgery. 
 
Who can I contact for more information or to discuss the study? 
There are a number of people you can contact for more information or to ask questions. 
The Lead researcher (contact details below) is probably the best first point of call, though 
you could also contact your Liver specialist nurse or your surgeon. 
 
Lead Researcher:    Mr Declan Dunne 
 
Contact via Aintree    Hepatobiliary Unit 
     Aintree Hospital                           
     Lower Lane                                  
     Fazakerly 
     Liverpool 
     L9 7AL 
 Mobile Phone Number : 07970501231 
 Telephone   0151 529 2740 / 0151 529 8578 
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Patient Identifier: 
Consent Form Page 1 
 
Preoperative Exercise Intervention in Liver Surgery 
 
 
Name of Researcher:  
 
Please initial each box  
 
1. I confirm that I have read and understand the information sheet dated February 2012 
 version 2.2, and have had the opportunity to consider the information, ask 
questions and have these answered satisfactorily. 
 
I understand my participation is entirely voluntary and that I am free to 
withdraw my  permission at any time without giving reason. This will not 
affect my treatment. I will not receive any compensation for my 
participation. 
 
If I wish to withdraw from the study, I will contact my surgeon or a member 
of the research team. They will contact the Lead researcher (or subsequent 
nominated guardian) who will destroy my samples and delete my records. 
They will contact other researchers who are using my sample to arrange 
their destruction. 
 
I give permission for samples to be taken. I understand I will not be told any 
results generated from my samples. I understand all data generated from 
my samples will be anonymous, and it will not be directly linked to me. 
 
I understand that relevant information from my medical notes will be linked 
to my samples. I understand that these notes will be anonymised, and only 
the lead researcher will be able  to identify me from this information. 
 
I understand that my medical notes and data collected during the study  
may be looked at by individuals from regulatory authorities or from the nhs 
trust where it is relevant to my taking part in this research.  I give 
permission for these individuals to have access to this information.  
 
I understand that my liver tissue sample will be stored under secure 
conditions in the University of Liverpool for as long as 10 years. 
 
I understand that decisions on who can use my samples and what research 
they can perform, will be only subject to future ethical approval 
 
 
I agree to my GP being informed of my participation in the study.  
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Patient Identifier: 
 
Consent Form Page 2 
 
Preoperative Exercise Intervention in Liver Surgery 
 
 
 
 
I agree to the collection of data, and its use for research purposes, for the 
duration of my follow-up at Aintree hospital. 
 
 
I agree to take part in the aforementioned study  
 
 
Name of Participant_______________________________Date_______________ 
 
Signature__________________________________________________________ 
 
Name of 
Researcher______________________________________Date______________ 
 
Signature__________________________________________________________ 
 
When completed: 1 for participant; 1 for researcher site file; 1 (original) to be kept in 
medical notes. 
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1.4 Study cohort candidate characteristics 
Table 6-1 Individual candidate characteristics candidates 1-13 
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Table 6-2 Individual candidate characteristics candidates 14-24 
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Table 6-3 Individual candidate characteristics candidates 25-31 
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Table 6-4 Individual candidate characteristics candidates 32-37 
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1.5 Questionnaire based assessments 
 
1.5.1 SF-36 
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SF-36 3
8. During the past 4 weeks, how much did pain interfere with your normal work (including both work outside the home and
housework)?
q Not at all
q Slightly
q Moderately
q Quite a bit
q Extremely
9. These questions are about how you feel and how things have been with you during the past 4 weeks. For each question,
please give the one answer that comes closest to the way you have been feeling. How much of the time during the past 4
weeks.
a. did you feel full of pep?
q All of the time
q Most of the time
q A good bit of the time
q Some of the time
q A little of the time
q None of the time
b. have you been a very nervous person?
q All of the time
q Most of the time
q A good bit of the time
q Some of the time
q A little of the time
q None of the time
c. have you felt so down in the dumps nothing could cheer you up?
q All of the time
q Most of the time
q A good bit of the time
q Some of the time
q A little of the time
q None of the time
d. have you felt calm and peaceful?
q All of the time
q Most of the time
q A good bit of the time
q Some of the time
q A little of the time
q None of the time
e. did you have a lot of energy?
q All of the time
q Most of the time
q A good bit of the time
q Some of the time
q A little of the time
q None of the time
f. have you felt downhearted and blue?
q All of the time
q Most of the time
q A good bit of the time
q Some of the time
q A little of the time
q None of the time
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SF-36 4
g. did you feel worn out?
q All of the time
q Most of the time
q A good bit of the time
q Some of the time
q A little of the time
q None of the time
h. have you been a happy person?
q All of the time
q Most of the time
q A good bit of the time
q Some of the time
q A little of the time
q None of the time
i. did you feel tired?
q All of the time
q Most of the time
q A good bit of the time
q Some of the time
q A little of the time
q None of the time
10. During the past 4 weeks, how much of the time has your physical health or emotional problems interfered with your
social activities (like visiting friends, relatives, etc.)?
q All of the time
q Most of the time
q Some of the time
q A little of the time
q None of the time
11. How TRUE or FALSE is each of the following statements for you?
a. I seem to get sick a little easier than other people
q Definitely true
q Mostly true
q Don't know
q Mostly false
q Definitely false
b. I am as healthy as anybody I know
q Definitely true
q Mostly true
q Don't know
q Mostly false
q Definitely false
c. I expect my health to get worse
q Definitely true
q Mostly true
q Don't know
q Mostly false
q Definitely false
d. My health is excellent
q Definitely true
q Mostly true
q Don't know
q Mostly false
q Definitely false
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1.5.2 EORTC 
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1.5.3 EORTC LMC  
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1.5.4 Dukes Activity Questionnaire 
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Current management of colorectal liver metastases.  GJ Sunderland, 
DFJ Dunne, HZ Malik, GK Poston, SW Fenwick. Colorectal Cancer 2014 
April 2 (2): 163-181 
 
Optimal preoperative imaging in colorectal liver metastatsis. YIP V, 
Collins B, Dunne DFJ, Koay MY, Tang JM, Wieshmann H, Fenwick SW, 
Poston GJ, Malik HZ. Published European Journal of Cancer 2014 50 (5): 
937-943 
 
Controversies in the Oncosurgical management of liver limited stage IV 
colorectal cancer. Jones RP, Stattner S, Sutton P, McWhirter D, Fenwick 
SW, Malik HZ, Poston GJ.  Published Surgical Oncology 2014 23: 53-60 
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1.7 Book Chapters 
Colorectal Liver Metastasis.  Dunne DFJ, Jones RP, Adam R, Poston GJ.  
Chapter in Hepatobiliary and Pancreatic Surgery: Companion to Specialist 
Surgical Practice. Companion to Specialist Surgical Practice. 5, illustrated. 
Elsevier Health Sciences; 2013. 
 
Colorectal Liver metastasis. Jones RP, Dunne DFJ, Poston GJ.  Chapter in 
Recent advances in Surgery.  Recent advances in surgery: 35. New Delhi: 
Jaypee Brothers Medical Publishers (P) Ltd.; 2013. 
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Appendix 2: Presentations and abstracts.  
2.1 Oral Presentations at Conferences 
Prehabilitation before liver surgery. Dunne DFJ, Jones RP, Lythgoe DT, 
Malik HZ, Poston GJ, Palmer DH, Jack S, Fenwick SW.  
ASGBI 2014, Harrogate 
Age should not be used to determine fitness for hepatectomy.  Dunne 
DFJ, Parry G, Miller S, Jones RP, McWhirter, D, Sutton P, Poston GJ, Malik 
HZ, Fenwick SW.  
BASO 2013, London 
The impact of fitness of the cost of hepatectomy. Dunne DFJ, Misra N, 
Estebanez G, Poston GJ, Malik HZ, Fenwick SW.  
Presented BASO 2013, London 
A prehabilitation program for liver surgery.  Dunne DFJ, Jones RP, Malik 
H, Poston GJ, Palmer DH, Jack S, Fenwick S.   
IHPBA 2012, Paris 
Predicting complications in liver surgery.  Dunne DFJ, Jones RP, 
Pilkington F, Misra N, Malik H, Jack S, Fenwick SW.   
ASGBI 2012, Liverpool 
Cardiopulmonary exercise testing increases hepatectomy rate in the 
elderly. Dunne DFJ, Malik H, Palmer DH, Poston GJ, Jack S, Fenwick SW.  
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Digestive Disease Federation 2012, Liverpool 
Improved patient selection combined with enhanced recovery can 
reduce length of stay in elderly patients undergoing resection of 
colorectal liver metastasis.  Dunne DFJ, Jones R, Grunhagen D, Mchwirter D, 
Smith R, Lacasia C, Malik H, Poston G.  
BASO 2011, London 
2.2 Invited speaker presentations 
Risk Assessment before Liver Surgery 
Invited speaker, NCRI Future of Surgery Workshop. Royal College of 
Surgeons. November 2016  
Prehabilitation before Liver Surgery 
Invited speaker, AUGIS 2016, Leeds 
Hepatectomy and the elderly: Cardiopulmonary exercise testing and 
prehabilitation.  
Invited speaker, Dutch national surgical conference 2015, Eindhoven 
Cardiopulmonary exercise testing in liver surgery: from research to 
practice.  
Invited speaker Austrian National Surgical Conference 2014, Salzburg 
Enhanced recovery in Liver surgery.  
Invited speaker, Salzburg University hospital. February 2013, Salzburg 
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2.3 Poster Presentations 
Age should not be used to determine fitness for hepatectomy. AUGIS 
2013, Newcastle 
The impact of fitness on hepatectomy. AUGIS 2013, Newcastle  
Enhanced recovery following colorectal liver metastasis resection. 
BASO 2012, London 
Routine Staging Laparoscopy should not be used in Colorectal liver 
metastasis. ESSO 2012, Valencia 
Cardiopulmonary exercise testing (CPET) as a predictor of outcome in a 
mixed hepatobiliary surgical cohort. ECCO 2011, Stockholm 
Liver Resection in the Elderly: combined anaesthetic assessment and 
enhanced recovery improves outcome. ECCO 2011, Stockholm 
Enhanced Recovery in colorectal liver metastasis resection: Shorter 
Hospital Stay and improved management of complications. AUGIS 
2011, Belfast 
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